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IMPACT OF FEEDING FOODS CONTAINING INDUSTRIAL HEMP-DERIVED 
CANNABIDIOL ON CANINE HEALTH AND WELL-BEING 
 
Anecdotal evidence of beneficial behavioral and health effects of cannabidiol 
(CBD) use in companion animals has amplified the need to elucidate safety and potential 
impacts of CBD use. The purpose of this investigation was to determine the impact of 
industrial hemp-derived CBD administration on canine health and well-being. We 
hypothesized that CBD would produce beneficial effects on canine behavior without 
negatively impacting animal health. Dog treats were formulated to include CBD and 
shown to be palatable across a range of CBD inclusion levels. Dogs were supplemented 
with CBD treats and subjected to a noise-induced fear response test to assess potential 
anxiolytic effect of CBD. Behavioral response to the noise-induced fear response test was 
unaffected by CBD and did not support an anxiolytic effect of CBD when supplemented 
at 1.4 mg/kg BW/d. Next, triaxial accelerometers were fitted to dogs’ collars to assess the 
impact of CBD treats on voluntary daily activity. While voluntary daily activity of 
healthy adult dogs was unaffected by 1.8 and 4.5 mg CBD/kg BW/d, a reduction in daily 
scratching suggested a potential antipruritic effect of CBD. Potential impacts on canine 
health were also assessed by evaluating changes in the canine metabolome, hematology, 
and serum chemistry, and immune response upon exposure to a novel antigen. The canine 
metabolome, including amine/phenol, carbonyl, carboxyl, and hydroxyl metabolites, was 
altered with 4.5 mg CBD/kg BW/d and suggested an impact on glucose, amino acid, 
vitamin, and nucleotide metabolism. Hematological and clinical indices of health and 
serum immunoglobulins (IgG and IgM) were largely unaffected by 5 mg CBD/kg BW/d; 
however, elevated liver enzyme alkaline phosphatase may suggest altered liver function. 
These findings may be used to formulate recommendations for CBD use in a clinical 
environment, spur investigation into other potential therapeutic effects of CBD, and may 
serve as a foundation for the development of regulations on CBD use, all of which are 
essential to supporting the health and well-being of companion animals. 
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CHAPTER 1. INTRODUCTION 
The 2018 amendment to the 2014 Farm Bill removed industrial hemp from the 
Controlled Substances Act (CSA) and cannabidiol (CBD) from the Schedule I drug list, 
opening up the possibility of expanding the market for and research on CBD products 
derived from industrial hemp (Johnson, 2019; Mead, 2017). Just one year later, the mean 
acreage devoted to hemp cultivation in the U.S. had increased by 54%, and the market for 
industrial hemp-derived CBD products was approximately $1.2 billion. This market is 
expected to grow to over $10 billion by 2024 (Hemp Industry Daily, 2019).  
Much of this growth can be attributed to public perception of the supposed health 
benefits of CBD. In a set of surveys distributed by a research group at Colorado State 
University, 60-80% of over 1,500 pet owners said they were currently feeding or had 
previously fed hemp or marijuana products to their dogs (Kogan et al., 2016; 2018). 
These surveys provide insight on the overwhelmingly favorable perceptions of pet 
owners on the safety and efficacy of CBD, though they likely over-estimate CBD use in 
dogs and cats due to the surveys being shared primarily within social media groups 
dedicated to cannabis use in pets. On the other hand, a survey of over 2,100 veterinarians 
indicated that the majority of veterinarians are still hesitant to recommend or prescribe 
CBD products to patients, either because they did not feel knowledgeable enough or they 
felt that the field needed more research (Kogan et al., 2019a). 
If CBD is shown to be safe and effective, it has the potential to improve the health 
and well-being of companion animals. Cannabidiol is already being supplemented to 
dogs for its potential therapeutic applications including, but not limited to, osteoarthritis, 
separation anxiety, noise phobias, glaucoma, and epilepsy (Blessing et al., 2015; Landa et 
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al., 2016). However, there is still limited in vivo work in canine models evaluating the 
safety of CBD supplementation and its efficacy in generating these beneficial effects. The 
literature available evaluating its therapeutic potential in osteoarthritic dogs has focused 
primarily on the subjective evaluation of CBD’s effects by owners or veterinarians, with 
little quantitative data to support its use (Gamble et al., 2018). Thus, despite the 
overwhelming public opinion that CBD is a safe and effective treatment for the 
previously mentioned diseases, there remains a substantial gap in scientific literature for 
these anecdotal claims.  
Therefore, the objective of this dissertation was to examine the potential impact of 
oral CBD supplementation on the health and well-being of dogs. The CBD was supplied 
in the form of treats, which were first assessed for palatability at increasing inclusion 
levels. These treats were then supplemented to assess the potential for CBD to influence 
canine behavior in both a normal, daily environment and while subject to fearful stimuli. 
Additionally, alteration of the canine metabolome, potential immunomodulatory effects, 
and impact on overall health indices by CBD were assessed.  
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CHAPTER 2. LITERATURE REVIEW 
Cannabidiol: Biosynthesis, History of Use, and Legal Status 
Hemp, a variety of Cannabis sativa L., is a dioecious, annual plant that is thought 
to be one of the earliest plants to be cultivated (Bonini et al., 2018; Russo et al., 2008). It 
is a multi-purpose plant, with its stem a source of both cellulosic and woody fibers that 
can be used to make animal bedding, textiles, paper, and more. Additionally, hemp seed 
is rich in protein and omega-3 fatty acids, which may make it a valuable feed additive in 
livestock and companion animal diets (Gibb et al., 2005; Skřivan et al., 2020; Zhang et 
al., 2018). The female flowers produce glandular trichomes, hair-like epidermal 
protrusions that cover the leaves, bracts, and stems. These trichomes are responsible for 
the production and storage of secondary metabolites, including terpenoids, flavonoids, 
and cannabinoids (Bonini et al., 2018; Grof, 2018; Huchelmann et al., 2017).  
Cannabidiol is one of more than 100 cannabinoids produced by these glandular 
trichomes. It was first isolated in 1940 and its structure was elucidated in 1963 (Adams et 
al., 1940; Mechoulam and Shvo, 1963). Both CBD and ∆9-tetrahydrocannabinol (THC) – 
the other primary cannabinoid produced by C. sativa – are prenylated polyketides 
primarily derived from fatty acids and isoprenoids; however, their biosynthetic pathway 
has only recently been elucidated, and several steps in the pathway are still under 
investigation (Gagne et al, 2012; Stout et al., 2012; Taura et al., 2007). Within the 
polyketide pathway, hexanoyl-CoA is produced from the short-chain fatty acid hexanoate 
before being converted into olivetolic acid via polyketide synthase. Geranyl diphosphate 
(GPP), a product of the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway, is added to 
olivetolic acid to produce cannabigerolic acid, the precursor for the acid forms of both 
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THC and CBD (Stout et al., 2012). The concentration of cannabinoids and other 
secondary metabolites produced is dependent on a number of factors, including the 
different cultivars of C. sativa, whether or not the female plant has been pollinated, and 
environmental conditions like humidity, soil nutrients, and temperature (Bonini et al., 
2018).  
Due to both the psychoactive effects of THC and the rise of alternative sources for 
industrial fibers, the production, possession, and transfer of C. sativa was first restricted 
in the United States by the Marihuana Tax Act of 1937. This law required all hemp 
growers to be registered and licensed (Bonini et al., 2018, USDA, 2000). In 1970, hemp 
and all its products, including CBD, were classified as illegal, Schedule I drugs under the 
CSA, which further restricted access to CBD (Corron and Kight, 2018; Mead, 2017). 
These restrictions severely limited the potential for research on CBD and its effects on 
mammalian physiological systems.  
Restrictions on hemp production first began to loosen at the state level in the early 
2000’s, with further federal relaxation of restrictions after the 2014 Farm Bill was 
enacted. This allowed research institutions to grow “industrial” hemp for research 
purposes, including the use of hemp-derived CBD (Mead, 2017). In order to be 
considered industrial hemp rather than marijuana, the plant and all its products must 
contain less than 0.3% THC on a dry weight basis (Johnson, 2019). Finally, in a 2018 
amendment to the 2014 Farm Bill, industrial hemp was removed from the CSA entirely, 
and hemp-derived CBD was removed from the Schedule I drug list of the CSA. But 
THC, whether produced from hemp or marijuana, remains a Schedule I drug (Johnson, 
2019; UDSA, 2000).  
5 
Despite the relaxation of restrictions on the production and research of industrial 
hemp-derived CBD, the Food and Drug Administration (FDA) still considers it illegal to 
market food or dietary supplements containing CBD, even if there are no therapeutic 
claims on the label (Johnson, 2019). The FDA has published several statements to the 
public emphasizing the lack of scientific evidence regarding the safety, proper dosage, 
and quality of products containing CBD, and they acknowledge the critical need to bridge 
public perception of the therapeutic effects of CBD and the scientific literature that is 
currently available (FDA, 2020; Hahn, 2020). 
The Endocannabinoid System 
The therapeutic potential of CBD is a major reason for the increased interest in its 
use, both in humans and companion animals. It has been proposed to induce a plethora of 
beneficial health effects through action on the endocannabinoid system (ECS). First 
described in the early 1990’s, the ECS signaling system was discovered secondarily to 
the elucidation of the structure of THC and the search for its biological target. The 
discovery of the G-protein coupled receptor (GPCR) target for THC, dubbed cannabinoid 
receptor 1 (CB1), during this investigation quickly led to the identification of a second 
cannabinoid receptor (CB2) as well as the major endogenous ligands, or 
endocannabinoids, for these receptors: arachidonoyl ethanolamide (AEA; also known as 
anandamide) and 2-arachidonoyl glycerol (2-AG) (De Petrocellis and Di Marzo, 2009; 
Silver, 2019). These receptors and endocannabinoids, along with the enzymes involved in 
their synthesis, degradation, and regulation, make up the ECS. (Lu and Mackie, 2015; 
Pacher et al., 2006; Russo et al., 2016). Additional endocannabinoids and receptors like 
peroxisome proliferator activated receptors (PPARs) and transient receptor potential 
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(TRP) channels have since been shown to contribute to the widespread actions of the 
ECS (De Petrocellis and Di Marzo, 2009).  
The ECS has been implicated in a number of physiological processes and is 
responsible for regulatory functions throughout the body, including the central nervous 
system (CNS), cardiovascular system, and immune system (Burstein, 2015; Russo, 2016; 
Silver, 2019). Receptor location and level of expression dictate their function. CB1 
receptors, for instance, are most abundant within the CNS, particularly in the cortex, 
basal ganglia, hippocampus, and cerebellum. Under normal conditions, CB1 receptors 
exert a general protective or pro-homeostatic effect by helping to regulate synaptic 
strength of neurons involved in cognitive, affective, and motivational processes (De 
Petrocellis and Di Marzo, 2009). However, CB1 receptors are also expressed to a lesser 
extent throughout the rest of the body, including, but not limited to, the enteric nervous 
system, liver, and thyroid (De Petrocellis and Di Marzo, 2009; Galiazzo et al., 2018; 
Pagotto et al., 2006). Conversely, CB2 receptors are primarily expressed in immune cells 
like monocytes, macrophages, B-cells, and T-cells, and are in part responsible for the 
regulation of cytokine and chemokine release (Vučković et al., 2018). They are also 
expressed in the peripheral nervous system, the gastrointestinal tract, skin, and more 
(Galiègue et al., 1995; Silver, 2019; Wright et al., 2008). 
Phytocannabinoids and the Endocannabinoid System 
 Plant-based cannabinoids, or phytocannabinoids, like CBD and THC are 
exogenous ligands for ECS receptors. For instance, THC is a high-affinity agonist for 
CB1, and the psychotropic effects of THC are a result of the abundant expression of CB1 
within the CNS (Lu and Mackie, 2015; Pacher et al., 2006). This effect is magnified in 
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the canine nervous system as dogs have higher expression of CB1 in the brain than 
humans, often leading to adverse reactions like static ataxia when a dog is exposed to 
THC (Silver, 2019). Conversely, CBD has low affinity for both CB1 and CB2 receptors, 
which explains its lack of psychotropic effects. It is, however, capable of acting as an 
antagonist of both cannabinoid receptors when in the presence of THC as well as a non-
competitive negative allosteric modulator of CB1 (Laprairie et al., 2015; Thomas et al., 
2007). In addition to interactions with the primary cannabinoid receptors, CBD is a 
known agonist or antagonist for several ECS-associated receptors, including transient 
receptor potential (TRP) vanilloid receptors 1 and 2 (TRPV1 and 2), ankyrin 1 (TRPA1), 
melastatin 8 (TRPM8), G protein-coupled receptor 55 (GPR55) and more (Wang and 
Multhoff, 2021; Vučković et al., 2018). The potential physiological and therapeutic 
effects of CBD result from the action of CBD on the various ECS-associated receptors 
and interactions with endocannabinoids. 
Potential Physiological Effects of Cannabidiol 
Analgesic 
Several ECS-associated receptors like TRPV1, serotonin (5-HT) 1A, and GPR55 
are present throughout peripheral and central nervous system pain pathways (Burston and 
Woodhams, 2014; Jesus et al., 2019). Cannabidiol may exert an analgesic effect either 
via direct action on these receptors or indirectly by inhibiting the cellular uptake and 
degradation of AEA. In rats, repeated administration of CBD was shown to attenuate 
both thermal and mechanical hyperalgesia in a dose-dependent manner after either 
injection of complete Freund’s adjuvant or injury to the sciatic nerve. The lower doses, 
ranging from 2.5 to 10 mg/kg, CBD reduced hyperalgesia whereas the 20 mg/kg dose 
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completely abolished hyperalgesia (Costa et al., 2007). As their findings saw no effect of 
CB1 and CB2 receptor antagonists, it was suggested that TRPV1 was the molecular target 
of this activity – either via direct action by CBD or indirect action through its effects on 
AEA (Costa et al., 2004; 2007).  
Anandamide is an endocannabinoid produced in response to tissue injury or 
excessive pain signaling and acts on receptors to reduce pain and inflammation 
(Maccarrone et al., 2015; Vučković et al., 2018). However, AEA is rapidly taken up into 
cells via the anandamide membrane transporter (AMT) and degraded via hydrolysis by 
fatty acid amide hydrolase (FAAH) (Hillard and Jarrahian, 2000; Ueda et al., 2000). 
Cannabidiol is thought to indirectly produce analgesia by inhibiting both cellular uptake 
of AEA by AMT and AEA hydrolysis by FAAH, thus prolonging the analgesic effect of 
AEA (Bisogno et al., 2001).  
Cannabidiol may also exert analgesic effects via activation of serotonin receptors. 
Jesus et al. (2019) investigated the potential analgesic effect of intraperitoneal CBD on 
pain in diabetic rats. The observed anti-allodynic effect of CBD treatment was not 
blocked by selective CB1, CB2, and glycine receptor antagonists; pretreatment with a 
selective 5-HT1A antagonist completely prevented the antinociceptive effect. The role of 
5-HT1A receptors in the analgesic effect of CBD is supported by in vitro work 
demonstrating agonistic effects on 5-HT1A receptors and inhibitory effects on serotonin 
reuptake (Rock et al., 2012; Russo et al., 2005).  
The analgesic action of CBD may also be modulated via action on GPR55. An 
orphan receptor expressed in both central and peripheral nociceptive systems, GPR55 is 
believed to help modulate pain receptor excitability (Guerrero-Alba et al., 2019; Ray et 
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al., 2018). The activation of GPR55 increases intracellular Ca2+ in large dorsal root 
ganglia responsible for the transmission of both proprioceptive and nociceptive peripheral 
stimuli (Lauckner et al., 2008). Additionally, GPR55 activation has been shown to 
produce mechanical hypersensitivity in mice (Gangadharan et al., 2013). Cannabidiol 
may exert analgesic action by blocking the activation of GPR55, which has been 
demonstrated both in vitro and in mouse models (Kaplan et al., 2017; Ryberg et al., 
2007).  
Collectively, action on these receptors supports the analgesic potential of CBD, 
for which there are many possible applications. Its analgesic effect may inhibit 
mechanosensitivity of joint nociceptors, which would be useful in the management of 
arthritis or other inflammatory conditions (Philpott et al., 2017). Cannabidiol may also 
attenuate nociception involved with neuropathic or chronic pain, which could be used to 
mitigate the pain associated with conditions like nerve injury, diabetes, or cancer 
(Elikottil et al., 2013; Vučković et al., 2018). However, current in vivo work with canine 
models have focused primarily on the impact of CBD on symptoms rather than 
mechanisms of action (Brioschi et al., 2020; Gamble et al., 2018; Verrico et al., 2020). 
Thus, the mechanism by which CBD produces the reported analgesic effects in dogs has 
yet to be elucidated.  
Anti-Arthritic 
 Arthritis is a general term encompassing more than 100 conditions in which one 
or more joints are inflamed. The most common types of arthritis – osteoarthritis and 
rheumatoid arthritis – are degenerative and characterized by chronic pain and 
inflammation (McDougall, 2006). The ECS is known to modulate joint homeostasis 
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through CB1, CB2, and TRPV1 (Richardson et al., 2008; Schuelert et al., 2008). These 
receptors are thought to be potential targets for the regulation of joint disease like arthritis 
(Philpott et al., 2017). To date, there is no evidence of CBD preventing or treating any 
form of arthritis. Instead, the so-called “anti-arthritic” effect of CBD is primarily 
attributable to its analgesic and anti-inflammatory effects discussed in pertinent sections 
of this work.  
Anti-Cancer 
 Cancer is one of the leading causes of worldwide disease-related death; there is a 
great need for anti-cancer drugs that are both well-tolerated and highly effective against 
cancer cells (Siegel et al., 2020). Several ECS receptors, such as CB2, TRPV1 and 2, 
TRPA1, TRPM8, and GPR55, are upregulated in cancer cells and have been shown to 
modulate cellular processes involved in tumor cell growth and proliferation (Lee et al., 
2021; Wang and Multhoff, 2021). Therefore, CBD is thought to serve as an anti-cancer 
agent through several potential mechanisms, including induction of cell apoptosis, 
induction of autophagy, increasing sensitivity to cytotoxic therapies, and the inhibition of 
cell growth and proliferation.  
 Cannabidiol may induce tumor cell apoptosis through several mechanisms, 
including the inhibition of AKT/mammalian target of rapamycin (mTOR) signaling, 
activation of pro-caspases, and increasing the production of reactive oxygen species 
(ROS). Under normal conditions, the mTOR signaling pathway regulates cell growth and 
division, but can lead to tumor development when abnormally activated (Zou et al., 
2020). In human breast cancer cells, CBD was shown to induce endoplasmic reticulum 
stress, thereby inhibiting AKT and mTOR signaling which led to cell death (Shrivastava 
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et al., 2011). In human gastric cancer and glioma cells, CBD has been shown to activate 
caspases-3/8/9, which directly trigger apoptosis (Massi et al., 2006; Zhang et al., 2019). 
Additionally, CBD has been shown to increase ROS production through both TRPV1 and 
TRPV 2 agonism (Kis et al., 2019; Massi et al., 2006; Wang and Multhoff, 2021). 
Increased ROS generation disrupts mitochondrial membrane potential, which leads to a 
release of cytochrome c, another pro-apoptotic factor (Olivas-Aguirre et al., 2019; 
Shrivastava et al., 2011). Remarkably, CBD did not impair normal primary glial cells 
under the same conditions (Massi et al., 2006).  
 In addition to inducing apoptosis, CBD is also thought to exert anti-cancer effects 
through the induction of autophagy. Autophagy is an intracellular degradation process 
that removes misfolded or aggregated proteins and damaged organelles from cells (Lee et 
al., 2021). Under normal conditions, autophagy helps maintain homeostasis, but can serve 
as a tumor suppressant in the early stages of cancer development or a tumor promoter in 
later stages (Amaravadi et al., 2019; Lee et al., 2021). Cannabidiol has been shown to 
induce autophagy in both human breast cancer and glioma cells through action on 
TRPA1 and TRPV2 (Nabissi et al., 2015; Shrivastava et al., 2011; Wang and Multhoff, 
2021). Additionally, when combined with traditional cytotoxic cancer treatments, 
cannabinoids have been shown to enhance autophagy and increase the uptake of those 
chemotherapeutic compounds into cancer cells, suggesting a potential benefit of 
combining CBD with conventional treatments (Torres et al., 2011). 
 Lastly, CBD may exert anti-cancer effects by inhibiting tumor cell growth and 
proliferation. One potential mechanism for this antiproliferative effect is the antagonistic 
action of CBD on GPR55, which is known to activate downstream proliferation pathways 
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and is implicated in tumor migratory behavior (Kargl et al., 2016; Kis et al., 2019; Lee et 
al., 2021). Treatment of mice pancreatic cancer cells with GPR55 antagonists, including 
CBD, prevented MAPK signaling, cell growth, and cell cycle progression (Ferro et al., 
2018; Lee et al., 2021). In male mice, treatment with 1 mg/kg CBD was shown to inhibit 
colon cancer cell growth (Aviello et al., 2012). In prostate cancer cell lines, CBD was 
also shown to inhibit cancer cell growth, potentially due to pro-apoptotic activity 
(Sharma et al., 2014; Sreevalsan et al., 2011). Another potential mechanism is CBD’s 
anti-angiogenic properties. Angiogenesis, or the process of forming new blood vessels 
from pre-existing ones, is essential for tumor growth and metastasis (Kis et al., 2019). 
Cannabidiol has been shown to reduce growth, migration, and invasion of human 
umbilical vein endothelial cells (HUVEC), a cell line commonly used for proliferation 
assays as well as glioma cells in vitro (Solinas et al., 2012; 2013).  
 All this work points to the potential for CBD to be a potent anticancer agent. 
Currently, CBD is most commonly used to alleviate symptoms of cancer treatment. 
Tumor-related adverse effects were shown to be alleviated by 50-600 mg CBD/d in a 
human phase I clinical trial (Good et al., 2019), and a THC/CBD combination helped 
reduce pain intensity, nausea, and vomiting in patients undergoing chemotherapy 
(Johnson et al., 2010). However, there is currently little clinical evidence of anticancer 
effects of CBD outside of preclinical studies in cell lines and animal models, and more in 
vivo research with larger samples sizes is needed. 
Anti-Epileptic 
 Epilepsy is a chronic neurological disease characterized by the occurrence of 
repeated and spontaneous seizures. In many cases, epilepsy can cause several 
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comorbidities that reduce a patient’s quality of life, including cognitive deficits, 
psychiatric disorders, anxiety, and depression (Boleti et al., 2020). While many forms of 
epilepsy can be controlled with conventional antiepileptic medications, an estimated one-
third of epileptic patients still suffer persistent seizures (Chen et al., 2018). Thus, 
investigation into alternative therapies such as CBD has increased substantially in recent 
years, culminating in the FDA approval of a CBD-based medication, Epidiolex®, for the 
treatment of seizures associated with Dravet and Lennox-Gastaut syndromes (Boleti et 
al., 2020).  
 There are several potential targets of CBD that may contribute to its anti-epileptic 
effect. The activation of TRPV1 has been implicated in the induction of epileptic seizures 
as it prompts a release of glutamate and an increase in Ca2+, resulting in neuronal 
excitability (Nazıroğlu, 2015). While CBD is a known agonist of TRPV1, it acts more as 
a functional antagonist, desensitizing the receptor and preventing further release of 
glutamate and Ca2+ (Boleti et al., 2020; Silvestro et al., 2019). A similar mechanism of 
action has been postulated for the functional antagonism of GPR55 by CBD (Gray and 
Whalley, 2020; Rosenberg et al., 2015). Additionally, agonism of 5-HT1A by CBD has 
been suggested to play a role through its inhibition of serotonergic neurons (Silvestro et 
al., 2019; Theodore, 2003). The antiseizure effect may also involve CBD’s action on 
adenosine receptors A1 and A2A. Adenosine is an endogenous compound known to 
modulate neuronal excitability and is considered an endogenous anti-convulsant (Weltha 
et al., 2019). Activation of adenosine receptors by either adenosine or CBD inhibit the 
presynaptic influx of Ca2+, thus preventing hyperpolarization (Boleti et al., 2020; Gray 
and Whalley, 2020).  
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 Several human clinical trials have been completed evaluating the safety and 
efficacy of CBD for use in patients with epilepsy. Cannabidiol doses ranging from 5 to 50 
mg CBD/kg/d have been shown to reduce seizure frequency and improve subjective 
quality of life in patients ranging from infants to adults suffering from a variety of 
seizure-related disorders (reviewed extensively in Silvestro et al., 2019). While CBD has 
been extensively studied in these clinical trials for safety and preliminary efficacy, work 
is ongoing to determine proper dosing and potential long-term psychiatric and cognitive 
effects. Adverse events are also of concern considering severe adverse events were 
reported in a number of these clinical trials as well as the possibility of interactions with 
other anti-seizure medication (Devinsky et al., 2018; Lattanzi et al., 2020). Altogether, 
CBD appears to be a promising prospect for the management of epileptic disorders.  
Anti-Inflammatory and Immunomodulatory 
 One of the most common reasons for CBD use is its suspected anti-inflammatory 
effect (Kogan et al., 2016). Inflammation is a normal but complex physiological process 
in which the body responds to the presence of foreign bodies or damage by recruiting the 
immune system to eliminate the threat or repair the damage. In some chronic 
inflammatory disorders like osteoarthritis and rheumatoid arthritis, however, the immune 
system remains active, resulting in prolonged inflammation that can eventually be 
harmful to the body (Pahwa et al., 2020). Chronic inflammation is often marked by 
elevated production of pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNFα 
as well as high-sensitivity C-reactive protein and NF-κB that are produced by immune 
cells as part of the immune response (Albensi, 2019; Zhang and An, 2007). 
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Cannabidiol is thought to exert anti-inflammatory effects through several 
mechanisms, including the reduction of pro-inflammatory cytokine production, alteration 
of T cell proliferation, activation of PPARγ, and more. Activation of ECS receptors like 
CB1 have been shown to stimulate the pro-inflammatory response; as a negative allosteric 
modulator of CB1, CBD may inhibit their activation and downstream inflammatory 
cascade (Han et al., 2009). Conversely, CBD can act as both a weak agonist and indirect 
agonist of CB2 that, when activated, has been shown to decrease TNFα (Han et al., 2009; 
Muller et al., 2019; Pertwee, 2008). The indirect actions of CBD on both CB1 and CB2 
may thus be a mechanism by which it produced anti-inflammatory effects. Decreased 
production of TNFα and other pro-inflammatory cytokines by CBD has also been shown 
to be mediated by its activation of A2A receptors (Liou et al., 2008; Sunda and Arwolo, 
2020), which may protect tissues from inflammation by down regulating over-reactive 
immune cells (Carrier et al., 2006; Ohta and Sitkovsky, 2001). Antagonism of GPR55 
(Lanuti et al., 2015) and TRP channels (Atalay et al., 2020; Bujak et al., 2019; Minke, 
2006) have also been suggested to facilitate the anti-inflammatory effect, though less 
studied. The anti-inflammatory effect of CBD may also be mediated by PPARγ activation 
as CBD has been shown to bind to and activate PPARγ (O’Sullivan, 2016). The 
inhibition of several cytokines by CBD has been shown to be PPARγ-mediated 
(Rockwell and Kaminski, 2004) along with the inhibition of myeloid‐derived suppressor 
cell induction (Hegde et al., 2015) and reduced expression of inflammatory proteins in 
enteric glial cells (De Filippis et al., 2011), all of which may contribute to an anti-
inflammatory effect. Cannabidiol has also been shown in vitro to modulate T cell 
proliferation through several mechanisms. Transcription of T-cell co-inhibitory 
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molecules – which are known to interfere with the interaction of T cells and antigen 
presenting cells required for differentiation – was enhanced by CBD treatment in 
encephalitogenic memory T cells (Kozela et al., 2011; 2016). Conversely, CBD has been 
shown to induce functional Tregs, which are a specialized population of T cells that 
suppress the immune response (Dhital et al., 2017). 
 The potential anti-inflammatory effect of CBD has been demonstrated in a limited 
number of studies in rats and humans. Rats with sodium monoiodoacetate-induced 
osteoarthritis demonstrated reduced joint inflammation when treated with localized CBD, 
and prophylactic CBD administration prevented the later development of pain and nerve 
damage from osteoarthritis induction (Philpott et al., 2017). Similarly, oral CBD 
administration reduced overexpression of prostaglandin E2 and nitric oxide in rats with 
induced unilateral neuropathy, though NF-κB and TNFα were unaffected (Costa et al., 
2007). In a human pilot study, a single dose of oral CBD was administered, and blood 
drawn over the course of 6 hours. When human peripheral blood mononuclear cells 
(PBMCs) were isolated and stimulated by lipopolysaccharide, TNFα was decreased 
(Hobbs et al., 2020). However, this was a small study using only a single dose and 
administration of CBD. Other retrospective studies have been performed to evaluate 
current use of CBD and other cannabinoids for orthopedic issues (Gusho and Court, 
2020) but no other controlled clinical trials have been published regarding the use of 
CBD for its anti-inflammatory effect.  
 While the anti-inflammatory effect of CBD has been pursued for potential 
treatments against chronic inflammatory conditions like multiple sclerosis and 
osteoarthritis, there is also evidence from in vitro work suggesting CBD may negatively 
17 
impact other functions of the immune system. Notably, CBD has been shown to inhibit 
IL-2, IL-10, and IFNγ production in mice (Condie et al., 1996; Jan et al., 2007). IL-2 is 
an essential cytokine for the activation and differentiation of T cells as well as the 
maintenance of peripheral tolerance, which is one mechanism for the regulation of self-
reactive immune cells (Arenas-Ramirez et al., 2015). T cell activation is an essential 
component of the T cell-dependent B cell response to antigen encounter. Without proper 
levels of IL-2, T cells cannot be activated, and thus B cells are unable to undergo somatic 
hypermutation and isotype switching, the processes that generate high affinity antibodies 
to bind antigens (Jeurissen et al., 2004). This suppression of antigen-specific antibody 
production has been observed in mice after a single intraperitoneal dose of CBD (Jan et 
al., 2007).  
There is also conflicting evidence regarding anti-inflammatory and 
immunomodulatory effects of CBD. Several studies have demonstrated an increase in IL-
2 secretion through enhancement of gene transcription in activated T cells by CBD and 
other cannabinoids (Chen et al., 2012; Jan et al., 2002). Jenny et al. (2009) reported a 
biphasic response in human PBMCs, with CBD exhibiting a stimulatory effect at lower 
doses and inhibitory effects at higher doses. Cannabidiol has also been shown, under 
certain conditions, to enhance production of pro-inflammatory cytokine mRNA, thus 
exacerbating lipopolysaccharide-induced inflammation in mice (Karmaus et al., 2013). 
These discrepancies between responses may be dependent upon age, cell type, CBD dose, 
mode of administration, magnitude of cellular activation, or other unknown factors (Chen 
et al., 2012; Karamus et al., 2013). Although these immunomodulatory effects may be 
beneficial in some conditions, they may also be detrimental, particularly regarding 
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immune responses to antigen encounters. Continued investigation is essential to better 
understand these mechanisms and to elucidate potential risks to health especially because 
of the lack of in vivo studies and clinical trials. 
Anti-Nausea and Anti-Emetic 
Hemp has been used for centuries for its anti-nausea and anti-emetic effects 
(Russo, 2007), and has recently been suggested as a management strategy for 
chemotherapy-induced nausea and vomiting in cancer patients (Smith et al., 2015; 
Whitling et al., 2015). Cannabidiol is believed to exert a biphasic effect on nausea and 
vomiting. Low doses (2.5-20 mg/kg) of CBD have been shown to suppress toxin-induced 
vomiting while higher doses (40 mg/kg) exacerbated toxin-induced vomiting in musk 
shrews (Parker et al., 2004; Rock et al., 2020). One potential mechanism of action may be 
reduction of the firing rate of 5-HT afferents to the terminal forebrain regions via 
agonism of 5-HT1A receptors, which has been demonstrated in musk shrews and rats 
(Rock et al., 2012). Alternatively, allosteric inhibition of 5-HT3A receptors may be 
another mechanism of this effect. 5-HT3A antagonists are known to be highly effective 
anti-nausea and anti-emetic drugs (Kaiser et al., 2004), and CBD has been shown to act 
as an allosteric inhibitor of 5-HT3A receptors (Yang et al., 2010). 
While there have been many clinical trials evaluating the use of cannabinoids or 
synthetic cannabinoids, either by themselves or in combination with other treatments, for 
nausea and vomiting, there have been no human clinical trials looking specifically at 
CBD. There have been a few phase I and II safety and efficacy studies using THC:CBD 
combinations (Duran et al., 2010; Mersiades et al., 2018) suggesting the combination is 
well-tolerated and may help reduce chemotherapy-induced nausea and vomiting. One 
19 
small phase II/III trial reported an association of oral THC:CBD with reduced nausea and 
vomiting, though approximately one-third of the participants experienced moderate to 
severe cannabinoid-related adverse events (Grimison et al., 2020). While this work is 
promising, additional investigation is necessary to elucidate what role CBD may play in 
this effect.  
Anti-Obesity 
 The ECS plays a well-established role in glucose and energy metabolism. 
Activation of ECS receptors have been shown to increase food intake, to activate 
anabolic metabolic pathways in peripheral organs that favor energy storage, and to 
enhance triglyceride accumulation in adipocytes (Boon et al., 2014; Gruden et al., 2016; 
Kunos and Tam, 2011). The ECS is also known to be up regulated in metabolic disorders 
like insulin resistance and type 2 diabetes and its dysregulation is thought to contribute to 
the development of these disorders (Bielawiec et al., 2020; Silvestri and Di Marzo, 2013). 
Consequently, cannabinoids like CBD and THC are thought to possess therapeutic 
potential for these disorders.  
The mechanisms by which CBD may exert an anti-obesity effect is unclear. It is 
possible that CBD may exert this effect through action on PPARγ or TRPV1. 
Cannabidiol is a known ligand for PPARγ, which plays an essential role in regulating 
glucose homeostasis and lipoprotein metabolism (Bielawiec et al., 2020; O’Sullivan, 
2016). Stimulation of PPARγ has been shown to improve glucose tolerance, insulin 
sensitivity (Picard and Auwerx, 2002), and treatment with a PPARγ ligand reduced 
triglyceride levels by increasing the fractional clearance rate of triglycerides from very 
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low-density lipoproteins (Nagashima et al., 2005). Thus, the action of CBD on PPARγ 
may play a role in its suspected anti-obesity effect; however, this effect has not been 
directly investigated. TRPV1 is highly expressed on sensory nerve fibers in the pancreas 
and has been implicated in diabetes and obesity. Ablation of TRPV1-positive fibers by 
capsaicin has been shown to improve glucose tolerance in rat models of type 2 diabetes 
and prevented immune-mediated destruction of pancreatic β-cells in mice (Gram et al., 
2007; Razavi et al., 2006). Silvestri et al. (2015), on the other hand, demonstrated a dose- 
and time-dependent reduction in hepatocyte lipid content in vitro that was shown to be 
independent of TRPV1, but their work was not able to identify a potential receptor 
responsible for the effect. They do suggest that the effect may have been a result of post-
translational modifications as the expression of several proteins involved in lipid 
metabolism were upregulated (Silvestro et al., 2015). Thus, mechanisms by which CBD 
may exert a direct anti-obesity effect are currently unclear, and continued investigation is 
necessary. 
Both CBD and THC have been shown to reduce hyperglycemia and increase 
insulin production in diabetic rats (Zorzenon et al., 2019). In a human pilot study, patients 
with type 2 diabetes receiving 100 mg CBD daily for 13 weeks had reduced resistin – a 
hormone linked to obesity and insulin resistance – compared to baseline, but there were 
no other changes in response to CBD treatment (Jadoon et al., 2016). However, it is 
possible these benefits of CBD may be attributable to its antioxidant and anti-
inflammatory effects rather than a specific anti-obesity effect. In mice with induced type I 
diabetes, treatment with CBD reduced markers of inflammation in the microcirculation of 
the pancreas and reduced leukocyte activation, suggesting the influence of CBD on 
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diabetes and obesity may be attributed to its anti-inflammatory effect (Lehmann et al., 
2016). Additionally, in a mouse model of type I diabetic cardiomyopathy, CBD 
attenuated the high glucose-induced increase in reactive oxygen species, cardiac fibrosis, 
and NF-κB activation (Rajesh et al., 2010). Collectively, current evidence points to CBD 
being beneficial for the management of complications associated with obesity and 
diabetes, though direct evidence of an anti-obesity effect remains elusive. 
Antioxidant 
 Closely associated with the anti-inflammatory effect of CBD is its action as an 
antioxidant. Production of free radicals through aerobic metabolism is a normal 
physiological process tightly controlled by a complex network of antioxidant enzymes 
and molecules that remove ROS before they can damage a cell (Vertuani et al., 2004). 
During periods of oxidative stress, however, ROS production exceeds removal or damage 
repair by antioxidants, which can lead to permanent damage of cellular components like 
DNA, lipid peroxidation, and eventually cell death (Evans and Cooke, 2004). 
Cannabidiol has been shown to be a powerful antioxidant acting through direct and 
indirect mechanisms. 
 At the most basic level, CBD acts as an antioxidant by directly interrupting free 
radical chain reactions. Free radicals can be scavenged by the hydroxyl group on CBD’s 
phenol ring, which then prevents further free radical propagation (Atalay et al., 2020; 
Borges et al., 2013). Cannabidiol can also directly reduce ROS generation by chelating 
transition metal ions involved in the production of free radicals by the Fenton reaction 
(Campos et al., 2016; Hamelink et al., 2005). Lastly, CBD prevents ROS production by 
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inhibiting pro-oxidant enzymes like xanthine oxidase, nitric oxide synthase, NADPH 
oxidases (Costa et al., 2007; Pan et al., 2009; Rajesh et al., 2007). 
 Indirect mechanisms by which CBD acts as an antioxidant include activation of 
PPARγ, reduction in lipid peroxidation, and enhanced expression and activity of 
antioxidant enzymes. Activation of PPARγ has been shown to inhibit cyclooxygenase 2, 
TNFα, IL-1, and IL-6 gene expression, and as CBD is a PPARγ agonist, it can indirectly 
exert antioxidant effects through this mechanism (Atalay et al., 2020; Hou et al., 2012). 
Administration of CBD also reduces lipid peroxidation, likely through its reduction of 
ROS production. Reduction of lipid peroxidation by CBD has been shown in both in vitro 
and rodent models by measuring malonodialdehyde (MDA) levels, which is a product of 
oxidative fragmentation of lipids (Ayala et al., 2014; Sun et al., 2017). Lastly, CBD has 
been shown to activate the redox-sensitive transcription factor nuclear erythroid 2-related 
factor (Nrf2), which regulates transcription of antioxidant genes (Atalay et al., 2020; 
Juknat et al., 2013). This activation leads to increased transcription of antioxidant 
enzymes like glutathione S-transferase and superoxide dismutase (SOD), whose activity 
is also increased by CBD (Jastrząb et al., 2019; Rajesh et al., 2010). 
 The antioxidant potential of CBD is one of the best studied. In combination with 
its potential effects on inflammation, the antioxidant effects of CBD make it a strong 
candidate for therapeutic use in diseases associated with oxidative stress and 
inflammation such as cancer, Alzheimer’s, and diabetes mellitus. However, most of this 
work has been in vitro or in rodent models. Additional work in humans and companion 




Dermatologic conditions like allergic contact dermatitis, atopic dermatitis, and 
psoriasis are common medical problems for both humans and companion animals. In 
dogs, atopic dermatitis is one of the primary causes of pruritis and is associated with 
immune and skin barrier dysfunction (Brément et al., 2019). Emerging evidence suggests 
a protective role of the ECS in the skin. For instance, Campora et al. (2012) reported 
elevated ECS receptor immunoreactivity in dogs with atopic dermatitis compared to 
clinically normal dogs, suggesting an upregulation of these receptors due to 
inflammation. While the antipruritic effect of cannabinoids has been observed in humans 
and mice (Dvorak et al., 2003; Visse et al., 2017; Yuan et al., 2014), none of these studies 
have evaluated CBD in vivo. Palmitoylethanolamide (PEA), for example, has been shown 
to reduce itch and inflammation in mice (Vaia et al., 2016) and topical THC decreased 
contact allergic swelling and myeloid immune cell infiltration in a mouse model of 
allergic contact dermatitis (Gaffal et al., 2013). 
While CBD has little affinity for CB1 and CB2 ECS receptors, it is a known 
agonist for the TRPV family of receptors (TRPV1-4), known ECS receptors widely 
expressed in the skin that are involved in itch sensation (Avila et al., 2020; Bisogno et al., 
2001; Caterina and Pang, 2016; Tóth et al., 2019). As TRPV1 is rapidly desensitized after 
activation, it is thought that CBD may exert antipruritic effects by keeping TRPV1 
desensitized, thus preventing neuronal activation by irritants (Imamachi et al., 2009; 
Muller et al., 2019; Xie and Hu, 2018). This potential mechanism is supported by an in 
vitro model of allergic contact dermatitis in which CBD elevated AEA and dose-
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dependently inhibited the release of pro-inflammatory IL-6, IL-8, and TNFα, an effect 
that was reversed by both CB2 and TRPV1 antagonists (Petrosino et al., 2018). 
Other potential mechanisms include action on other receptors or through genetic 
regulation. CBD has been shown to be an antagonist for transient receptor potential 
melastatin 8 (TRPM8) receptors (De Petrocellis et al., 2008; Muller et al., 2019). In the 
skin, TRPM8 is responsible for environmental cold detection and has been suggested to 
contribute to the perception of pain and itch, which may indicate it is another target for 
the potential antipruritic effect of CBD (Caterina and Pang, 2016; Jankowski et al., 
2017). In an in vitro model using canine keratinocytes, CBD downregulated several genes 
associated with inflammatory pathways though increased DNA methylation of key sites 
(Massimini et al., 2021), which may indicate that CBD is affecting gene transcription in 
addition to action on receptors. However, as this effect has not been evaluated in vivo, 
more research is needed to determine if any of these mechanisms produce a 
physiologically relevant response.  
Anxiolytic and Antipsychotic 
 Cannabis has been used for centuries to treat anxiety and to improve mood 
(Graczyk et al., 2021), and the ECS is known to play an essential role in the regulation of 
cognitive abilities, stress, sleep, and mood (Hill et al., 2013; Morena et al., 2016). While 
THC induces psychotic symptoms through its action on CB1 (D'Souza et al., 2004; 
Morrison et al., 2011), CBD is a non-psychotropic that can inhibit anxiety and psychotic-
like symptoms produced by THC use (Englund et al., 2013; Klein et al., 2011). Because 
of this, CBD has been investigated for its therapeutic potential for a wide range of 
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medical conditions, including psychiatric disorders like anxiety, schizophrenia, and 
depression. 
 One possible mechanism by which CBD exerts antipsychotic effects is through 
the inhibition of FAAH and subsequent increase in AEA. Elevated AEA is associated 
with psychiatric symptom improvement (Giuffrida et al., 2004; Leweke et al., 2012), so 
CBD may indirectly produce an antipsychotic effect by inhibiting AEA breakdown by 
FAAH (Bisogno et al., 2001). Additionally, both CBD and AEA are agonists of TRPV1, 
which plays a role in emotional and cognitive responses in the brain in addition to pain 
detection (Campos et al., 2012; Nazıroğlu and Demirdaş, 2015). Anxiety was reduced in 
TRPV1 knockout mice, and the desensitization of TRPV1 by either CBD or AEA may 
produce a similar response (Marsch et al., 2007). The antipsychotic effect of CBD may 
alternatively be a result of its action on 5-HT1A receptors (Bonaccorso et al., 2019). A 5-
HT1A antagonist was shown to attenuate the reduction in anxiety by CBD in rats using 
contextual fear conditioning, elevated plus maze, and Vogel conflict test models (Campos 
et al., 2008; Gomes et al., 2012).  
 In addition to the work examining CBD use as an anxiolytic and antipsychotic in 
rodent models, there is also considerable evidence of this effect in humans. In human 
studies evaluating the impact of CBD/THC ratios in cannabis on psychosis measures, 
CBD content was inversely related to psychosis symptoms like memory impairment, 
depression, and anxiety (Morgan et al., 2010; 2012) as well as age of onset of psychiatric 
disorders (Di Forti et al., 2014; Iseger and Bossong, 2015). In a study of patients with 
Parkinson’s disease, CBD improved psychosis scores and did not alter motor function 
(Zuardi et al., 2008). In a clinical trial of CBD versus a conventional antipsychotic, CBD 
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was as effective as the conventional medication in improving symptoms of schizophrenia 
and displayed less side effects (Leweke et al., 2012). Additionally, CBD supplementation 
was reported to attenuate the cortisol decrease associated with the circadian rhythm of the 
hormone in humans (Appiah-Kusi et al., 2020; Zuardi et al., 1993), which may also 
contribute to anxiolytic effects outside of its effects on cognition. Despite these 
promising clinical trials, larger scale, long-term, placebo-controlled studies still need to 
be conducted in the future, especially considering CBD has been proposed for use in 
psychiatric issues that have not been investigated, like depression or post-traumatic stress 
disorder 
Sedative 
 The ECS has been implicated in the regulation of the circadian sleep–wake cycle 
(Sanford et al., 2008; Vaughn et al., 2010) and has been suggested to be the link between 
the superchiasmatic nucleus – which regulates circadian regulation systems – and 
associated behavioral and physiological processes like sleep (Babson et al., 2017). 
Considering approximately 10% of adults suffer from chronic insomnia and the resulting 
decrease in productivity (Kuhathasan et al., 2019), the potential sedative effect of CBD 
may be a therapeutic benefit if shown to aid in treatment of sleep disorders through its 
actions on the ECS. 
 The primary mechanism by which CBD is thought to exert a sedative effect is 
through inhibition of AEA transport and breakdown. Cannabidiol is thought to indirectly 
enhance AEA signaling through both the inhibition of AEA uptake via anandamide 
membrane transporters and prevention of AEA degradation via FAAH inhibition 
(Bisogno et al., 2001; Rakhshan et al., 2000; Leweke et al, 2012). Anandamide is thought 
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to promote sleep through both action on the CB1 receptor and an increase in adenosine, 
which is a sleep-inducing molecule (Murillo-Rodriguez, 2008; Murillo-Rodriguez et al., 
2003; 2016). Thus, the delayed transport and degradation of AEA may result in a sedative 
effect of CBD indirectly by elevating AEA levels in the brain. 
Cannabidiol has been shown to have differential effects on sedation and sleep – 
larger doses exerting sedative effects and low doses increasing wakefulness. In humans 
and rats, CBD doses ranging from 2 to 40 mg/kg BW/d have been reported to induce 
sedative effects, improve sleep quality, and increase total sleep time (Chagas et al., 2013; 
Hsiao et al., 2012; Zuardi et al., 1993). In 15 patients with insomnia, 160 mg CBD/d 
increased total sleep time and decreased the frequency of arousals during the night, 
(Carlini and Cunha, 1981), and a long-term study assessing the effect of CBD on sleep 
quality in adults found a modest improvement in sleep (Shannon et al., 2019). However, 
some work has demonstrated no influence of CBD on the sleep cycle in humans (Linares 
et al., 2018), and others report that CBD promotes alertness and wakefulness rather than 
sedation. Nicholson et al. (2004) reported that 15 mg CBD increased wakefulness of 
young adults during sleeping time, and increased alertness has been observed in rats 
following CBD administration (Murillo-Rodríguez et al., 2006; 2008; 2014). These 
discrepancies may be due to differences in length of CBD supplementation, small sample 
sizes, route of administration, vehicle used, CBD dose, combination of CBD with other 
cannabinoids, or subject species. Based on the numerous conflicting reports on the 
potential sedative or wakefulness effects of CBD, it is clear that additional research is 
needed in the area of CBD use for sleep disorders.  
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Bioavailability, Pharmacokinetics, and Metabolism of Cannabidiol 
 Compared to intravenous or inhalation administration, the bioavailability of oral 
CBD by itself is low, ranging from 5% to 19% due to factors such as low absorption rate 
and extensive first-pass metabolism in the liver (Lim et al., 2020; Samara et al., 1988). 
Variable increases in bioavailability of oral CBD have been demonstrated when 
administered in lipid formulations, such as infused in oil, encapsulated, or formulated 
into a chew or treat (Atsmon et al., 2018; Bartner et al., 2018; Deabold et al., 2019). 
Administering CBD with a fat meal may also contribute to increased bioavailability by 
increasing bile release while slowing gastric emptying and gastrointestinal motility, 
which increases the time available for CBD dissolution and absorption (Lim et al., 2020; 
Welling, 1996). The increase in oral bioavailability when combined with lipids may also 
be a result of intestinal lymphatic absorption and transport. A study in rats demonstrated 
an almost 3-fold increase in the bioavailability of oral CBD when administered in a lipid-
based formulation compared to a lipid-free vehicle (Zgair et al., 2016).  
Pharmacokinetic data from oral CBD administration suggests, in both human and 
canine models, that the half-life of elimination (t1/2) ranges from 1 to 4 hours while the 
maximal concentration (Cmax) and area under the curve (AUC) vary considerably 
depending on the dose and whether the CBD was administered with food (Bartner et al., 
2018; Deabold et al., 2019; Gamble et al., 2018; Hobbs et al., 2020; Millar et al., 2018). 
Major elimination pathways of CBD may include both urinary excretion and fecal 
excretion via biliary secretion. In dogs, unmetabolized CBD is the predominant 
compound excreted within the first several hours after administration (Samara et al., 
1990a). Once absorbed, CBD undergoes extensive metabolism in the liver by various 
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cytochrome P450 enzymes, involving hydroxylation, oxidation, side-chain degradation, 
and conjugation (Jiang et al., 2011; Samara et al., 1990a). Metabolites produced during 
these processes differ considerably between species. In humans, major routes of 
transformation include 7-hydroxylation, oxidation of C9 to the alcohol and carboxylic 
acid, and side-chain oxidation (Harvey et al., 1991a, b; Huestis, 2007). In mice and rats, 
hydroxylation at C2 is a major route of biotransformation alongside acid products of 
beta-oxidation (Harvey et al., 1991b; Samara et al., 1991). In dogs, 6β-hydroxylation and 
oxidation of resulting alcohol is the dominant oxidative pathway compared to the 7-
hydroxylation in humans. Additionally, side-chain hydroxylation is less extensive in dogs 
than in humans (Samara et al., 1990b). Canine and human CBD metabolite production is 
similar in the production of glucoside conjugates, like 6-oxo CBD, while similar 
conjugates are not found in rat urine (Harvey et al., 1991a; Samara et al., 1990a). Rats 
and dogs are similar in the production of acids via beta-oxidation whereas acids formed 
in humans are primarily derived from side-chain degradation and 3” hydroxylation 
(Harvey et al., 1991a).  
Cannabidiol Use in Dogs 
Cannabidiol is currently supplemented to dogs for its potential therapeutic 
applications including osteoarthritis, separation anxiety, noise phobias, and epilepsy 
(Kogan et al., 2018; Landa et al., 2016). Several studies have evaluated its effectiveness 
in dogs with osteoarthritis (Brioschi et al., 2020; Gamble et al, 2018; Verrico et al., 
2020), behavior (Corsetti et al., 2021) and epilepsy (McGrath et al., 2019) with mixed 
results. Considerable work has also been done investigating pharmacokinetics (Bartner et 
al., 2018; Deabold et al., 2019; Gamble et al., 2018; Wakshlag et al., 2020) of oral CBD 
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administration. However, there is still limited in vivo work in canine models evaluating 
long-term safety of CBD supplementation and its efficacy in generating these beneficial 
effects.  
A preliminary investigation of the safety of escalating CBD doses in 20 healthy 
dogs reported mild constitutional adverse events recorded for dogs receiving 1.7-64.7 
mg/kg CBD oil, which included both lethargy and hyperesthesia (Vaughn et al., 2020). A 
similar investigation into the safety of a 1:20 THC:CBD herbal extract reported mild 
neurological adverse events, like ataxia and delayed hopping, after single and multiple 
oral doses of 2 and 5 mg/kg CBD extract (Chicoine et al., 2020). While adverse events in 
both studies were mild and rare, they do highlight the potential for CBD to cause 
undesirable side effects as well as the need for continuing research evaluating the safety 
and efficacy of CBD use in dogs.  
The literature available evaluating the therapeutic potential of CBD in dogs is 
sparce. Work in osteoarthritic dogs has focused primarily on the subjective evaluation of 
CBD’s effects by owners or veterinarians, with little quantitative data to support its use. 
In those studies, administration of either oral or transmucosal CBD oil at 2 mg/kg 
increased canine brief pain inventory (CBPI) and Hudson scores in dogs with 
osteoarthritis (Brioschi et al., 2020; Gamble et al., 2018), suggesting an increase in 
activity and comfort with CBD use. Before this work, only one other study evaluated 
behavioral effects of CBD, in which the effect of a CBD-predominant hemp extract on 
aggressive behaviors was assessed in shelter dogs. Authors reported a reduction in 
aggressive behaviors in dogs towards humans after treatment but no differences between 
CBD and placebo, suggesting acclimation of animals to humans and the environment 
31 
rather than a result of CBD (Corsetti et al., 2021). McGrath et al. (2019) reports the first 
randomized, blinded clinical trial assessing the addition of CBD to conventional 
antiepileptic treatment in dogs with epilepsy. Treatment with 2.5 mg CBD/kg reduced 
seizure frequency compared to placebo, but the proportion of responders to treatment was 
similar between groups. Lastly, an in vitro model of canine atopic dermatitis, a primary 
cause of pruritus in dogs, demonstrated the potential for a combination of CBD and 
polyphenols to modulate transcription of inflammatory genes related to atopic dermatitis 
(Massimini et al., 2021). 
Despite this lack of scientific evidence, use of CBD by dog owners is gaining in 
popularity due to the possibility of therapeutic benefits. Some owners have turned to 
hemp products because it is from a natural source versus conventional medications while 
others believe hemp products to be better at managing specific symptoms than 
conventional medicine (Wallace et al., 2020). Kogan et al. (2016; 2018) reported that of 
dog owners who gave hemp products to their pets, most said they perceived the products 
to be helpful in the reduction of symptoms associated with pain, anxiety, nausea and 
vomiting, noise phobias, and more. A survey of Canadian dog owners reported that 
owners generally perceived the cannabis products to be equally or more effective than 
conventional medications for similar issues (Kogan et al., 2019b). Veterinarians, on the 
other hand, are more hesitant to use or recommend hemp products. While the majority of 
veterinarians and veterinary students responding to surveys report their hesitancy is due 
to awareness of the lack of research, they still expressed positive views on the potential 
benefit of the use of hemp products in animals and overwhelmingly supported continued 
research in animals (Kogan et al., 2019a; Vogt et al., 2019). 
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Conclusions 
 Despite centuries of cannabis use and favorable public opinion of CBD use for a 
variety of ailments, there is limited evidence of safety or efficacy of CBD in both humans 
and companion animals. While investigations into CBD effects have increased since its 
removal from the CSA in 2018, evidence supporting its use is largely limited to in vitro 
work, rodent models, or under-powered clinical trials. Regardless of desired effect, more 
research is necessary to clarify safety of use, proper dosing, and which, if any, actions of 
CBD have physiological relevance in dogs.  
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CHAPTER 3. PALATABILITY OF CANNABIDIOL-CONTAINING DOG TREATS 
Introduction 
 Palatability is the capacity of a food or ingredient to stimulate the appetite to 
encourage eating and satiety. It is dependent on several factors, including formulation of 
ingredients, processing method, texture, and the freshness and stability of raw materials 
(Aldrich and Koppel, 2015). Additionally, palatability can be difficult to quantify as it is 
individually perceived and therefore highly subjective (Tobie et al., 2015). Despite the 
difficulty, assessment of food palatability is essential in the development of any new 
product. It does not matter how well a product is formulated if animals will not consume 
it.  
In the case of CBD, there are reports of human oromucosal sprays like Sativex® 
having an unpleasant taste (Lus et al., 2018). However, there is no literature available 
regarding the palatability of CBD-containing canine products like treats nor their 
potential effect on daily diet consumption. Therefore, the objective of this study was to 
determine the palatability of dog treats formulated with increasing amounts of industrial 
hemp-derived CBD and to examine the potential for CBD inclusion in treats to alter daily 
food consumption. The underlying hypothesis was that inclusion of CBD in treats would 
not alter food consumption nor treat consumption compared to control. 
Materials and Methods 
This study was approved by the Lincoln Memorial University (LMU) Institutional 
Animal Care and Use Committee (IACUC) (protocol 1801-RES) before the start of the 
study. All housing and husbandry received were in accordance with the Animal Welfare 
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Act, the Guide for the Care and Use of Laboratory Animals (8th ed.), and all applicable 
LMU standard operating procedures (SOPs). 
Subjects and Housing 
Twenty-four dogs (12 male, 12 female, 16.0 ± 3.6 kg BW) were received from a 
local shelter for inclusion in this study. The shelter was asked to provide dogs weighing 
16 ± 4 kg. Additionally, the shelter was informed and gave consent for the use of the 
dogs for research purposes prior to their arrival. Prior to beginning the experiment, each 
dog had a complete blood count (CBC) and serum chemistry analysis (IDEXX 
Laboratories, Inc., Westbrook, ME) performed, along with physical evaluation by a 
veterinarian and a fecal examination to rule out any underlying disease that might 
preclude enrollment. Dogs were excluded if they demonstrated serious behavioral issues, 
such as aggression that would endanger research personnel, were severely emaciated, 
classified as a body condition score < 3.5 or > 7.5 on a 9-point scale (where 1 is 
emaciated and 9 is obese; Laflamme, 1997), or if their initial evaluations revealed an 
underlying disease that required more than routine treatments (such as heartworm 
positive dogs). Three dogs were excluded for being spayed and one dog was excluded for 
behavioral issues. Dogs were individually housed in 1.2 x 1.8 m kennels within one of 
two dog wards at the LMU DeBusk Veterinary Teaching Center (DVTC, Ewing, VA). 
Dogs were stratified by treatment and sex and evenly distributed between the two wards. 
Treatments and Diets 
 Twenty dogs were included in this study (10 male, 10 female, 16.1 ± 3.8 kg BW) 
and were stratified by weight and sex before being randomized into four treatment groups 
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(n = 5 per treatment). The treatments consisted of 0, 5, 10, or 25 mg CBD/d. The CBD 
was the primary constituent of a proprietary industrial hemp isolate (AgTech Scientific, 
Paris, KY) that was incorporated into treats and administered in the form of 1 treat twice 
daily with each treat containing half the daily dose. Treats were offered as a reward 
within 30 min of a meal upon kennel re-entry following twice daily exercise, with 
consumption scored for five days. Based on an average body weight, dogs received 
approximately 0, 0.313, 0.625, or 1.563 mg CBD/kg BW/d.   
 Dogs were fed Purina Pro Plan EN Gastroenteric Dry Dog Food (Nestle Purina, 
Inc., St. Louis, MO) during the initial measure and Purina Pro Plan EN Gastroenteric Wet 
Dog Food during the final as these foods provide a large difference in palatability of the 
basal diet. Both foods were fed to meet the daily metabolizable energy requirements of 
intact adult dogs at maintenance, calculated as (70 * BW0.75) * 1.8 and split into two 
meals per day.  
Data Collection 
 Prior to scoring treat consumption for 5 days (Treatment Period), dogs were 
adapted to each test food for 5 days (Adaptation Period). Daily intake of the basal food 
was monitored to determine if treat consumption affected food intake. The dogs were 
then adapted to the second commercial food (the canned food) for 5 days before offering 
the treatment treats for 5 days and again scoring consumption. 
 Palatability was scored based on their consumption of each treat: Rapid, Hesitant or 
No consumption. Consumption was considered “rapid” if the treat was consumed within 
5 seconds of being offered and was given a numerical score of 2 for statistical analysis. 
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Consumption was considered “hesitant” if the treat was consumed between 5-10 seconds 
of being offered, where it was then given a numerical score of 1. Lastly, “no 
consumption” was recorded if the treat was not consumed within 10 seconds of being 
offered, in which case the numerical score was 0. If the treat was not consumed within 10 
seconds, it was left in the dog’s food bowl until the next feeding. If the treat was still 
present before the next feeding, its presence was noted, and the treat was removed prior 
to receiving the next meal. Persons administering the treats were blinded as to the actual 
IHE content.  
Statistical Analysis 
Food intake and treat consumption were analyzed using the MIXED procedure in 
SAS 9.4 (SAS Institute, Cary, NC) including the fixed effects of treatment (CBD), period 
(Adaptation and Treatment), and treatment by period interaction. Food intake was 
assessed as mean intake per kg of metabolic body weight per day (g/kg BW0.75/d) over 
each 5-d period. Treat consumption was analyzed as the mean numerical treat 
consumption score (range of 0-2) over each 5-d period. Results are presented as the mean 
± SE and effects were considered significant when P ≤ 0.05. 
Results 
Food intake was unaffected by treatment when dogs were fed either dry (31.4 ± 
0.66 g/kg BW0.75/d) or wet dog food (102.9 ± 3.94 g/kg BW0.75/d; Figure 3.1; P = 0.280 
and 0.669, respectively). Similarly, food intake did not differ between adaptation and 
treatment periods for either the dry or wet foods (P = 0.968 and 0.500, respectively). 
Cannabidiol inclusion had no effect on the consumption of treats when fed either a dry or 
wet dog food (P = 0.308 and 0.571, respectively). Similarly, treat consumption did not 
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differ between adaptation and treatment periods when dogs were fed wet food (P = 
0.171). However, when fed dry dog food, treat consumption was increased during the 
Treatment period compared to the Adaptation period (Figure 3.2; P = 0.005). 
Discussion 
 During the first adaptation phase of this study, when the dogs were being adapted to 
the dry food diet, the control treats offered were a commercially available treat (Purina 
Pro Plan Gentle Snackers). During the remainder of the study, the control treats were the 
test treats prepared for the study (0 mg CBD) and were given during the Adaptation 
period. The test treats were quite different from the commercial treats in smell, texture, 
and taste and were extremely palatable. The consumption of the commercial treats during 
the dry food adaptation phase was lower than the consumption of the test treats during the 
treatment period because of the differences in the treats. There were several dogs who 
refused to eat a single commercial treat but consumed every single test treat without 
hesitation. During the second adaptation phase, when dogs were being adapted to the wet 
food diet, the test treats were offered and no difference was found between those control 
treats and the treatment treats. Additionally, as there were no differences between 
treatments, there was no apparent effect of increasing levels of CBD on the palatability of 
the treats when included at up to 25 mg CBD per day.  
 The presence of CBD in these treats also did not alter daily intake. There were no 
differences in intake on a metabolic body weight basis between the different treatments, 
or between the adaptation and treatment periods for both dry and wet food diets. Intake 
was greater when dogs were fed wet food; however, this was likely due to the increased 
intake required to meet daily dietary maintenance requirements. Wet dog foods have a 
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much lower caloric density than dry dog food because of the high-water content, and as 
such, larger amounts needed to be offered each day to meet requirements. Since intake 
did not differ between the adaptation and treatment periods while dogs were on wet 
foods, individual dog preference was potentially a more important factor affecting daily 
food intake. The majority of dogs displayed no hesitation in the consumption of their 
twice daily meals. A few of the dogs were picky eaters, and those few dogs were the 
primary source of refusals for their treatment groups during both adaptation and treatment 
periods.   
 It is worth noting, however, that all dogs exhibited loose stools when switched to 
the strictly wet food diet, regardless of treatment. The wet dog food fed was much lower 
in fiber than the dry dog food, despite being the same brand and type of food, indicating a 
much more gradual adaptation to the wet food would be needed for all dogs. There were 
no recorded reports of diarrhea while the dogs were receiving test treats during the dry 
food treatment period, and diarrhea presented during the adaptation to the wet food 
before the test treats were being administered. As such, it is unlikely that this 
gastrointestinal upset was a result of the CBD supplemented in the treatment treats. It 
does, however, reinforce that any change in diet should take place over a longer period of 
time and should involve a slow transition from one food to another. 
Conclusions 
These results suggest the palatability of CBD-containing treats is comparable to 
treats without CBD, and that the presence of CBD does not affect daily feed intake when 
supplemented up to 25 mg CBD per day. Future studies can utilize these treats to 
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examine any potential effects of CBD on various physiological processes in a canine 
model.  
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Tables and Figures 
 
Figure 3.1. Mean intake (g/kg BW0.75/d) of all animals across all treatments during each 
5-d adaptation and treatment period for both dry and wet food diets. Error bars represent 





Figure 3.2. Mean treat consumption for animals across all treatments during each 5-d 
adaptation and treatment period for both dry and wet food diets. Scores of 2, 1, or 0 were 
assigned to each treat offering based on rapid, hesitant, or no consumption of the treat. 
Asterisks above bars represent a difference in treat consumption between periods (P ≤ 
0.05). Error bars represent the standard error of the treatment mean (SEM).   
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CHAPTER 4. THE IMPACT OF FEEDING CANNABIDIOL CONTAINING TREATS 
ON CANINE RESPONSE TO A NOISE-INDUCED FEAR RESPONSE TEST 
Frontiers in Veterinary Science, 2020, 7:569565 
Introduction 
Noise aversion or reactivity is one of the most common fearful behaviors in dogs, 
with 40 to 50% of dogs demonstrating at least one fearful behavior in response to noise 
exposure (Blackwell et al., 2013; Tiira et al., 2016). There is, however, considerable 
variation in the behavioral responses to noise. Some dogs will reduce activity while 
others become hyperactive. Some behavioral changes, such as panting and hiding, are 
mild, while others, like destructiveness and self-trauma, are more extreme and potentially 
hazardous to the health and well-being of both dog and owner (Sherman and Mills, 
2008). Such extreme and detrimental stress associated with fear reduces overall health 
and lifespan (Dreschel, 2010; Dreschel and Granger, 2005).  
Despite the prevalence of noise aversion behaviors in dogs, they frequently go 
untreated with less than one-third of dog owners reporting that they would seek advice 
for the treatment of noise aversion (Blackwell et al., 2013). Potential treatment regimens 
for various noise aversion behaviors include systematic desensitization with a compact 
disk-based training system and administration of medications or natural products 
(Sherman and Mills, 2008). There are several commonly prescribed drugs for the 
treatment of canine behavior disorders associated with fear and anxiety, including but not 
limited to benzodiazepines, selective serotonin reuptake inhibitors, and tricyclic anti-
depressants (Overall, 2013; Gruen et al., 2014). However, some owners may be hesitant 
to administer such medications, whether due to the possibility of undesirable side effects, 
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personal bias against drug use, or cost. This has led to increased interest in the use of 
natural extract products to alter fearful behaviors, like dog-appeasing pheromones or oral 
supplementations such as L-theanine, a tryptic hydrolysate of milk protein and fish 
hydrolysate (Araujo et al., 2010; Landsberg et al., 2015; Mills et al., 2006; Palestrini et 
al., 2010; Sheppard and Mills, 2003). Additionally, there has been renewed interest in the 
use of cannabinoids, CBD in particular, to regulate anxiety disorders in both humans and 
companion animals (Tambaro and Bortolato, 2012). 
The potential anxiolytic effects of CBD have been attributed to several 
mechanisms, including its activation of 5-HT1A receptors and its ability to indirectly 
activate cannabinoid receptors by inhibiting the metabolism of the endocannabinoid 
anandamide (Blessing et al., 2015; Lee et al., 2011). This has produced great interest in 
using CBD as a potential alternative to conventional therapies to reduce anxiety. While 
there is considerable work examining its use as an anxiolytic in human and rodent models 
(reviewed extensively in Lee et al., 2017), this effect has yet to be examined in a canine 
model. But despite the lack of evidence, canine anxiety and noise aversion are some of 
the most common reasons that pet owners seek information on and administer CBD to 
their pets (Kogan et al., 2019a). 
The objective of this study was to evaluate the influence of CBD on behavioral 
responses to fear-inducing stimuli in dogs, with the underlying hypothesis was that CBD 
would reduce fearful and anxious responses. This hypothesis was tested using a fireworks 
model of noise-induced fear and anxiety in which the effectiveness of CBD was assessed 
by comparing CBD to both a positive and negative control and to the combination of 
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CBD with the positive control. All treatments were expected to reduce fearful and 
anxious responses compared to the negative control. 
Materials and Methods 
This study was reviewed and approved by the LMU IACUC (protocol 1811-RES) 
prior to the start of the study. All housing and husbandry received were in accordance 
with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (8th 
ed.), and all applicable LMU SOPs. 
Subjects and Housing 
Twenty-four intact, adult dogs (12 male, 12 female; 1 to 5 years old; 17.7 ± 3.9 
kg) of various mixed breeds, including cur, Labrador, hound, Boxer, shepherd, dane, 
Schipperkee, Springer Spaniel, and terrier mixes were received from a local shelter for 
inclusion in this study. The shelter was asked to provide dogs weighing 16 ± 4 kg. 
Additionally, the shelter was informed and gave consent for the use of the dogs for 
research purposes prior to their arrival. Prior to beginning the experiment, each dog had a 
CBC and serum chemistry analysis (IDEXX Laboratories, Inc., Westbrook, ME) 
performed, along with physical evaluation by a veterinarian and a fecal examination to 
rule out any underlying disease that might preclude enrollment. Dogs were excluded if 
they demonstrated serious behavioral issues, such as aggression that would endanger 
research personnel, were severely emaciated, classified as a body condition score < 3.5 or 
> 7.5 on a 9-point scale (where 1 is emaciated and 9 is obese; Laflamme, 1997), or if 
their initial evaluations revealed an underlying disease that required more than routine 
treatments (such as heartworm positive dogs). Two dogs were excluded from the 
experiment due to positive heartworm tests and 4 additional dogs were excluded due to 
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other health or behavioral concerns. Dogs were individually housed in 1.2 x 1.8 m 
kennels within one of two dog wards at the LMU DeBusk Veterinary Teaching Center. 
Dogs were stratified by sex and evenly distributed between the two wards. 
Diets and Treatments 
Dogs were fed Purina Pro Plan EN Gastroenteric Dry Dog Food (Nestle Purina 
Inc., St. Louis, MO) to meet the daily metabolizable energy requirements of intact adult 
dogs at maintenance, calculated as (70 * BW0.75) * 1.8 and split into two meals fed at 
approximately 0730 and 1830 h each day. Dogs were weighed and body condition scored 
(5-point scale) weekly and diets adjusted accordingly. Treatments were arranged in a 2 x 
2 factorial and consisted of 1) control (placebo treats), 2) 25.2 mg CBD/d, 3) Trazodone 
+ 0 mg CBD, and 4) 25.2 mg CBD/d + Trazodone. Trazodone, a serotonin antagonist and 
reuptake inhibitor, was dosed at 100 mg for dogs weighing 10.0-20.0 kg and at 200 mg 
for dogs weighing 20.1-40 kg as recommended by the veterinarian and based on previous 
work (Jay et al., 2013). Because trazodone does not require an extensive adaptation 
period, trazodone tablets were dosed via a Pill Pocket (Mars Petcare US, Franklin, TN) 
the evening prior and morning of the behavioral assessment.  
The CBD was the primary constituent of a proprietary industrial hemp isolate 
(AgTech Scientific, Paris, KY) that was incorporated into treats and administered in the 
form of 2 treats daily, with each treat containing half the daily dose. Groups not receiving 
CBD treatment received control treats (0 mg CBD). Both control and CBD treats were 
composed of the following ingredients: chicken, chicken liver, Asian carp, catfish, and in 
the case of the CBD treats, industrial hemp extract. Dosage of CBD was selected based 
on previous work utilizing oral CBD in dogs (Gamble et al., 2018). CBD was the primary 
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constituent of the industrial hemp extract (12.6 ± 1.2 mg/treat); no other cannabinoids 
were detected in the treats. Treats were formulated to target CBD at 2 mg/kg BW/d based 
on an estimation that dogs would weigh an average of 16 kg. However, based on the 
mean weight of dogs included on the study, actual dosage of CBD was 1.4 mg/kg BW/d.  
Treats were offered solely as a reward upon kennel re-entry following twice daily 
exercise at approximately 0700 and 1800 h each day. Trazodone tablets hidden in Pill 
Pockets were administered at approximately 1830 h the evening before and 1000 h the 
morning of each noise-induced fear response test. Empty Pill Pockets were administered 
to the control and CBD treatment groups on those days to ensure that research personnel 
administering the treats were blinded as to the treatments administered. 
Testing Room and Equipment 
The testing room was an approximately 2.72 x 3.38 m isolation room located on 
the opposite side of the building relative to where dogs were housed. The room contained 
a wall-mounted table and cabinets, a set of closed metal kennels, and a cloth dog bed. 
The dogs could interact with these objects, but none obstructed the dogs from view of the 
cameras. Two recording cameras (Model BRC-Z700, Sony Co., New York, NY and 
Model B07DQPS3KY, QallExpress International, China) were secured on opposite sides 
of the room near the ceiling – approximately 2 m from the floor – to ensure the dogs 
would be within sight at all times. Dogs were isolated in the testing room; handlers 
monitored the dogs from the adjacent room via the cameras and could not be seen by 
dogs. Two Bluetooth speakers (Bose Co., Framingham, MA) were placed on opposite 
sides of the room near the cameras to create a surround-sound effect during the noise 
tests. Between each dog’s test, the room was cleaned with Rescue™ Concentrate (Virox 
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Animal Health, Oakville, ON, Canada), an accelerated hydrogen peroxide-based 
disinfectant. 
Acclimation 
After intake and entrance into the study, all dogs were adapted to their 
environment, diet, daily routine, and the testing room for 3 d (Table 4.1), in which the 
dogs spent 6 minutes in the testing room where behavior was monitored, but not scored. 
A baseline open field test followed the 3-d adaptation, where dogs were placed in the 
testing room, behavior was scored, but no noise track was played (described below). The 
next day, a 6-min baseline fireworks test was conducted (described below). Both the open 
field test and baseline fireworks test were used solely to select dogs for inclusion in the 
study. Dogs not exhibiting at least one behavioral change between the open field test and 
the fireworks test, behaviors such as cowering, shaking, vocalization, destructiveness, or 
tail tucking, were excluded from the study. Dogs included in the study spent 6 min in the 
test room every day throughout the experiment to eliminate the possibility of behavioral 
changes due to the novel environment of the test room. In order to acclimate dogs to the 
testing procedure, heart rate monitors bands were placed on the dogs for each adaptation 
to the test room. Additionally, blood draws were simulated on non-testing days by 
restraining dogs and holding off cephalic and jugular veins prior to placing them in the 
testing room.  The fireworks test was conducted on the last day of each 7-d period (Table 
4.1).  
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Open Field and Fireworks Tests 
A fireworks model of noise-induced fear and anxiety was utilized to assess the 
effectiveness of the treatments. All dogs received from the shelter (n = 24) received 1 
open field test and 1 baseline fireworks test. All dogs included on the study (n = 16) also 
received 1 fireworks test per 7-d period (5 total fireworks tests), each lasting 6 min. 
During the open field test, the dogs were placed in the testing room and their behavior 
was recorded in two 3-min blocks where no fireworks track was played in order to assess 
baseline behavior of dogs in the testing room. During the fireworks tests, the first 3-min 
block was the same as the open field test where no noise was played (Pre-Noise), and the 
fireworks track was played over a stereo speaker system (mean) during the second 3-min 
block (Noise).  
In previous work using this model, a thunderstorm track was utilized to test the 
noise-induced fear response in dogs (Araujo et al., 2013; Landsberg et al., 2015). 
However, a fireworks video (https://www.youtube.com/watch?v=5eLcHJLDlI8) was 
used according to Blackwell et al. (2013) that reported a larger percentage of dogs 
respond to fireworks than to thunderstorms. This noise-induced fear response test used in 
this study was a modified version of the one developed and validated by Araujo et al. 
(2013). They utilized a 9-min test that included a “before,” “during,” and “after” 
thunderstorm time points. Because they saw no behavioral differences (i.e. near door 
duration, inactivity duration) between the “during” and “after” thunder time points, the 
test for this study was shortened to 6 min, ending immediately after the fireworks track 
(Noise time point) ended. This allowed for the immediate post-test blood sample 
collection to be obtained more quickly after the fireworks test. The mean of 90 dB was 
49 
selected based on previous work (Araujo et al., 2013; Landsberg et al., 2015) that were 
both successful in generating a response using equal or lesser decibel thunderstorm track. 
Behaviors in each 3-min time block were recorded and analyzed as separate time points 
(Pre-Noise and Noise). 
Experimental Design 
Sixteen dogs were included in this study (7 male, 9 female; 1 to 4 years old, mean 
BW 18.1 ± 0.2 kg). Dogs were selected based on their behavioral response to the baseline 
noise-induced fear test (described above), in which behaviors such as cowering, shaking, 
vocalization, destructiveness, and tucking tail upon the start of the fireworks track 
indicated the dog was reactive to noise. These behaviors were selected as they have been 
previously used to assess noise reactivity (Franzini de Souza et al., 2017; Landsberg et 
al., 2015; Sheppard and Mills, 2003). Included dogs were then arranged in a multiple 
square, replicated 4 x 4 Latin Square design in which dogs within each square (4 dogs per 
square) were randomly assigned to receive one of the four treatments each week (Periods 
1 – 4). Each square was tested on successive days for scheduling purposes. Dogs received 
each treatment for a 7-d period prior to each of the noise-induced fear response tests 
(Table 4.1).   
On testing days, all experimental procedures started at 1200 h. CBD treats were 
administered approximately 4 to 6 hours prior to the test, and the morning dose of 
trazodone was administered approximately 2 to 4 hours prior to the test. At the time of 
the completion of this study (July 2018), there was little literature available on the 
pharmacokinetics of oral CBD administration. Samara et al. (1988) reported that the half-
life of IV CBD administration was 6 to 9 hours but had no estimate for an oral dose. For a 
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similar dose of trazodone, Jay et al. (2013) reported a mean half-life of elimination of 166 
min. No washout period was included between treatment periods. From the reported half-
lives of both CBD and trazodone, it was decided that the 7-d treatment period would be 
sufficient to allow for elimination of previous treatments prior to the next test while also 
allowing for acclimation to the next treatment. Additionally, time constraints on the 
availability of the kennels in which the dogs were housed prevented the inclusion of 
washout periods. Dogs received the test at the same time each week. 
Because of scheduling constraints, the test started as soon as the dogs entered the 
testing room on testing days. This did not allow for either HRV or behavior to return to 
normal after movement from kennel to testing room. To account for this, only data from 
the last minute of the Pre-Noise time point was utilized to represent the behavior and 
HRV of dogs during that time point, which served as a reference of their normal behavior 
prior to the fireworks track starting. Additionally, only the first minute of the Noise time 
point was utilized to represent the dogs’ behavior and HRV during that time point in 
order to assess the dogs’ initial reaction to the fireworks track. 
Data Collection 
Consumption of food and treats, consistency of stool, frequency of elimination, 
activity during exercise, mucus membrane color, and other indicators of general health 
status were monitored twice daily by research personnel. Evidence of any adverse event – 
defined as any symptom occurrence that would not be expected in normal dogs – was 
also monitored. However, no adverse events were observed in any dogs following the 
administration of CBD treats during this study. 
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On the day of each fireworks test, blood samples (5 mL) were collected via 
jugular or cephalic venipuncture 1 h prior to testing, immediately after testing (5-10 min 
after cessation of noise exposure), and again 1 h post testing for cortisol analysis. Blood 
samples were collected into EDTA plasma tubes, centrifuged at 1645 x g, and stored at -
80°C for later analysis. Plasma samples were analyzed in duplicate for cortisol using a 
commercial radioimmunoassay kit (MP Biomedicals, LLC, Solon, OH). The sensitivity 
reported for the radioimmunoassay was 1.7 ng/mL, and the intra- and inter-assay 
coefficients of variation were 5.3-8.9% and 7.5-9.3%, respectively.  
Polar H10 (Polar Electro Inc., Bethpage, NY) heart rate sensors were used for the 
collection of heart rate (HR) and heart rate variability (HRV) parameters via Bluetooth 
connection to an iPhone app (Heart Rate Variability Logger, Marco Altini). Parameters 
measured are defined in Table 4.2. In general, HR will increase and HRV will decrease in 
response to stressful stimuli as a result of an increase in sympathetic nervous system 
activity (Kim et al., 2018). Thus, an effective treatment would be expected to decrease 
HR and increase HRV, indicating higher parasympathetic activity. Just prior to the open 
field and fireworks tests, the heart rate monitor bands were placed around the chest of the 
dogs immediately behind the front legs, with the rubberized surface placed ventrally 
immediately behind the left front leg. Electrode gel was applied liberally to the 
rubberized surface of the transmitter band to promote conductivity. Due to all dogs 
having short hair and the use of electrode gel, dogs did not have to be shaved to promote 
conductivity.  
Two cameras mounted approximately 2 m from the floor on opposite corners of 
the testing room continuously recorded all video and audio data for each test. The 
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duration of behaviors given in Table 4.3 were logged by a single trained observer who 
was blinded to treatments using The Observer XT software (Noldus Information 
Technology Inc., Leesburg, VA). Three of the dogs included on the study had docked 
tails, and as such had no data on tail posture. The behaviors assessed were selected based 
on behavioral measures used in previous work evaluating canine anxiety and fear 
(Dreschel and Granger, 2005; Franzini de Souza et al., 2017; Korpivaara et al., 2017). 
Based on these previous studies, duration of fearful behaviors such as panting, cowering, 
and tail tuck were expected to increase during the fireworks test. Thus, an effective 
treatment was expected to decrease the duration of such fearful behaviors. Behaviors in 
different behavioral categories (i.e. Movement vs. Tail Posture) were not mutually 
exclusive, whereas behaviors within a behavioral category were mutually exclusive. 
Statistical Analysis 
The normality of data distribution was tested using the UNIVARIATE procedure 
in SAS 9.4 (SAS Institute, Cary, NC) on the residual of the data. In instances where data 
did not meet normality assumptions, statistical analysis was performed on the natural 
logarithm transformation of the data. However, data were then back transformed for 
reporting purposes. The standard error of the back transformed data was calculated from 
the confidence limits of the transformed data as follows: SEM = (back-transformed upper 
limit – back-transformed lower limit)/3.92. The denominator relates to the Z-value of a 
95% confidence interval (± 1.96). Cowering, pacing, destruction, tail wagging, tail 
tucked, and all muzzle behaviors could not be analyzed due to insufficient occurrences 
that prevented data from meeting normality assumptions. With the exception of HR, 
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pNN50, and HF, parameters were not normally distributed and were analyzed using the 
natural logarithm of the data.  
Blood cortisol was then analyzed using the MIXED procedure in SAS including 
the fixed effects of CBD, trazodone, period (Weeks 1 – 4), time (-60, 0, and 60 min), the 
interaction of CBD and trazodone, and the interaction of CBD by trazodone by time. 
Random effects included square and dog nested within square and repeated effect of time. 
All behavioral and HRV data from the 1-min immediately prior to (Pre-Noise) and the 
first min of the noise-induced fear response test (Noise) were also analyzed using the 
MIXED procedure in SAS including the fixed effects of CBD, trazodone, period (Weeks 
1 – 4), time (Pre-Noise and Noise), and all accompanying interactions. Random effects 
included square and dog nested within square and repeated effect of time. Effects were 
considered significant when P ≤ 0.05 and considered a tendency when P ≤ 0.10. 
Results 
Blood Cortisol 
There was an overall effect of period on blood cortisol (P = 0.024). Blood cortisol 
was reduced in period 1 compared to both periods 3 and 4 (P = 0.003 and 0.003, 
respectively), but was similar across all other periods (P > 0.05). Blood cortisol was 
unaffected by time of collection and CBD (P = 0.189, 0.104, respectively). Similarly, 
neither the CBD x trazodone, time x CBD, time x trazodone, nor the time x CBD x 
trazodone interactions affected blood cortisol (P = 0.238 0.772, 0.667, and 0.812, 
respectively). However, trazodone lowered overall blood cortisol concentrations (Figure 
4.1; P < 0.0001). 
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Heart Rate and Heart Rate Variability 
There was a period effect on both HR and AVNN (Table 4.4; P = 0.005 and 
0.046, respectively). Heart rate in period 4 tended to be lower than in period 1 (P = 
0.075) and was lower than in periods 2 and 3 (P = 0.004 and 0.001, respectively). Heart 
rate was similar between periods 1, 2, and 3 (P > 0.05). The mean beat-to-beat intervals 
(AVNN) was increased in period 4 compared to all other periods (P = 0.021, 0.018, and 
0.030, respectively), but was similar between all other periods (P > 0.05). All other HR 
and HRV variables were unaffected by period (P > 0.05).  
With the exception of SDNN and RMSSD, HR and all other HRV variables were 
affected by the time point (Pre-Noise vs. Noise) (Table 4.4; P < 0.05). HR was lower 
during the Pre-Noise time point compared to the Noise time point (P < 0.001), while 
HRV parameters affected by time – AVNN, pNN50, LF, and HF – were all higher during 
the Pre-Noise time point than the Noise time point (P < 0.05). The LF/HF ratio tended (P 
= 0.053) to be higher in the Pre-Noise time point compared to the Noise time point.  
CBD tended to increase overall HR (Table 4.4; P = 0.093) and decreased LF 
regardless of time point (P = 0.011). All treatments reduced HF compared to control (P < 
0.05). AVNN, SDNN, RMSSD, and pNN50 were unaltered by CBD and trazodone (P < 
0.05). No HRV variables were affected by the CBD by time nor the trazodone by time 
interaction (P > 0.05).  The CBD by trazodone by time interaction influenced the LF/HF 
ratio (P = 0.039). During the Pre-Noise time point, trazodone tended (P = 0.061) to 
increase the LF/HF ratio compared to control and increased the LF/HF ratio compared to 
the combination of CBD and trazodone (P = 0.038). During the Noise time point, the 
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combination of CBD and trazodone tended (P = 0.083) to reduce the LF/HF ratio 
compared to control.  
Behavior 
There were no period effects on any behavioral variables (Table 4.5; P > 0.05). 
With the exception of Facing Door and Tail Relaxed, all other behaviors were affected by 
time point (Pre-Noise vs. Noise; P < 0.05). During the Noise time point, duration of 
inactivity (P = 0.011), Glancing Around (P < 0.001), and Ears Moving (P < 0.001) were 
increased compared to their duration during the Pre-Noise time point. Conversely, the 
duration of Other Eyes, Ears Relaxed, Ears Erect, and Tail Stiff were reduced during the 
Noise time point compared to the Pre-Noise time point (P < 0.05). Across both time 
points, dogs fed CBD tended (P = 0.072) to spend less time focused on something in the 
room (Other Eyes). Conversely, trazodone increased overall duration of Other Eyes (P = 
0.044) and time spent with Tail Relaxed (P = 0.001), but CBD did not alter tail posture (P 
= 0.753). No behavioral variables were affected by the CBD by time nor the trazodone by 
time interaction (P > 0.05).   
These changes between the Pre-Noise and Noise time points may indicate that the 
fireworks test generated the desired fearful behavioral response. However, the behaviors 
Glancing Around and Ears Moving could be considered a normal response to hearing a 
loud noise and may not necessarily indicate a fearful response to the noise. However, 
since the common fearful behaviors measured – cowering, pacing, vocalizations, etc. – 
could not be analyzed due to insufficient occurrences, it is difficult to determine if the 
fireworks test was severe enough to generate a fearful response. 
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Discussion 
Since the passage of the Agriculture Improvement Act of 2018, which removed 
industrial hemp from the Controlled Substances Act and removed CBD from the 
Schedule I drug list, the market for industrial hemp-derived CBD has be able to expand 
considerably (Johnson, 2019). Just one year after the act passed, the market was 
estimated to be $1.2 billion and is expected to grow to over $10 billion by 2024 (Hemp 
Industry Daily, 2019). Much of this growth can be attributed to public perception of the 
supposed health benefits of CBD, including analgesic, antioxidant, anti-inflammatory, 
and anti-anxiety effects. However, despite general public opinion that CBD is a safe and 
effective treatment for these conditions, the lack of scientific clarity on the safety, dosage, 
and efficacy of CBD makes it critical for continued research in both humans and 
companion animals.  
 The present study is one of the first to describe the effect of CBD on the fear and 
anxiety response of dogs. The fear-response test was developed and validated by Araujo 
et al. (2013), in which dogs were placed in the test room for 9 min and a thunderstorm 
track was played from 3-6 min. A modified version of this test was used in the current 
study, with a fireworks track being used instead of a thunderstorm track as previous 
literature has shown a greater percentage of dogs to be fearful of fireworks than of 
thunderstorms (Blackwell et al., 2013). Additionally, because Araujo et al. (2013) saw no 
behavioral differences during the “after thunder” time period, the test for this study was 
shortened to 6 min, ending immediately after the fireworks track ended. This allowed for 
the immediate post-test blood sample collection to be obtained within 10 min of the end 
of the fireworks test.  
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 If cortisol concentrations had decreased with each subsequent period of the 
experiment, it would have been an indication that the dogs were adapting to the sound 
stimulus. While there was a period effect on cortisol, it was due to cortisol in periods 3 
and 4 being increased compared to period 1. This may indicate a heightened response to 
the sound stimulus upon repeated exposure, which suggests that the dogs were being 
conditioned to be stressed in the testing room despite being placed in the room on non-
testing days to avoid such conditioning. The potential for conditioned place aversion is a 
limitation of the crossover design used in this study. It may be beneficial in future work 
to either include washout periods or utilize a different design to reduce the number of 
tests administered to each dog to prevent this conditioning; however, the latter would 
require a larger sample size than is needed when using a Latin Square design. 
The lack of a time effect on blood cortisol concentration was also unexpected. It 
is possible that cortisol concentrations did not change because the fireworks test may not 
have produced a sufficient change in fear or stress in these dogs. However, Landsberg et 
al. (2015) demonstrated that the use of a thunderstorm noise-induced fear response test – 
also averaging 90 dB – resulted in a time-dependent change in blood cortisol, with higher 
concentrations 5 min post-test compared to 1 hour pre- and post-test samples. This time 
effect was not replicated in this study. Instead, cortisol concentrations decreased at each 
subsequent timepoint, though not enough to produce an overall effect of time. Other 
studies have also demonstrated that blood and saliva cortisol concentrations peak 
between 5 and 20 minutes after noise exposure and begin to decline as early as 30 
minutes post-exposure (Franzini de Souza et al., 2017; 2018; Hydbring-Sandberg et al., 
2004). For this study, while the blood sample taken immediately after the test was taken 
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within this window, it is possible that cortisol levels had not yet peaked after noise 
exposure. It would be beneficial in future work to take additional blood samples 
throughout the first hour after noise exposure to better show cortisol changes after noise 
exposure. Alternatively, it is also possible that the lack of time effect on cortisol may 
have been due to elevated initial stress due to the use of shelter animals. Franzini de 
Souza et al. (2017) demonstrated differences in endocrine and behavioral responses 
between laboratory and companion dogs in response to sound stimuli. While shelter 
animals were not represented in that study, it is possible that increased stress from the 
shelter environment, transport, and new environment could impact cortisol concentrations 
and warrants further investigation.  
It is also possible that the time of testing influenced cortisol concentrations. 
Kolevská et al. (2003) showed that dogs not undergoing an exercise regimen had the 
highest blood cortisol concentrations between 1000 h and 1300 h and the lowest 
concentrations between 1600 h and 1900 h. A similar pattern was seen in this experiment, 
with the highest cortisol concentrations at the 60-min pre-test sample, which would have 
been taken between 1200 h and 1400 h, and the lowest concentrations at the 60-min post-
test sample period, which would have been taken between 1400 h and 1600 h. While 
blood cortisol concentrations in samples taken from 1300 h to 1600 h were lower than 
those taken between 1000 h and 1300 h (Kolevská et al., 2003), that effect was not seen 
in this study. This could indicate that the noise-induced fear response test did in fact 
affect blood cortisol concentrations, maintaining the elevated levels through the afternoon 
rather than the normal drop expected from the circadian rhythm of the hormone. These 
results warrant further investigation, and future work should consider administering the 
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noise test earlier in the day to account for possible influence of the circadian rhythm of 
cortisol. 
 In humans, trazodone has been shown to decrease plasma cortisol concentrations 
compared with placebo and is commonly prescribed for the treatment of anxiety, 
depression, and to facilitate sleep (Gruen et al., 2014; Monteleone, 1991). While 
trazodone is not currently labeled for use in dogs, off-label use of trazodone is common 
for the treatment of anxiety disorders as well as to reduce the agitation and distress 
associated with post-surgery confinement and reduced exercise (Chea and Giorgi, 2017; 
Gruen and Sherman, 2008). In this experiment, treatment with trazodone lowered blood 
cortisol concentrations compared to all other treatments. On the other hand, CBD did not 
alter plasma cortisol concentrations compared to control in this experiment. In humans, 
CBD administration has been shown to attenuate the cortisol decrease associated with the 
circadian rhythm of the hormone (Appiah-Kusi et al., 2020; Zuardi et al., 1993). While 
other anxiolytic supplements seem to reduce anxiety in dogs at least in part by reducing 
the cortisol response to stressors (Landsberg et al., 2015), the results of this study may 
suggest that CBD does not exert an anti-anxiety effect by lowering blood cortisol 
concentrations. However, Hurd et al. (2019) demonstrated a decrease in salivary cortisol 
when CBD was dosed to humans at ~5 and 10 mg/kg BW, which may indicate that the 
CBD dosage selected for this study (1.4 mg/kg BW) was too low to exert an effect on 
cortisol.  
Another possibility is that CBD was administered too early the day of the 
fireworks test. Recent work with other oral CBD products with similar dosages to this 
study demonstrated the time of maximum CBD concentration to be around 1.5 hours after 
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administration and the half-life of elimination to be between 1 and 4 hours (Bartner et al., 
2018; Deabold et al., 2019; Gamble et al., 2018). However, at the time this study was 
completed (July 2018), these works on CBD pharmacokinetics had not yet been 
published, and earlier literature (Samara et al., 1988) reported much longer half-life for 
IV administration of CBD. This resulted in CBD treats being administered between 4 and 
6 hours prior to the test in this study. In the future, it may be necessary to administer 
treatments within 2 hours of the noise test in order for CBD to have the greatest effect. 
This was accounted for in the administration of trazodone, as Jay et al. (2013) reported 
that the same dose of oral trazodone had a mean half-life of 166 min in dogs.  
 Even if CBD was administered too early to exert an anxiolytic effect, CBD did 
appear to inhibit the ability of trazodone to lower blood cortisol in the combination 
treatment compared with trazodone alone. This observation may support previous work 
that shows CBD to be a potent inhibitor of the cytochrome P450 family of enzymes, 
which is responsible for the metabolism of trazodone to its active metabolite, m-
chlorophenylpiperazine, in the liver (Rotzinger et al., 1998; Yamaori et al., 2011). 
Several studies have highlighted these potential CBD-drug interactions as well as the lack 
of information regarding CBD doses that can be deemed safe for use – whether 
administered alone or in combination with other medications (Ewing et al., 2019; Foster 
et al., 2019; Iffland and Grotenhermen, 2017; Zendulka et al., 2016). The potential 
interaction between CBD and trazodone demonstrated in this study lends support to these 
concerns. While there has been some work investigating specific CBD-drug interactions 
(Manini et al., 2015), it may be inadvisable to administer CBD concomitantly with other 
products or medications until these interactions are more fully elucidated.  
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 In agreement with previous work in both dogs and other species, oral CBD 
administration in this experiment was well-tolerated. No gastrointestinal or constitutional 
adverse events were observed in dogs receiving CBD during this study. Additionally, 
food consumption and body weight remained consistent throughout the experiment. 
However, other studies evaluating the safety of oral CBD administration in dogs have 
reported the potential for adverse events, including lethargy, gastrointestinal issues such 
as vomiting or diarrhea, and hematological changes such as increases in liver enzymes 
(Deabold et al., 2019; Gamble et al., 2018; McGrath et al., 2018; Vaughn et al., 2020). 
However, aside from initial bloodwork evaluated upon animal intake from the shelter, 
hematological changes were not evaluated during this experiment. As increases in liver 
enzymes may be indicative of altered liver function, the potential effects of oral CBD 
administration on clinical chemistry parameters should be monitored in future work.  
 Heart rate variability has been used as a measure of stress and anxiety in a number 
of animal species, including dogs. In particular, considerable work has been done using 
HRV as an indicator of canine fear and anxiety in response to stressful stimuli, in which 
HRV generally decreases and HR increases when animals are under stress, indicating 
impaired parasympathetic function and autonomic nervous system dysregulation (Craig 
et al., 2017; Gácsi et al., 2013; Wormald et al., 2017). The results of this study concur, 
showing increased HR and decreased HRV – AVNN, pNN50, LF, and HF – during the 
fireworks stimulus compared to the Pre-Noise time point when no sound was played. As 
AVNN represents the interval between heart beats, the decrease in AVNN was expected 
alongside the increase in HR during the fireworks stimulus. The pNN50 is thought to 
relate to parasympathetic activity and was also expected to decrease with increased stress 
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from the fireworks stimulus (Kim et al., 2018; Shaffer and Ginsberg, 2017). The low 
frequency band (LF) mainly reflects baroreceptor activity in the heart while at rest, but 
can be generated by parasympathetic, sympathetic, or baroreceptor activity depending on 
the situation. Unlike other HRV parameters, the LF band is expected to increase with 
stress as an increase in baroreceptor activity would be expected to accompany a rise in 
blood pressure (Kim et al., 2018; McCraty and Shaffer; 2015). This was not replicated in 
this study, where LF actually decreased during the fireworks stimuli. The high frequency 
band (HF), or respiratory band, corresponds to heart rate variations related to the 
respiratory cycle. Unlike LF, HF only reflects parasympathetic activity, and lower HF is 
correlated with stress and anxiety (Grossman and Taylor, 2007; Thayer et al., 2010). 
Because LF can be influenced by both sympathetic and parasympathetic activity while 
HF is only produced by parasympathetic activity, the LF/HF ratio has been used as a way 
to estimate sympathetic versus parasympathetic activity (Shaffer et al., 2014). An 
increased LF/HF ratio is thought to indicate higher sympathetic drive, which would be 
expected when exposed to stressful stimuli and has been demonstrated in dogs exposed to 
sound stimuli (Franzini de Souza et al., 2017; 2018; Maccariello et al., 2018). In this 
study, however, the LF/HF ratio tended to be reduced during the fireworks track 
compared to the Pre-Noise time point. This, combined with the reduction in LF, may 
indicate that the fireworks track was not sufficient to cause a fearful or stress response. 
Additionally, the fireworks tract did not alter SDNN nor RMSSD in this study. 
The standard deviation of interbeat-intervals (SDNN) measures how interbeat-intervals 
change over time and has been shown to be reduced by stress (Kim et al., 2018; Schaffer 
and Ginsberg, 2017). As such, SDNN is generally measured over a 24 h collection 
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period, though short-term periods have also been used to evaluate short-term variability 
(Baek et al., 2015; Katayama et al., 2016). The RMSSD reflects beat-to-beat variance and 
is used to estimate vagally mediated changes in HRV, which reflects self-regulatory 
capacity (Shaffer et al., 2014). Reduced RMSSD has been associated with smoking, high 
LDL cholesterol, and work stress in humans and has been shown to be reduced in sound-
sensitive dogs in response to sound exposure (Franzini de Souza et al., 2018; Thayer et 
al., 2010). As some of the findings of this study concur with previous work and other 
results conflict with what was expected upon exposure to fireworks, it is possible that the 
fireworks test was not successful in generating the desired fearful response. However, 
some of this conflicting evidence may be a result of the ultra-short time frame used for 
recording HRV, particularly for some variables that are more commonly measured over 
longer time periods. Future work should consider recording HRV over longer time 
frames in order to better assess changes. Only HR and AVNN were affected by the period 
of the experiment, where HR was reduced in period 4 and AVNN was increased in period 
4 compared to all other periods. This may suggest that the dogs were acclimating to the 
fireworks stimulus, a limitation to this study design. Future work should consider either 
washout periods or a study design that does not require multiple noise-induced fear 
response tests in order to avoid this problem. 
To our knowledge, no work has been done to evaluate the effect of CBD or 
trazodone administration on HRV in dogs, though there is some evidence that CBD may 
improve HRV in healthy humans (Schmid et al., 2010). Since an increase in stress and 
anxiety due to sound stimuli has been shown to increase HR, LF, and the LF/HF ratio 
while decreasing RMSSD, and HF (Franzini et al., 2017; 2018; Maccariello et al., 2018), 
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it was expected that both CBD and trazodone would attenuate these changes. In contrast 
to these expectations, both LF and HF were decreased by CBD in this study compared to 
control. Conversely, CBD tended to increase HR, while SDNN, RMSSD, and pNN50 
were unaffected by treatment. While the reduction in LF would indicate that CBD 
attenuated the increase in cardiac sympathetic modulation, the increase in HR and 
decrease in HF suggest the opposite. Trazodone, again in contradiction to expectations, 
reduced overall HF in this study, tended to increase the LF/HF ratio during the Pre-Noise 
time point, and did not affect any other HRV parameters. The combination of CBD and 
trazodone also reduced HF compared to control and tended to reduce the LF/HF ratio 
compared to all other treatments during the Noise time point when the fireworks track 
was playing. The lack of effect on other HRV parameters such as SDNN and RMSSD 
may be due to the fireworks track not producing a change in these variables rather than a 
lack of treatment effect.  These conflicting results warrant further investigation, 
particularly considering the lack of information available regarding the effects of both 
CBD and trazodone on HRV in dogs.  
 When the fireworks track started, there was a visible change in the demeanor of 
the dogs compared to both the open field test and the first 3-min block of the noise-
induced fear response tests (Pre-Noise). While this may indicate that the fireworks track 
was able to generate the desired behavioral response, it is also possible that the change in 
behavior was a result of the dogs’ interest in the noise rather than a fearful response. 
However, the considerable variability in the type of observed responses makes it difficult 
to elucidate whether the change was due to fear or if it was just a reflexive response. The 
predominant response was a decrease in activity, which may or may not have been 
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accompanied by a variety of other behaviors, such as a tucked tail, shaking, or nervous 
vocalizations like whining. These fearful behaviors would have been a better 
representation of the behavior changes due to the fireworks test as they have been used to 
evaluate such changes in other work (Franzini de Souza, 2017; 2018; Landsberg et al., 
2015; Maccariello et al., 2018). However, these behaviors occurred too infrequently in 
this study to allow for statistical analysis. This may be indicative of a lack of behavioral 
response to the fireworks test. However, as all dogs were selected for this experiment 
based on the presentation of one or more fearful behaviors during baseline testing, this 
may simply highlight the variation in behavioral responses to sound exposure. Other 
anxiolytic supplements and medications have been shown to increase activity or distance 
travelled using this model (Araujo et al., 2013; Landsberg et al., 2015); however, neither 
CBD nor trazodone treatment changed activity compared to control. This is particularly 
surprising for the treatment groups receiving trazodone, which has previously been 
shown to visibly reduce behaviors associated with a number of stressful situations 
(Gilbert-Gregory et al., 2016; Gruen and Sherman, 2008; Herron and Shreyer, 2014). 
However, several of these studies relied on owner-completed surveys rather than 
objective data to assess effectiveness.  
In contrast, CBD has been shown to reduce anxious behaviors in mouse, rat, and 
human models, but at this time there is little to no literature regarding its effect on canine 
behavior. In mouse and rat models, responses to threatening or unpleasant stimuli were 
assessed by several methods, including the elevated plus-maze, Vogel-conflict test, 
contextual fear conditioning, and elevated T maze (Campos et al., 2013; Marinho et al., 
2015; Moreira et al., 2006). The use of these models has shown that intraperitoneal 
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administration of CBD in doses ranging from 1 to 20 mg/kg produced anxiolytic effects 
with some responses being dose-dependent (Blessing et al., 2015; Lee et al., 2017). 
Though different models of anxiety were used in rodents, this may indicate that a higher 
dose is necessary to produce the desired behavioral changes associated with reduced 
stress and anxiety, particularly if dosed orally due to the considerable first-pass effect on 
CBD in the liver (Samara et al., 1988; Trevaskis et al., 2009). Future research should 
investigate the effect of higher dosage of CBD for dogs above the dose tested in this 
study. Another important consideration is the time of CBD administration prior to noise 
exposure. As previously mentioned, oral CBD has been shown to have a half-life of less 
than 4 hours (Bartner et al., 2018; Deabold et al., 2019; Gamble et al., 2018), but CBD 
treats in this experiment were dosed between 4 and 6 hours of testing. Thus, it is possible 
that the dose used in this study would be sufficient to generate an anxiolytic effect if 
dosed closer to the fireworks test. Alternatively, CBD may need to be dosed for longer 
than 7 days in order to produce anxiolytic effects. Future investigation into these 
possibilities is warranted.  
While there was no period effect on any behavioral variables, the lack of behavioral 
response to treatment could also have been due to acclimation of some of the animals to 
the firework track. While dogs were selected for inclusion into the study based on their 
reaction to the baseline noise-induced fear response test, it is possible that the weekly 
exposure to the stimulus diminished the reaction of some of the dogs during the later 
tests. This hypothesis is supported by the effect of period on other variables measured in 
this study, including plasma cortisol, HR, and AVNN. This highlights an important 
limitation of this study design, where time constraints prevented washout periods. To 
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avoid this issue in future work, dogs could be blocked by their reaction to the baseline 
test and assigned to just one treatment for the duration of the study. This would eliminate 
the need for multiple firework tests and would allow baseline and treatment tests to be 
spaced out over time but would also require a much larger sample size. However, 
considering the high level of variability in behavioral responses to the fireworks test, it 
would be difficult to ensure even distribution of dogs even with blocking. If feasible, it 
would be ideal to utilize the crossover design with longer washout periods to minimize 
the potential for acclimation to the stressful stimulus. The variability in behavioral 
responses also makes it difficult to quantify different fear responses. Several of the most 
common fearful behaviors (shaking, cowering, panting, etc.) were measured, but could 
not be analyzed due to insufficient occurrences, which may be accounted for in future 
work by aggregating such behaviors together into one behavioral category. The inclusion 
of a non-fearful control group should also be considered for future work as it would allow 
for better evaluation of changes in fearful behaviors in reactive dogs. 
Conclusions 
The results of the current study do not provide strong support of an anxiolytic 
effect of CBD in dogs when supplemented at 1.4 mg CBD/kg BW/d. Trazodone, but not 
CBD, decreased plasma cortisol concentration. When combined with trazodone, CBD 
appeared to attenuate the effects of trazodone on plasma cortisol. Cannabidiol decreased 
LF and HF, tended to increase HR, and tended to decrease duration of Other Eyes. 
Conversely, trazodone increased duration of Other Eyes, increased time spent with tail 
relaxed, reduced HF, increased the LF/HF ratio.  
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It would be beneficial in future studies to use increasing doses of CBD to clarify 
any potential anxiolytic effect, if present, and the dose necessary to elicit that effect. This 
study demonstrates the considerable variation in canine anxiety behaviors, which makes 
it difficult to accurately measure the response to treatments. It may be inadvisable to 
administer CBD concomitantly with other products or medications as the results from this 
study highlight potential drug interactions associated with CBD use.  Considering the 
increased interest of CBD use in companion animals, continued research is essential to 
understanding the mechanisms by which CBD may exert anxiolytic effects as well as 
possible risks, like drug interactions, associated with CBD administration. 
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Tables and Figures 
Table 4.1. Schedule of events. 
 
Study Day Key Event 
-7 to -6 Animal intake, physical exam, and bloodwork (CBC/serum chemistry) 
-5 to -3 Acclimation to diet, daily routine, and testing room 
-2 Open Field Test 
-1 Baseline Fireworks Test 
1 to 4 Start of treatment 1 (Squares 1 – 4 started on consecutive days) 
7 to 10 Period 1 Fireworks Test, start of treatment 2 evening after test 
14 to 17 Period 2 Fireworks Test, start of treatment 3 evening after test 
21 to 24 Period 3 Fireworks Test, start of treatment 4 evening after test 
28 to 31 Period 4 Fireworks Test  
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Table 4.2. Definition of heart rate (HR) and heart rate variability (HRV) variables. 
 
Variable Definition 
HR Heart rate, bpm 
AVNN Mean beat-to-beat intervals, ms 
SDNN Standard deviation of beat-to-beat intervals, ms 
RMSSD Square root of the mean squared difference of successive RRs or inter-beat intervals, ms 
pNN50 Percentage of successive RR intervals that differ by more than 50 ms, % 
LF Peak frequency of the low-frequency band (0.04 - 0.15 Hz) 
HF Peak frequency of the high-frequency band (0.15 - 0.40 Hz) 
LF/HF Ratio of LF-to-HF  
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Table 4.3. Ethogram of behaviors tracked by a single trained observer blinded to 
treatments using The Observer XT (Noldus Information Technology Inc., Leesburg, VA). 
 
Behavioral 
Category Behavior Definition Used 
Movement Inactive Standing still, sitting, or laying down 
 Cowering Sudden cessation of movement in response to a stimulus 
 Pacing Frantically moving back and forth, restlessness 
 Destruction Scratching or chewing at room furnishings 
Eyes Facing Door Eyes are focused on the door of the room 
 Glancing 
Around 
Eyes are shifting back and forth, possibly 
looking for the source of a sound 
 Other Eyes are focused on something else in the room 
Ears Ears Relaxed Ears are held in natural position 
 Ears Erect Ears raised in response to stimulus 
 Ears Moving Ears moving back and forth 
Tail Posture Tail Relaxed Tail is not rigid and is lower than the top of the body 
 Tail Stiff Tail is rigid and horizontal 
 Tail Wagging Tail is wagging back and forth 
 Tail Tucked Tail is tucked between hind legs 
Muzzle Barking Emitting a short, loud sound 
 Whining Emitting a long, high pitch sound, often repeated 
 Panting Mouth open wide with tongue protruding while breathing heavily 
 Licking Using the tongue on own body or another object 
 Yawning Opening the mouth wide and inhaling 




Figure 4.1. Cortisol concentration (ng/mL) for each treatment (n = 16), back transformed 
after analysis. Error bars represent the standard error of the treatment mean (SEM), which 
was calculated from the back-transformed confidence interval for each treatment: SEM = 
(upper limit – lower limit)/3.92. Due to lack of effect of time (P = 0.189) and any 
interactions with time (P > 0.05), all time points (Pre-Noise and Noise) have been 
combined. Trazodone treatment reduced overall cortisol concentration compared to 
control (P < 0.001), whereas there was no effect of CBD nor the CBD by trazodone 
interaction (P = 0.104, and 0.238, respectively). *Bars with asterisk differ from control at 
P < 0.001. 
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Table 4.4. Effect of trazodone (T), CBD (C), CBD by trazodone (C*T) interaction, time (Pre-Noise and Noise), CBD by trazodone by 
time (C*T*Time) interaction, and period on mean heart rate (HR) and heart rate variability (HRV) parameters for 1-minute 






Control Trazodone (T) CBD (C) T+C2 Trazodone CBD C*T Time C*T*Time Period 
HR, bpm 118.03 118.02 124.20 124.07 10.968 0.985 0.093 0.987 <.001 0.637 0.005 
AVNN, 
ms 555.96 539.85 539.42 517.50 25.988 0.276 0.266 0.850 0.040 0.807 0.046 
SDNN, ms 108.16 102.96 106.54 88.18 7.129 0.200 0.359 0.450 0.977 0.419 0.695 
RMSSD, 
ms 100.35 89.28 91.70 69.71 12.649 0.130 0.189 0.538 0.366 0.654 0.538 
pNN50, % 41.19 36.99 36.88 33.73 5.774 0.180 0.168 0.847 0.032 0.773 0.306 
LF, Hz 0.090 0.062 0.050 0.048 0.0071 0.188 0.011 0.315 0.010 0.273 0.533 
HF, Hz 0.142a 0.076b 0.059b 0.068b 0.0221 0.205 0.022 0.071 0.036 0.853 0.481 
LF/HF 
Ratio 0.729 0.803 0.711 0.540 0.1052 0.595 0.126 0.183 0.053 0.039 0.908 
Pre-Noise 0.651a,b 0.992a* 0.907a,b 0.607b 0.1402       
Noise 0.808a 0.615a 0.515a 0.474a* 0.1461       
1 With the exception of HR, pNN50, and HF, variables were not normally distributed and were analyzed using the natural logarithm. 
Data were back transformed for reporting purposes. In the event of a treatment by time interaction, parameters are given as their 
treatment mean within each time point (Pre-Noise and Noise). 
2Treatment T+C indicates the combination treatment of CBD and trazodone 
3The standard error (SE) of the back transformed data was calculated from the confidence limits of the transformed data as follows: 
SE = (back-transformed upper limit – back-transformed lower limit)/3.92. 
ab*Within rows, values with different letters differ at P ≤ 0.05 and asterisks indicate a trend at P < 0.10. 
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Table 4.5. Effect of trazodone (T), CBD (C), CBD by trazodone interaction (C*T), time (Pre-Noise and Noise), CBD by trazodone by 
time interaction (C*T*Time), and period on the duration of behavioral parameters (s) for 1-minute immediately prior to (Pre-Noise) 
and the first minute (Noise) of the noise-induced fear response tests administered after each 7-d treatment period. 
Variable1, s 
Treatment  P-value 
Control Trazodone (T) CBD (C) T+C2 SE3 Trazodone CBD C*T Time C*T*Time Period 
Inactive 55.35 56.33 55.21 56.26 1.214 0.329 0.918 0.971 0.011 0.092 0.993 
Facing Door 37.45 33.90 34.96 37.70 4.198 0.872 0.796 0.217 0.561 0.556 0.786 
Glancing 
Around 16.90 15.65 17.93 15.91 3.460 0.396 0.736 0.841 <.001 0.142 0.819 
Other Eyes 5.10 13.33 4.10 5.48 1.885 0.044 0.072 0.182 <.001 0.469 0.792 
Ears Relaxed 11.37 7.76 12.35 11.43 4.913 0.179 0.168 0.422 <.001 0.868 0.567 
Ears Erect 29.33 34.29 29.93 29.80 5.614 0.304 0.408 0.279 <.001 0.747 0.982 
Ears Moving 19.25 17.79 17.20 18.78 2.076 0.970 0.742 0.351 <.001 0.457 0.493 
Tail Relaxed 37.90 49.86 38.93 50.96 4.857 0.001 0.753 0.992 0.611 0.898 0.990 
Tail Stiff 18.45 5.55 16.39 6.65 4.582 0.002 0.887 0.644 0.010 0.757 0.896 
1Variables were not normally distributed and were analyzed using the natural logarithm. Data were back transformed for reporting 
purposes. 
2Treatment T+C indicates the combination treatment of CBD and trazodone 
3The standard error (SE) of the back transformed data was calculated from the confidence limits of the transformed data as follows: 
SE = (back-transformed upper limit – back-transformed lower limit)/3.92.
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CHAPTER 5. FEEDING CANNABIDIOL-CONTAINING TREATS DID NOT 
AFFECT CANINE DAILY VOLUNTARY ACTIVITY 
Frontiers in Veterinary Science, 2021, 8:645667 
Introduction 
Pet owners and caretakers are increasingly interested in monitoring their animal’s 
behavior and activity as indicators of health and well-being. While several subjective 
measures like the canine brief pain inventory and the Hudson visual analog scale are 
available for use (Brown et al., 2008; Hudson et al., 2004), the ability to measure activity 
through objective, non-invasive means such as accelerometers is a potentially preferable 
tool that can provide an impartial measure of animal activity (Dow et al., 2009; Eskander 
et al., 2020; Hansen et al., 2007; Michel and Brown, 2011). The use of accelerometers, 
kinesiology, and gait analysis are becoming popular methods by which to evaluate the 
health status of an animal as well as response to treatment. Several triaxial accelerometers 
have been validated for the measurement of canine activity and can be easily attached to 
a collar or harness for home use (den Uijl et al., 2017; Griffies et al., 2018; Preston et al., 
2012; Yam et al., 2011). They have been used to evaluate the effectiveness of treatments 
for osteoarthritis and pruritic behaviors (Brown et al., 2010; Meijia et al., 2019; Muller et 
al., 2018; Wernimont et al., 2018), the effects of exercise and rest on the voluntary 
activity of active sled dogs (Robinson et al., 2020; 2021), and to predict rest in dogs and 
sleep in humans (Clarke and Fraser, 2015; Ladha and Hoffman, 2018; Nam et al., 2016). 
 Normal activity of healthy dogs is influenced by many factors, including breed, 
age, degree of socialization, and amount of exercise (Pickup et al., 2017; Rosado et al., 
2012; Siwak et al., 2001). Additionally, canine activity may be negatively influenced by 
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factors such as disease, chronic illnesses like osteoarthritis, or behavioral issues such as 
anxiety (Brown et al., 2010; Overall et al., 2001; Tiira et al., 2016). There are also certain 
circumstances where canine activity needs to be reduced as a result of normal activity in 
high energy dogs, pruritic behaviors like scratching, or anxious behaviors like pacing and 
destruction. Activity may also need to be prevented or reduced following an illness, 
medical treatment or surgical procedure (Tiira et al., 2016; Wernimont et al., 2018). In 
such instances, many turn to medications like sedatives or antidepressants that have been 
shown to reduce canine activity (Gruen et al., 2014). However, some pet owners may be 
hesitant to use such medications due to potential side effects, cost, or personal bias 
against their use. Instead, they often investigate alternatives to conventional medications 
such as CBD (Kogan et al., 2016; 2018).  
 There has been considerable interest in the use of CBD for both humans and 
companion animals due to its reported benefits, such as analgesia, anti-inflammatory, 
anxiolytic, and sedative effects (Andre et al., 2016; Bonini et al., 2018; Huchelmann et 
al., 2017). The analgesic effect of CBD has been documented in rodent and human 
models (Costa et al., 2007; van de Donk et al., 2018; Yassin and Robinson, 2017), and 
the use of oral and transmucosal CBD oil formulations increased canine brief pain 
inventory (CBPI) and Hudson scores in dogs with osteoarthritis, suggesting an increase in 
activity and comfort with CBD use (Brioschi et al., 2020; Gamble et al., 2018). However, 
despite evidence of an anxiolytic effect of CBD in both rodents and humans with doses 
ranging from 2.5 to 10 mg/kg (Appian-Kusi et al., 2020; Campos et al., 2013; Crippa et 
al., 2011), a recent report failed to demonstrate an anxiolytic effect of treats containing 
1.4 mg CBD/kg BW in dogs exposed to a noise-induced fear response test (Morris et al., 
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2020). Other effects attributed to CBD, such as sedative effects, are thought to be 
biphasic. Larger doses have been shown to exert sedative effects in both rats and humans, 
whereas low doses of CBD may increase wakefulness (Babson et al., 2017; Chagas et al., 
2013; Nicholson et al., 2004). While the effect of CBD on sedation has not been 
specifically investigated in a canine model, a preliminary investigation of the safety of 
escalating CBD doses in 20 healthy dogs reported mild constitutional adverse events 
recorded for dogs receiving 1.7-64.7 mg/kg CBD oil, which included both lethargy and 
hyperesthesia (Vaughn et al., 2020). A similar investigation into the safety of a 1:20 
THC:CBD herbal extract reported mild neurological adverse events, like ataxia and 
delayed hopping, after single and multiple oral doses of 2 and 5 mg/kg CBD extract 
(Chicoine et al., 2020). While adverse events in both studies were mild and rare, they do 
highlight the potential for CBD to cause undesirable side effects as well as the need for 
continuing research evaluating the safety and efficacy of CBD use in dogs.  
Despite the lack of scientific evidence demonstrating the safety and efficacy of 
CBD use in dogs, a recent survey of over 1000 dog owners recruited on social media 
showed that almost 80% of owners surveyed had purchased hemp or marijuana products 
for their dogs to provide pain relief, relieve anxiety, aid with sleep, and treating other 
health conditions. Many also indicated that they believed hemp products were more 
effective than conventional medications (Kogan et al., 2016; 2018). The study population 
included owners of both healthy and diseased animals as well as owners that either had or 
had not ever purchased hemp products for their dogs; however, this is likely an over-
estimation of overall hemp use in companion animals due to the surveys being shared 
primarily within social media groups dedicated to cannabis use in pets. Nevertheless, 
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these surveys provide insight on the overwhelmingly favorable perceptions of pet owners 
on the safety and efficacy of CBD use in companion animals. Due to this interest in the 
use of CBD in companion animals, there is a critical need for further evaluation of CBD 
use in dogs and its potential effects on canine activity. Thus, the objective of the current 
study was to determine the impact of CBD on the daily activity of healthy adult dogs with 
the underlying hypothesis that CBD would reduce the overall daily activity of dogs 
compared with control. This hypothesis was tested using triaxial accelerometers to 
measure the activity of dogs receiving two levels of CBD administration compared to a 
control. 
Materials and Methods 
This study was approved by the LMU IACUC (protocol 1911-RES) prior to the 
start of the study. All housing and husbandry received were in accordance with the 
Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (8th ed.), 
and all applicable LMU SOPs. 
Subjects and Housing 
 Thirty neutered, adult dogs (15 male, 15 female, 9 months to 4 years old, 17.6 ± 
3.4 kg) of various mixed breeds, including terrier, hound, Bassett, shepherd, Border 
Collie, Husky, cur, Labrador, Boxer, and Pug mixes were received at the LMU DVTC 
from a local shelter for inclusion in this study. The shelter was asked to provide dogs 
weighing 16 ± 4 kg. Additionally, the shelter was informed and gave consent for the use 
of the dogs for research purposes before their arrival. Before beginning the experiment, 
each dog had a complete blood count (CBC) and serum chemistry analysis (IDEXX 
Laboratories, Inc., Westbrook, ME) performed, along with a physical evaluation by a 
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veterinarian and a fecal examination to rule out any underlying disease that might 
preclude enrollment. Dogs were excluded if they demonstrated serious behavioral issues, 
such as extreme fear or aggression that would endanger research personnel, were severely 
emaciated or obese, classified as a body condition score < 3.5 or > 7.5 on a 9-point scale 
(where 1 is emaciated and 9 is obese; Laflamme, 1997), or if initial evaluations revealed 
an underlying disease that required more than routine treatments, such as heartworm 
infection, metabolic or infectious disease, and mobility issues. Three dogs were excluded 
due to positive heartworm tests and another three dogs were excluded for behavioral 
concerns. The remaining 24 dogs (12 male, 12 female, 9 months to 4 years old, 18.0 ± 3.4 
kg) were selected for inclusion in the study. Dogs were individually housed in 1.2 x 1.8 
m kennels within one of two dog wards at the LMU DVTC for the duration of the study. 
Diets and Treatments 
 Dogs were fed Purina Pro Plan EN Gastroenteric Fiber Balance Dry Dog Food 
(Nestle Purina Inc., St. Louis, MO) to meet the daily metabolizable energy requirements 
of neutered adult dogs at maintenance, calculated as (70 * BW0.75) * 1.6 and split into two 
meals per day fed between 0700 and 0900 h in the morning and between 1700 and 1900 h 
in the evening each day. Dogs were weighed and body condition scored (5-point scale) 
weekly and diets adjusted accordingly. Treatments were arranged in a randomized 
complete block design and consisted of 0 (placebo treats; CON), 34.0 ± 1.16 (LOW), or 
75.6 ± 5.86 (HIGH) mg CBD/d. The CBD was the primary constituent of a proprietary 
industrial hemp isolate (AgTech Scientific, Paris, KY) that was incorporated into treats 
and administered in the form of 2 treats daily, each containing half the daily dose. Both 
control and CBD treats were composed of the following ingredients: chicken, chicken 
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liver, Asian carp, catfish, and – in the case of CBD treats – industrial hemp extract. While 
CBD was the primary constituent of the industrial hemp extract, trace ∆9-
tetrahydrocannabinol (THC) was present in both LOW and HIGH treatments (1.1 ± 0.37 
and 2.9 ± 0.22 mg THC/d, respectively). Treats were formulated to target CBD at doses 
of 2.5 and 5.0 mg/kg BW/d for LOW and HIGH treatments, respectively, based on an 
estimation that dogs would weigh an average of 16 kg. The LOW dose was selected 
based on previous literature that utilized a similar dose in dogs to assess single-dose 
pharmacokinetics of CBD and to evaluate its potential to alleviate pain in dogs with 
osteoarthritis (Gamble et al., 2018). That dose was then doubled to achieve the HIGH 
dosage. However, based on the mean BW of dogs included in the study and analysis of 
the treats, mean doses of CBD were 1.8 and 4.5 mg CBD/kg BW/d for LOW and HIGH 
treatments, respectively. Treats were offered solely as a reward upon kennel re-entry 
following twice-daily exercise, which occurred within 30 min of meals. 
Experimental Design and Data Collection 
 Upon completion of intake exams, dogs underwent a 7-d acclimation period for 
adjustment to environment, diet, collars, and daily routine (Table 5.1). Kennels were 
maintained on a 12-h light schedule. Dogs received two 15-min exercise periods each 
day, with morning exercise occurring between 0700 and 0900 h and evening exercise 
occurring between 1700 and 1900 h. During exercise periods, dogs that were aggressive 
towards other dogs were individually hand-walked by research personnel; all other dogs 
were allowed to exercise freely in playgroups of 2 – 4 dogs in one of two grassy 
enclosures. The number of dogs being hand-walked and in playgroups was balanced 
across all treatments. Four hours each day – 1000 to 1200 h (AM) and 1330 to 1530 h 
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(PM) – were designated as the time when no persons were allowed to enter the kennels. 
Two of those hours were designated as Quiet time, and the other two as Music time 
where calming classical music was played over speakers in each kennel. Quiet and Music 
sessions were randomly allotted to either AM or PM times each day. All dogs started 
receiving control treats (0 mg CBD) twice daily as a reward for kennel re-entry after the 
twice-daily exercise.  
After the acclimation period, Vetrax® activity sensors (AgLogica Holdings, 
Norcross, GA) were fitted to dogs’ collars using the attachment provided by the 
manufacturer and placed ventral to the mandible. These triaxial accelerometers were used 
for the continuous collection of activity variables – activity points, activity duration 
(min), duration of no activity (h), duration of resting (h), running duration (min), walking 
duration (min), scratching duration (s), head shaking duration (s), and sleep quality 
(Table 5.2). Data collected by the sensors was automatically uploaded to the Vetrax® 
server via Wi-Fi once an hour for behavior algorithm processing, which has been 
previously validated (Griffies et al., 2018). Except for a weekly consistent 2-3 h charging 
period, sensors remained on the dogs at all times. Before the start of the experiment, data 
were collected over a 14-d baseline period to block dogs by mean daily activity – high 
(mean 118.6 min; range 88.6-157.5 min) or low (mean 59.3 min, range 30.2-85.1 min) – 
before stratifying dogs by age, weight and sex and randomly assigning dogs within each 
block to treatments. Dogs were stratified by treatment and sex, evenly distributed 
between the two wards, and adapted to treatments for 7 d before another 14-d collection 
of activity via Vetrax® sensors (Table 5.1).  
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Consumption of food and treats, consistency of stool, frequency of elimination, 
subjective assessment of activity during exercise, mucus membrane color, and other 
indicators of general health status were monitored twice daily by research personnel. 
Evidence of any adverse event – defined as any symptom occurrence that would not be 
expected in normal dogs – was also monitored. However, no adverse events were 
observed in any dogs following the administration of CBD treats during this study. 
Statistical Analysis  
Based on variation in activity and behaviors reported in previous work using these 
sensors (Griffies et al., 2018; Wernimont et al., 2018), it was calculated that n = 8 
dogs/treatment was sufficient to detect a 25% change with a 16% CV (Berndtson, 1991). 
Activity monitors for two of the dogs in the control group (one in the high activity block 
and one in the low activity block) spontaneously stopped transmitting halfway through 
the treatment period, and activity data from the last 7 d of the experiment for those two 
dogs were lost.  
The normality of the residuals was tested using the UNIVARIATE procedure in 
SAS 9.4 (SAS Institute, Cary, NC). In instances where data did not meet normality 
assumptions, statistical analysis was performed on transformed data. However, data were 
then back-transformed for reporting purposes. The standard error of the back-transformed 
data was calculated from the confidence limits of the transformed data as follows: SEM = 
(back-transformed upper limit – back-transformed lower limit)/3.92. The denominator 
relates to the Z-value of a 95% confidence interval (± 1.96). For the baseline period, 
activity duration, running, scratching, and head shaking were not normally distributed 
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and were log-transformed for statistical analysis. Activity points and walking were not 
normally distributed and were transformed into the square root for statistical analysis.  
During the baseline period, dogs allotted to CBD treatments tended (P = 0.061) to 
run more than control; thus, the mean duration of running from the baseline period was 
utilized as a covariate for the duration of running in the treatment period. All other 
variables were similar across treatments in the baseline period. For overall daily activity 
during the treatment period, running, scratching, and head shaking were not normally 
distributed and were log-transformed for statistical analysis. For Quiet and Music session 
activity periods, all variables – except for No Activity and Resting – were not normally 
distributed and were log-transformed for statistical analysis. For exercise activity periods, 
activity points, activity duration, and scratching were not normally distributed and were 
log-transformed for statistical analysis, whereas running and head shaking were not 
normally distributed and were transformed to the cube root for statistical analysis.  
From the treatment period, overall daily activity and activity during exercise 
periods (0700-0900 h and 1700-1900 h) were analyzed using the MIXED procedure in 
SAS including the fixed effects of treatment, day, and the treatment by day interaction. 
Dog nested within activity block (high or low) was included as a random effect and day 
was included as a repeated measure with dog nested within treatment as the subject. 
Activity during the Quiet and Music sessions were analyzed using the MIXED procedure 
in SAS including the fixed effects of treatment, day, session (Quiet or Music), time of 
day (AM or PM), and all accompanying interactions. Dog nested within the activity block 
was again included as a random effect. Time (AM or PM) was included as a repeated 
measure with dog nested within treatment as the subject. Treatment effects are described 
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as the contrast between CON and both CBD treatments and the contrast between LOW 
and HIGH CBD treatments. Results are presented as the mean ± SE. Effects were 
considered significant when P ≤ 0.05 and considered a tendency when P < 0.10. 
Results 
Total Daily Activity 
 CBD did not alter total activity points, activity duration, no activity, resting, 
running, walking, head shaking, or sleep quality compared to CON (Table 5.3; P > 0.05). 
However, CBD tended to reduce scratching compared with CON (P = 0.071) but was not 
different between LOW and HIGH treatments (P = 0.209). Level of CBD inclusion 
(LOW vs. HIGH) did not affect any variables measured (P > 0.05). With the exceptions 
of activity duration, running, walking, and scratching, all variables were affected by day 
of treatment (P < 0.05), but no treatment by day interactions were observed (P > 0.05). 
Quiet and Music Session Activity 
 Overall, dogs were more active in the PM sessions than the AM, with all variables 
affected by the time of day (Table 5.4; P < 0.001). Activity points, activity duration, 
running, walking, and resting increased in the PM compared to the AM (P < 0.001) while 
the duration of No Activity decreased in the PM compared to AM (P < 0.001). During 
these sessions, the Music session tended to reduce activity points (P = 0.055) and running 
(P = 0.098) compared to the Quiet session. The Music session reduced activity duration 
(P = 0.002), walking (P < 0.001), and resting (P = 0.045) while increasing duration of no 
activity (P = 0.014) compared to the Quiet session.  
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Session by time interactions were observed for activity points, no activity, and 
resting (Table 5.4; P < 0.05), and a trend for session by time interactions was observed 
for activity duration, running, and walking (P = 0.076, 0.078, and 0.084, respectively). 
Type of session (Quiet or Music) did not alter activity points or duration of activity 
during the AM session (P = 0.502 and 0.522, respectively). When the Quiet session was 
allotted to the PM, however, activity points (P = 0.002), duration of activity (P < 0.001), 
resting (P < 0.001), running (P < 0.001), and walking (P < 0.001) were increased 
compared to when the Music session was allotted to the PM. Duration of No Activity was 
similar between Quiet and Music sessions when allotted to the AM (P = 0.230) but was 
increased in the Music session compared to the Quiet session when allotted to the PM (P 
< 0.001).  
Activity points, running, and head shaking were unaffected by treatment, and all 
treatment interactions during the Quiet and Music sessions (Table 5.4; P > 0.05). 
Scratching was reduced by CBD during Quiet and Music sessions compared to CON (P = 
0.030), but the level of CBD inclusion did not affect time spent scratching (P = 0.612).  
A treatment by time interaction was observed for No Activity and resting (Table 
5.4; P = 0.013 and 0.006, respectively) and a trend for a treatment by time interaction was 
observed for activity and walking duration (P = 0.079 and 0.060, respectively). 
Regardless of Quiet or Music session, activity duration was similar across treatments in 
the AM (P > 0.05), but dogs receiving HIGH CBD tended (1.44 ± 0.172 min; P = 0.091) 
to be less active than CON (2.64 ± 0.324 min) in the PM and tended (1.37 ± 0.162 min; P 
= 0.059) to walk less than CON (2.60 ± 0.326 min) in the PM. Similarly, duration of No 
Activity was unaffected by treatment in the AM (P > 0.05) but in the PM tended to 
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increase in the HIGH CBD treatment (1.13 ± 0.060 h) compared to both CON (0.95 ± 
0.063 h) and LOW (0.97 ± 0.060 h) treatments (P = 0.054 and 0.068, respectively). 
Conversely, resting duration increased in the LOW treatment (0.96 ± 0.051 h) compared 
to the HIGH treatment (0.80 ± 0.051 h) in the PM (P = 0.038), but was similar across all 
other time points and treatments (P > 0.05). No treatment by session nor treatment by 
session by time interactions were observed (P > 0.05) for any variables measured. All 
activity variables were affected by day of treatment period (P < 0.05), but no treatment 
by day interactions were observed (P > 0.05). 
Exercise Activity 
 Neither CBD treatment nor inclusion level affected any variables measured during 
the exercise periods (Table 5.5; P > 0.05). Day of treatment period tended (P = 0.066) to 
affect scratching and affected head shaking (P = 0.003), but no other variables were 
impacted by day of treatment (P > 0.05). Additionally, no treatment by day interactions 
were observed (P > 0.05). 
Discussion 
Triaxial accelerometer sensors were used in this study to determine the effect of 
daily CBD dosing on activity in healthy adult dogs by measuring daily activity, pruritic 
behaviors, and an assessment of rest and sleep quality. The objective of this study was to 
evaluate the impact of CBD on the daily activity of healthy adult dogs with the 
hypothesis that CBD would reduce overall daily activity compared to control. However, 
results showed that oral CBD administration did not alter the overall daily activity of 
healthy adult dogs. The lack of effect on overall daily activity and sleep quality was 
unexpected based on previous reports of sedative and hypnogenic effects of CBD in 
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rodent, human, and canine models. In humans and rats, CBD doses ranging from 
approximately 2 to 40 mg/kg BW/d have been reported to induce sedative effects, 
improve sleep quality, and increase total sleep time (Chagas et al., 2013; Carlini and 
Cunha, 1981; Zuardi et al., 1993). However, more recent work has reported CBD to have 
no influence on the sleep cycle in humans, (Linares et al., 2018) and others argue that 
CBD by itself does not produce sedative effects but rather modulates the sedative effect 
of ∆9-tetrahydrocannabinol (THC), even if THC is only present in minute amounts 
(Kesner and Lovinger, 2020; Nicholson et al., 2004; Spindle et al., 2020).  
The potential for the sedative effect of CBD to be caused by the presence of THC 
may be supported by an escalating dose study in dogs where placebo, CBD-predominant, 
THC-predominant, and CBD/THC combination oils were administered to dogs to 
evaluate the occurrence and severity of adverse events after administration (Vaughn et 
al., 2020). Doses for the CBD-predominant oil started at 1.7 mg CBD/kg BW/d and was 
incrementally increased to a maximum of 64.7 mg CBD/kg BW/d over 30 days. Lethargy 
was reported with the CBD-predominant oil formulation, however, that oil was not THC-
free; it was reported to contain 0.7 mg/mL THC (Vaughn et al., 2020). The industrial 
hemp extract included in the CBD treats used in this experiment contained similar THC 
content as the oil reported in Vaughn et al. (2020) but did not produce a similar effect. 
The reason for these conflicting results remains unclear. These differences could be due 
to the difference in animals utilized for the study – shelter vs. research-bred dogs – or the 
different modes of delivery – eating a treat versus oral gavage of an oil. There have been 
reports of variation in the pharmacokinetics of CBD depending on the mode of delivery. 
In one experiment, CBD-infused oil demonstrated increased maximum plasma CBD 
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concentration than the same dose administered as microencapsulated oil beads and a 
CBD-infused transdermal cream (Bartner et al., 2018). Other reports using similar doses 
of oral CBD oil and chews report an increased maximum plasma CBD concentration 
when administered as a chew compared to an oil; however, this has yet to be investigated 
in a single, controlled experiment (Deabold et al., 2019; Gamble et al., 2018) 
Additionally, dogs used in Vaughn et al. (2020) fasted before administration of the CBD 
oil whereas dogs in the current experiment consumed CBD treats within 30 min of a 
meal. It has been suggested that administering cannabinoids with a fat-meal increased 
bioavailability (Zgair et al., 2017). Since the CBD used in Vaughn et al. (2020) was 
mixed in a lipid-based formulation, it is unclear if these differences in methodology 
would lead to the difference in sedative effects observed between their report and the 
current study. Additional investigation using THC-free CBD is needed to evaluate the 
potential for CBD to exert a sedative effect in dogs. 
While there was no observed effect on overall daily activity with CBD treatment, 
it tended to influence activity during different times of the day. Dogs in the current study 
were more active in the PM than the AM regardless of treatment and type of session. 
Playing calming music in the kennels (Music session) did reduce activity compared to 
when no music was played (Quiet session), which supports previous work showing that 
playing music can reduce stress and increase relaxed behaviors in kenneled dogs (Amaya 
et al., 2020; Bowman et al., 2017; Engler and Bain, 2017). This effect, however, appears 
to be independent of the effect of CBD as there was no interaction between treatment and 
session nor a treatment by session by time interaction. The tendency for dogs in the 
HIGH CBD treatment to be less active than CON dogs in the PM may indicate that CBD 
89 
exerted some sedative or calming effect on the dogs. However, this potential sedative 
effect was expected to be observed in the AM as previous pharmacokinetic reports 
showed a half-life for CBD of 1-4 h (Deabold et al., 2019; Bartner et al., 2018; Gamble et 
al., 2018; Wakshlag et al., 2020). As this effect was not observed during the AM 
sessions, exercise periods, nor overall daily activity, these collective results do not 
support a sedative or calming effect of CBD in dogs. Thus, the claim that CBD exerts a 
sedative or calming effect in dogs remains unsubstantiated, but further investigation may 
provide clarification to these results.  
In the present study, dogs were necessarily regimented into a strict schedule of 
daily activities.  It is possible that in a setting where dogs were entirely free to choose 
their activities, such as a home, the outcome could have been different. The strict, 
consistent schedule of the kennel environment did not allow for much activity outside of 
scheduled exercise periods, which may have prevented normally high-energy dogs from 
being as active as they might be with consistent free access to more space. Conversely, 
shelter environments have been shown to increase activity in dogs compared to a home 
environment and may prevent dogs from resting due to increased stress (Hoffman et al., 
2019; Part et al., 2014). This may have artificially increased activity in dogs that would 
have otherwise been less active. As a result, it may be preferable to evaluate the effect of 
these treatments in familiar environments that have more space for dogs to exhibit normal 
activity and rest behaviors. Additionally, the small sample size and use of healthy adult 
dogs were limitations of this study. The dogs included in this study exhibited high 
variability in voluntary activity despite being blocked by baseline activity and having no 
known mobility or behavioral issues. These limitations may preclude extrapolation of 
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these results to other canine populations. Since CBD is often used to increase comfort 
and activity in dogs with mobility issues like osteoarthritis or to decrease the activity of 
anxious or hyperactive dogs (Kogan et al., 2018), future work should evaluate voluntary 
activity in animals with mobility or behavioral issues like osteoarthritis or anxiety.  
 Results from this study suggest a potential antipruritic effect of CBD. 
Phytocannabinoids like CBD act on the body through the endocannabinoid system (ECS), 
which is a signaling system including endocannabinoids like anandamide and 2-
arachidonylglycerol, their receptors, and regulatory enzymes (Pacher et al., 2006). The 
ECS helps regulate metabolic homeostasis, thermoregulation, epidermal homeostasis, and 
more (Avila et al., 2020; Bellocchio et al., 2008). While CBD has little to no affinity for 
CB1 and CB2 ECS receptors, it is a known agonist for the transient receptor potential 
vanilloid family of receptors (TRPV1-4), which are known ECS receptors widely 
expressed in the skin and plays a role in itch sensation (Avila et al., 2020; Bisogno et al., 
2001; Caterina and Pang, 2016; Tóth et al., 2019). As TRPV1 is rapidly desensitized after 
activation, it is thought that CBD may exert antipruritic effects by keeping TRPV1 
desensitized, thus preventing neuronal activation by irritants (Imamachi et al., 2009; 
Muller et al., 2019; Xie and Hu, 2018).  
Additionally, CBD has been shown to be an antagonist for transient receptor 
potential melastatin 8 (TRPM8) receptors (De Petrocellis et al., 2008; Muller et al., 
2019). In the skin, TRPM8 is responsible for environmental cold detection and has been 
suggested to contribute to the perception of pain and itch, which may indicate it is 
another target for the potential antipruritic effect of CBD (Caterina and Pang, 2016; 
Jankowski et al., 2017). The antipruritic effect of cannabinoids has been observed in 
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humans (Dvorak et al., 2003; Visse et al., 2017; Yuan et al., 2014), but this is the first 
report of a potential antipruritic effect of CBD in dogs as a reduction in scratching 
duration was observed in dogs. While this experiment was not designed to assess the 
antipruritic effect of CBD, these results may suggest a potential for CBD to be beneficial 
in the treatment of skin conditions and pruritic behaviors in dogs. To investigate this 
potential effect, it would be beneficial for future work to specifically examine the effect 
of CBD in dogs with skin issues such as allergies, atopic dermatitis, or unexplained 
pruritus. 
Conclusions 
 The results of the current study indicate that when supplemented with up to 4.5 
mg/kg BW/d, CBD does not impact the overall daily activity of adult dogs. Total daily 
activity including duration of the activity, sleep quality, and resting were unaffected by 
CBD. Similarly, activity during exercise periods was also unaffected by CBD. During 
Quiet and Music session periods, 4.5 mg CBD/kg BW/d tended to reduce activity in dogs 
compared to both 1.8 mg CBD/kg BW/d and CON, but this did not translate to an overall 
daily effect. Playing classical music in the kennels reduced activity compared to having 
no music played but did not alter the response to CBD. Cannabidiol reduced total daily 
scratching as well as scratching during Quiet and Music sessions, which may indicate a 
possible antipruritic effect. Future work examining the effect of CBD on activity is 
warranted, particularly in dogs with mobility and behavioral issues like osteoarthritis and 
anxiety. Additionally, the potential antipruritic effect of CBD should be investigated 
using dogs with dermatological issues like skin allergies or atopic dermatitis. 
  
92 
Tables and Figures 
Table 5.1 Schedule of events for monitoring activity in dogs receiving cannabidiol 
containing treats. 
Day of 
Study Event Data Collection Treats 
-2 and -1 Intake and initial health exams None Control 
1 to 7 Acclimation None Control 
8 to 21 Baseline Period Activity Collection Vetrax activated  Control 
22 to 28 Treatment Adaptation None Treatment 
29 to 43 Treatment Period Activity Collection Vetrax activated  Treatment 
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Table 5.2. Activity variables measured by Vetrax® activity sensors (AgLogica Holdings, 
Inc., Norcross, GA). 
Variable Definition 
Activity Points 
Total activity of dogs weighted by each individual activity (ex. 
running worth more points than walking), calculated using a 
proprietary algorithm. 
Activity, min Duration of total activity including running and walking.  
No Activity, h Duration of complete inactivity. 
Resting, h Duration of time not actively walking or running, but not completely inactive. 
Running, min Duration of running.  
Walking, min Duration of walking.  
Scratching, s Time spent scratching.  
Head Shaking, s Time spent shaking head. 
Sleep 
Scale of sleep quality measured using a proprietary algorithm 
based on absence of night-time disturbance; scaled 0-100 with 
100 being undisturbed sleep.  
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Table 5.3. Effect of treatment (TRT), day, and TRT*day interaction on total daily activity variables collected via Vetrax® activity 
sensors (AgLogica Technology, Norcross, GA). Treatment effects are shown as the contrast between control (CON) and both CBD 








1.8 mg CBD/kg 
BW/d (LOW) 
4.5 mg CBD/kg 
BW/d (HIGH) 
CON v.  
CBD 
LOW v.  
HIGH Day TRT*Day 
Activity Points 56834 57079 56634 4952.5 0.985 0.950 0.017 0.857 
Activity, min 80.1 82.7 82.0 11.90 0.882 0.966 0.421 0.773 
No Activity, h 13.6 13.9 14.3 0.58 0.496 0.652 0.002 0.394 
Resting, h 8.8 8.5 8.1 0.43 0.364 0.513 <.001 0.389 
Running, min 5.8 5.6 6.9 0.36 0.612 0.172 0.172 0.447 
Walking, min 76.2 76.5 71.8 10.94 0.878 0.760 0.531 0.749 
Scratching, s 69.6 35.8 51.9 7.33 0.071 0.209 0.162 0.485 
Head Shaking, s 32.4 27.3 42.4 5.49 0.878 0.229 0.006 0.194 
Sleep Quality 77.2 76.1 75.1 2.21 0.500 0.722 0.029 0.679 
1Running, Scratching, and Shaking were not normally distributed and were transformed for statistical analysis. Data were back-
transformed for reporting purposes. 




Table 5.4. Effect of treatment (TRT), day, session (Quiet or Music), time of day (AM or PM), and all relevant interactions on activity 
variables collected via Vetrax® activity sensors (AgLogica Technology, Norcross, GA) from 1000-1200 h (AM) and 1330-1530 h 
(PM) each day. Treatment effects are shown as the contrast between control (CON) and both CBD treatments (CBD) and the contrast 
between CBD treatments (LOW v. HIGH).  
1Except for No Activity and Resting, variables were not normally distributed and were transformed for statistical analysis. Data were 
back-transformed for reporting purposes. There was no effect of the treatment by day nor the Session by time by treatment interactions 
on any variable (P > 0.05) and thus are not shown. 
2Standard error (SE) of the back-transformed data was calculated as follows: SE = (back-transformed upper limit – back-transformed 






























Activity Points 2884 2509 2308 148.6 0.152 0.550 <.001 0.055 0.014 0.287 0.465 <.001 
Activity, min 1.23 0.87 0.85 0.144 0.204 0.937 <.001 0.002 0.076 0.079 0.257 <.001 
No Activity, h 1.21 1.25 1.34 0.059 0.273 0.327 <.001 0.014 <.001 0.013 0.443 0.002 
Resting, h 0.71 0.70 0.62 0.050 0.384 0.234 <.001 0.045 <.001 0.006 0.203 0.002 
Running, min 0.04 0.03 0.04 0.006 0.602 0.544 <.001 0.098 0.078 0.369 0.834 0.223 
Walking, min 1.29 0.87 0.82 0.148 0.138 0.857 <.001 <.001 0.084 0.060 0.217 <.001 
Scratching, s 4.18 2.29 2.62 0.413 0.030 0.612 <.001 0.930 0.274 0.326 0.886 0.730 
Head Shaking, s 1.78 1.65 1.82 0.128 0.882 0.600 <.001 0.926 0.305 0.319 0.212 0.375 
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Table 5.5. Effect of treatment (TRT), day, and TRT*day interactions on activity parameters collected via Vetrax® activity sensors 
(AgLogica Technology, Norcross, GA) during the 2 periods of daily exercise, which included all data from 0700-0900 h and 1700-
1900 h each day. Treatment effects are shown as the contrast between control (CON) and both CBD treatments (CBD) and the 







1.8 mg/kg BW/d 
CBD (LOW) 
4.5 mg/kg BW/d 
CBD (HIGH) 
CON v.  
CBD 
LOW v.  
HIGH Day TRT*Day 
Activity Points 21736 25735 26122 2096.8 0.143 0.910 0.117 0.283 
Activity, min 37.66 48.09 48.07 3.213 0.143 0.998 0.528 0.305 
No Activity, h 0.82 0.75 0.77 0.132 0.708 0.899 0.359 0.842 
Resting, h 2.47 2.24 2.31 0.116 0.312 0.838 0.338 0.847 
Running, min 4.9 4.5 5.3 0.31 0.940 0.298 0.258 0.531 
Walking, min 35.0 43.8 40.7 0.12 0.207 0.446 0.958 0.576 
Scratching, s 21.1 14.1 20.3 2.53 0.442 0.267 0.066 0.875 
Head Shaking, s 17.8 14.7 25.8 0.27 0.682 0.167 0.003 0.273 
1Except for No Activity and Resting, variables were not normally distributed and were transformed for statistical analysis. Data were 
back-transformed for reporting purposes. 
2Standard error (SE) of the back-transformed data was calculated as follows: SE = (back-transformed upper limit – back-transformed 
lower limit)/3.92.
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CHAPTER 6. ALTERATION OF THE CANINE METABOLOME AFTER A THREE-
WEEK SUPPLEMENTATION OF CANNABIDIOL-CONTAINING TREATS 
Frontiers in Veterinary Science, 2021, 8:685606;  
Journal of Animal Science and Research, 2021, 5(2) 
Introduction 
Mass spectrometry-based metabolomics has been increasingly used to assess the 
health and status of animals and to analyze metabolic alterations caused by diet, disease, 
or other factors (Sethi and Brietzke, 2015; Ogunade et al., 2018; Yang et al., 2018). 
Targeted metabolomics can be used to quantify defined groups of metabolites, whereas 
untargeted metabolomics provides a comprehensive analysis of all measurable analytes in 
a sample, including any unknowns (Adeyemi et al., 2019; Roberts et al., 2012). In 
instances where the specific metabolites of interest are unknown, untargeted 
metabolomics can also be used to discover specific biomarkers for later use in targeted 
metabolomics studies as well as pathway analysis (Xia et al., 2013; Goldansaz et al., 
2020). In recent years, Chemical isotope labeling (CIL) liquid chromatography mass 
spectrometry (LC–MS)-based untargeted metabolomics has provided an opportunity to 
analyze metabolites based on chemical groups, including metabolites containing 
amine/phenol chemical groups, which are common intermediate products of amino acid 
metabolism; metabolites containing carbonyl groups, which are common intermediate 
products of energy metabolism; metabolites containing carboxyl groups, including fatty 
acids and their derivatives; and metabolites containing hydroxyl groups, which include 
important biological compounds like homones (Ogunade et al., 2021; Zhao et al., 2016; 
2019).  
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To date, there has been no evaluation of the effect of CBD on the canine 
metabolome. Therefore, the objective of this explorative study was to evaluate the impact 
of CBD supplementation on the canine metabolome with the underlying hypothesis that 
after 3 weeks of supplementation, CBD would alter the canine metabolome compared 
with control. This was accomplished through the use of untargeted metabolomics and 
biomarker analysis of amine/phenol-, carbonyl-, carboxyl-, and hydroxyl-containing 
metabolites. 
Materials and Methods 
This study was approved by the LMU IACUC (protocol 1911-RES) before the 
start of the study. All housing and husbandry received were in accordance with the 
Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (8th ed.), 
and all applicable LMU SOPs. 
Subjects and Housing 
Sixteen dogs (8 male, 8 female, 9 months to 4 years of age, 18.2 ± 3.4 kg BW) of 
various mixed breeds, including terrier, hound, Bassett, shepherd, Border Collie, Husky, 
cur, Labrador, Boxer, and Pug mixes were received from a local shelter for inclusion in 
this study. The shelter was asked to provide dogs weighing 16 ± 4 kg. Additionally, the 
shelter informed of and gave consent for the use of the dogs for research purposes before 
their arrival. Prior to beginning the experiment, each dog had a CBC and serum chemistry 
analysis (IDEXX Laboratories, Inc., Westbrook, Maine) performed, along with physical 
evaluation by the attending veterinarian and a fecal examination to rule out any 
underlying disease that might preclude enrollment. Dogs were excluded if they 
demonstrated serious behavioral issues, such as aggression that would endanger research 
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personnel, were severely emaciated, classified as a body condition score < 3.5 or > 7.5 on 
a 9-point scale (where 1 is emaciated and 9 is obese; Laflamme, 1997), or if their initial 
evaluations revealed an underlying disease that required more than routine treatments 
(such as heartworm positive dogs). Dogs were individually housed in 1.2 x 1.8 m kennels 
within one of two dog wards at the LMU DVTC. Dogs were stratified by treatment and 
sex and evenly distributed between the two wards. Dogs were fed Purina Pro Plan EN 
Gastroenteric Fiber Balance Dry Dog Food to meet the daily metabolizable energy 
requirements of neutered adult dogs at maintenance, calculated as (70 * BW0.75) * 1.6 and 
split into two meals per day. Dogs were weighed and body condition scored (5-point 
scale) weekly for the adjustment of diets. Dogs arrived from the shelter and were started 
on the study diet more than 37 days prior to starting treatments and 58 days before 
collecting samples for this study. 
Experimental Design and Treatments 
These dogs were participating in a concurrent study evaluating the impact of CBD 
on canine voluntary activity (Morris et al., 2021) with treatments consisting of 0 (placebo 
treats; CON) or 75.6 ± 5.86 mg CBD/d (CBD). Dogs were blocked by baseline activity 
before being stratified by age, weight, and sex and randomly assigned to treatments 
within each block. The CBD was the primary constituent of a proprietary industrial hemp 
isolate (AgTech Scientific, Paris, KY) that was incorporated into treats and administered 
in the form of 2 treats daily, each containing half the daily dose. Both CON and CBD 
treats were composed of the following ingredients: chicken, chicken liver, Asian carp, 
catfish, and in the case of the CBD treats, industrial hemp extract. Cannabidiol was the 
primary constituent of the industrial hemp extract; however, trace THC was present in the 
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CBD treatment (2.9 ± 0.22 mg THC/d). Based on the mean BW of dogs included in the 
study and analysis of the treats, mean dose of CBD was 4.5 ± 0.77 mg CBD/kg BW/d. 
Treats were offered solely as a reward upon kennel re-entry following twice-daily 
exercise, which was within 30 min of meals. 
Blood Sample Collection 
After 21 d of treatment administration, approximately 6 mL of blood was 
collected via cephalic catheter or jugular venipuncture approximately 2 hours after the 
final treat administration. The selection of this time point was based on previous work 
demonstrating the half-life of elimination of CBD to be between 1 and 4 hours after oral 
administration (Bartner et al., 2018; Deabold et al., 2019; Gamble et al., 2018). Blood 
samples were collected into tubes containing sodium heparin and were immediately 
centrifuged at 1645 x g for 10 min. Plasma was collected after centrifugation then stored 
at -20°C (<12 hours) before long-term storage at -80°C. 
CIL/LC-MS-Based Untargeted Metabolomics Analysis 
Untargeted metabolomic profiling was done using a CIL/LC-MS-based technique 
with an Agilent 1100 LC system (Palo Alto, CA) connected to a Bruker Impact HD 
quadrupole time-of-flight (QTOF) MS (Billerica, MA). This technique uses a differential 
isotope labelling (12C and 13C-labelling) to separate metabolites based on chemical 
groups followed by LC-MS analysis (Zhao et al., 2019). Detailed information regarding 
sample preparation, labeling, normalization, LC-UV and LC-MS setup, and metabolite 
quantification have been reported elsewhere (Wu and Li, 2012; Mung and Li, 2017). 
Typical coefficient of variation for this high-performance chemical isotope labeling LC-
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MS method for metabolome analysis is in the range of 5–10% for individual metabolites 
(Guo and Li, 2009; Zhao et al., 2016; Zhao et al., 2017). In this study, the amine/phenol-, 
carbonyl-, carboxyl-, and hydroxyl-containing metabolites were analyzed. A total of 19 
LC-MS data files were generated (3 quality control samples, 8 CBD samples, and 8 CON 
samples). 
Metabolite Data Processing 
Raw data processing on the 19 LC-MS data files was performed using ISOMS 
Pro 1.0 according to procedures described by Mung and Li (2017). Peak pairs whose 
mean (sample) / mean (blank) was ≤ 4.0 were filtered out. Peak pairs with no data present 
in at least 80% of the samples were filtered out. The final metabolite-intensity table was 
generated using IsoMS-Quant (Huan and Li, 2015). 
Metabolite Identification 
A two-tier identification approach was used to perform metabolite identification. 
In tier 1, peak pairs were searched against a chemical isotope labeled metabolite library 
(CIL Library) based on accurate mass and retention time (Huan and Li, 2015). In tier 2, a 
linked identity library (LI Library) was used for identification of the remaining peak 
pairs. The LI Library includes over 2000 human endogenous metabolites from 68 
metabolic pathways, providing high-confidence putative identification results based on 
accurate mass and predicted retention time matches (Li et al., 2013). 
Statistical Analysis 
The final metabolite intensity tables for the amine/phenol-, carbonyl-, carboxyl-, 
and hydroxyl-containing metabolome were imported separately into MetaboAnalyst 5.0 
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software package (www.metaboanalyst.ca; Chong et al., 2019) for statistical analysis. 
Prior to statistical analysis, the data were log-transformed, normalized by median, and 
auto-scaled. Median scaling was performed to eliminate unwanted inter-sample variations 
to make the individual samples more comparable to each other. Auto-scaling was used to 
make the metabolites more comparable in magnitude to each other.  
Univariate (volcano plot) and multivariate analysis (Partial least squares 
discriminant analysis [PLS-DA] scores plot) were then generated to identify overall 
treatment differences across the multivariate dataset. The volcano plot was constructed by 
plotting the fold change (FC; CBD/CON) of each metabolite against its P-value. The 
volcano plot was constructed by plotting the FC (CBD/CON) of each metabolite against 
its adjusted P-value. Metabolites with FC ≥ 1.2 or ≤ 0.83 having a false discovery ratio 
(FDR) ≤ 0.05 were considered to be differentially increased or decreased relative to 
CON, respectively.  
The utility of the metabolites with FC ≥ 1.2 or ≤ 0.83 and FDR ≤ 0.05 to serve as 
potential biomarkers of the effects of CBD was tested using receiver operating 
characteristic (ROC) curves as calculated by the ROCCET web server using 
MetaboAnalyst 5.0 software package. Metabolites with an area under ROC (AUROC) ≥ 
0.90 and a P ≤ 0.05 were considered excellent biomarkers as defined in Xia et al. (2013). 
Results 
Amine/Phenol Metabolites 
 Within the amine/phenol analysis, a total of 2681 unique peak pairs (representing 
different compounds) were detected. Of those peak pairs, 134 metabolites were positively 
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identified in tier 1 (CIL Library; Supplementary Table 6.1) and 103 metabolites were 
putatively identified with high confidence in tier 2 (LI Library; Supplementary Table 
6.2). The PLS-DA scores plot (Figure 6.1A) shows clear separation between CON and 
CBD samples, and the permutation test (P < 0.01) confirms the validity of the PLS-DA 
model (Supplementary Figure 6.1).  
 Volcano plot analysis showed that 32 metabolites were differentially altered (FC 
≥ 1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD (Table 6.1; Figure 6.1B). Eighteen of those 
metabolites – pyrimidodiazepine, 4-amino-4-deoxychorismate, isoferulic acid, an isomer 
of D-glucosamine, 7-carboxy-7-carbaguanine, 2,4-dihydroxyhept-2-enedioate, ascorbate, 
2’-deamino-2’-hydroxy-6’-dehydroparomamine, trans-2,3-dihydroxycinnamate, gamma-
glutamyl-gamma-aminobutyraldehyde, 1,4-diaminobutane, tyramine, an isomer of 2-
deoxy-scyllo-inosamine, isoleucyl-alanine, 3,4-hydroxyphenylpyruvate, aspartyl-
threonine, vanillic acid, and D-lysopine – were differentially increased (FC ≥ 1.2, FDR ≤ 
0.05) by CBD. The other 14 metabolites – N-acetyl-L-asparagine, alanyl-proline, 
asparaginyl-aspartic acid, seryl-aspartic acid, phenylalanyl-glycine, prolyl-glutamine, o-
tyrosine, N-acetyl-L-adrenaline, L-threo-3-methylaspartate, Z-3-peroxyaminoacrylate, L-
glutamate-5-semialdehyde, 2-methyl-3-hydroxy-5-formylpyridine-4-carboxylate, 
gamma-aminobutyric acid, and aspartyl-glutamine – were differentially reduced (FC ≤ 
0.83, FDR ≤ 0.05) by CBD compared to CON.  
 Univariate ROC analysis of the 32 identified amine/phenol-containing metabolites 
that were differentially increased or decreased by CBD revealed 24 metabolites – 
aspartyl-glutamine, gamma-aminobutyric acid, gamma-glutamyl-gamma-
aminobutyraldehyde, L-glutamate-5-semialdehyde, prolyl-glutamine, pyrimidodiazepine, 
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4-amino-4-deoxychorismate, trans-2,3-dihydroxycinnamate, alanyl-proline, N-acetyl-L-
asparagine, (Z)-3-peroxyaminoacrylate, 1,4-diaminobutane, 2’-deamino-2’-hydroxy-6’-
dehydroparomamine, ascorbate, D-lysopine, o-tyrosine, phenylalanyl-glycine, 2,4-
dihydroxyhept-2-enedioate, asparaginyl-aspartic acid, isoferulic acid, 7-carboxy-7-
carbaguanine, 3-(4-hydroxyphenyl)pyruvate, aspartyl-threonine, and isoleucyl-alanine – 
that appear to be highly predictive of the metabolomic changes between CBD and CON 
(AUROC ≥ 0.90; P < 0.001; Figure 6.2). 
Carbonyl Metabolites 
 Within the carbonyl analysis, a total of 612 unique peak pairs were detected. Of 
those peak pairs, 6 peak pairs were positively identified in tier 1 (CIL Library; 
Supplementary Table 6.1) and 15 peak pairs were putatively identified with high 
confidence in tier 2 (LI Library; Supplementary Table 6.2). The PLS-DA scores plot 
(Figure 6.3A) shows clear separation between CON and CBD samples, and the 
permutation test (P < 0.01) confirms the validity of the PLS-DA model (Supplementary 
Figure 6.2).  
 Volcano plot analysis showed that 5 metabolites were differentially altered (FC ≥ 
1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD (Figure 6.3B; Table 6.2). Glucose and 2-
formylglutarate were differentially increased (FC ≥ 1.2, FDR ≤ 0.05) by CBD, while 
glyceraldehyde, isomer of glyceraldehyde, and 4-oxoglutaramate were differentially 
reduced (FC ≤ 0.83, FDR ≤ 0.05) by CBD compared to control.  
 Univariate ROC analysis of the 5 carbonyl metabolites positively and putatively 
identified that were differentially altered by CBD revealed that plasma glucose appears to 
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be highly predictive of the metabolomic changes between CBD and CON (AUROC = 
0.91; P = 0.020; Figure 6.4). 
Carboxyl Metabolites 
Within the carboxyl analysis, a total of 2943 unique peak pairs were detected. Of 
those peak pairs, 29 peak pairs were positively identified in tier 1 (CIL Library; 
Supplementary Table 6.1) and 144 peak pairs were putatively identified with high 
confidence in tier 2 (LI Library; Supplementary Table 6.2). The PLS-DA scores plot 
(Figure 6.5A) shows clear separation between CON and CBD samples, and the 
permutation test (P = 0.02) confirms the validity of the PLS-DA model (Supplementary 
Figure 6.3).  
 Volcano plot analysis showed that 42 metabolites were differentially altered (FC 
≥ 1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD (Figure 6.5B; Table 6.3) Twenty-eight metabolites 
– 2,5-dioxopentanoate, isomer of hydroxypropionic acid, 4-cumarate, isomer of D-
glycerate, acetic acid, D-glycerate, isomer of glycolate, isomer of threonate, 5-deoxy-D-
glucuronate, citramalic acid, glycolate, 3-oxopropanoate, ethyl malonate, isomer of 4-
oxopropanoate, isomer of 3-hydroxybutyric acid, 2-hydroxy-3-oxopropanoate, 
hydroxyisobutyric acid, isovaleric acid, butyric acid, glyoxylate, nicotinate, 3-
hydroxybutyric acid, (S)-5-amino-3-oxohexanoic acid, hydroxypropionic acid, lactic 
acid, isomer of lactic acid, and isovanillic acid – were differentially increased (FC ≥ 1.2, 
FDR ≤ 0.05) by CBD. Fourteen metabolites – 4-oxoproline, 2-aminomuconate 
semialdehyde, isomer of 9-oxononanoic acid, L-1-pyrroline-3-hydroxy-5-carboxylate, 
(S)-4-amino-5-oxopentanoate, isomer of 1-aminocyclopropane-1-carboxylate, L-
allothreonine, arginine, isomer of aspartate, isomer of jasmonic acid, isojasmonic acid, 2-
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oxo-4-phenylbutyric acid, 9,10-12,13-diepoxyoctadecanoate, jasmonic acid, and isomer 
of 1-pyrroline-2-carboxylate – were differentially reduced (FC ≤ 0.83, FDR ≤ 0.05) by 
CBD compared to control.  
 Univariate analysis of the 42 carboxyl metabolites positively and putatively 
identified that were differentially increased or decreased by CBD revealed that 23 
metabolites – jasmonic acid, (S)-4-amino-5-oxopentanoate, 3,4-dihydroxymandelic acid, 
isomer of 1-aminocyclopropane-1-carboxylate, isomer of hydroxypropionic acid, L-1-
pyrroline-3-hydroxy-5-carboxylate, L-allothreonine, 2-oxo-4-phenylbutyric acid, 
arginine, citramalic acid, 4-oxoproline, 5-deoxy-D-glucuronate, 9,10-12,13-
diepoxyoctadecanoate, isomer of 1-pyrroline-2-carboxylate, isomer of aspartate, 2-
aminomuconate semialdehyde, isomer of 9-oxononanoic acid, acetic acid, ethyl 
malonate, isomer of jasmonic acid, 3-oxopropanoate, D-glycerate, and isomer of D-
glycerate – appear to be highly predictive of the metabolomic changes between CBD and 
CON (AUROC ≥ 0.90; P < 0.001; Figure 6.6). 
Hydroxyl Metabolites 
Within the hydroxyl analysis, a total of 3759 unique peak pairs were detected. Of 
those peak pairs, 141 peak pairs were positively identified in tier 1 (CIL Library; 
Supplementary Table 6.1) and 65 peak pairs were putatively identified with high 
confidence in tier 2 (LI Library; Supplementary Table 6.2). The PLS-DA scores plot 
(Figure 6.7A) shows clear separation between CON and CBD samples, and the 
permutation test (P < 0.01) confirms the validity of the PLS-DA model (Supplementary 
Figure 6.4).  
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 Volcano plot analysis showed that 32 metabolites were differentially altered (FC 
≥ 1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD (Figure 6.7B; Table 6.4). Fifteen metabolites – 
17α,20α-dihydroxypregn-4-en-3-one, D-tagatose, 3,4-dihydroxyphenylpropanoate, L-
rhamnono-1,4-lactone, L-rhamnofuranose, isomer of L-rhamnofuranose, 6-deoxy-L-
galactose, D-galactosamine, sepiapterin, isomer of sepiapterin, L-fuculose, isomer of 
deoxyadenosine, deoxyadenosine, and 3-hydroxy-L-proline – were differentially 
increased (FC ≥ 1.5, FDR ≤ 0.05) by CBD. Eighteen metabolites – N-acetyl-trans-3-
hydroxy-L-proline, ethanolamine, 2,3-dihydroxyindole, N2’-acetyl-3’-
hydroxykynurenamine, cyanate, isomer of cyanate, glycerol, alpha-ribazole, isomer of 3-
phenoxybenzyl alcohol, dihydroshikonofuran, glycoaldehyde, N-acetyl-2-carboxy-2,3-
dihydro-5,6-dihydroxyindole, allotetrahydrodeoxycorticosterone 3-O-glucuronide, 
phenethyl alcohol, propane-1,3-diol, cortolone, arabitol, and cortisol 21-O-sulfate – were 
differentially reduced (FC ≤ 0.83, FDR ≤ 0.05) by CBD compared to control.  
 Univariate analysis of the 35 hydroxyl metabolites positively and putatively 
identified that were differentially increased or decreased by CBD revealed that 15 
metabolites – L-fuculose, glyceraldehyde, L-rhamnofuranose, L-rhamnono-1,4-lactone, 
arabitol, D-tagatose, propane-1,3-diol, 6-deoxy-L-galactose, D-galactosamine, phenethyl 
alcohol, isomer of L-rhamnofuranose, isomer of 3-phenoxybenzyl alcohol, 3,4-
dihydroxyphenylpropanoate, cortolone, and isomer of deoxyadenosine – appear to be 
highly predictive of the metabolomic changes between CBD and CON (AUROC ≥ 0.90; 
P < 0.001; Figure 6.8). 
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Discussion 
Amino Acid Metabolism 
 Increased concentrations of tyramine, 3-(4-hydroxyphenyl)pyruvate, 2,4-
dihydroxyhept-2-enedioate, gamma-glutamyl-gamma-aminobutyraldehyde, 1,4-
diaminobutane, 2,5-dioxopentanoate, 3-hydroxy-L-proline, D-lysopine, D-glycerate, 
isomer of D-glycerate, glycolate, isomer of glycolate, glyoxylate, 2-hydroxy-3-
oxopropanoate, glycolaldehyde 3,4-dihydroxymandelic acid, hydroxyisobutyric acid, 
isovaleric acid, butyric acid, S-5-amino-3-oxohexanoic acid, 3-hydroxypropionic acid, 
and isomer of hydroxypropionic acid indicate that CBD altered amino acid metabolism.  
 Tyramine, 3-(4-hydroxyphenyl)pyruvate, and 2,4-dihydroxyhept-2-enedioate are 
intermediates in tyrosine and phenylalanine metabolism (Lehmann and Pollmann, 2009; 
Miller and Litwack, 1971; Wang et al., 2010). Tyramine, in particular, is also involved in 
the biosynthesis of many secondary metabolites in plants, such as isoquinoline alkaloids, 
flavonoids, and hydroxycinnamic acid amines (Leonard et al., 2020; Sato et al., 2007).  
 Gamma-glutamyl-gamma-aminobutyraldehyde, 2,5-dioxopentanoate, 3-hydroxy-
L-proline, and 1,4-diaminobutane (i.e. putrescene) are intermediates in arginine, proline, 
hydroxyproline, and ornithine degradation pathways (Kurihara et al., 2005; Jo et al., 
2008; Visser et al., 2012; Watanabe et al., 2012). Putrescene is also known to play a role 
in the regulation of cell growth, protein synthesis, apoptosis, and other cellular processes 
(Igarashi and Kashiwagi, 2010; Larqué et al., 2007). 2,5-dioxopentanoate can be 
converted into 2-oxoglutarate, by which it can enter the citric acid cycle through 
conversion into succinyl-CoA in several prokaryotic organisms, including several species 
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of Pseudomonas, Escherichia coli, and Haloferax volcanii (Brouns et al., 2006; Johnsen 
et al., 2009; Watanabe et al., 2006).   
 D-lysopine is an amino opine derivative of L-lysine found in crown gall tumors 
produced by pathogenic bacteria that infect plants, including C. sativa. While not known 
to be produced in mammalian systems, other opines like saccharopine are known 
intermediates in the metabolism of lysine in mammals (Darling and Larsen, 1961; 
Lippincott et al., 1972; Moore et al., 1997). 3,4-Dihydroxymandelic acid is a metabolite 
of norepinephrine with potent antioxidant activity (Ley et al., 2002). If the increase in 
3,4-dihydroxymandelic acid, it is possible that its increase may contribute to the 
antioxidant effect of CBD, which warrants further investigation.  
 Hydroxyisobutyric acid is an intermediate in valine degradation that in humans is 
used as a biomarker of 3-hydroxyisobutyric aciduria and methylmalonic semialdehyde 
dehydrogenase deficiency, rare metabolic diseases (Podebrad et al., 2000). In dogs, 
alpha-hydroxyisobutyric acid was shown to be upregulated in a small group of dogs with 
diabetes compared to healthy controls (O’Kell et al., 2017), though it was not identified 
as a potential CBD biomarker in this study. Isovaleric acid is a branched-chain fatty acid 
intermediate in leucine catabolism (Parimoo and Tanaka, 1993), and S-5-Amino-3-
oxohexanoic acid is an intermediate in lysine degradation (Bellinzoni et al., 2011; 
Kreimeyer et al., 2007). 
 D-glycerate is an essential intermediate in the catabolism of glycine, serine, and 
threonine in plants. Once formed, D-glycerate can then feed into either glyoxylate 
metabolism via hydroxypyruvate or be converted into 3-phospho-D-glycerate and fed 
into glycolysis (Bartsch et al., 2008; Randall and Tolbert, 1971). In humans with a 
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glycerate kinase mutation, D-glycerate levels are elevated to the point of acidemia which, 
if left untreated, can lead to progressive neurological impairment, hypotonia, seizures, 
failure to thrive, and metabolic acidosis (Guo et al., 2006; Sass et al., 2010). In plants, 
glycolate is an intermediate in glyoxylate metabolism, converting hydroxypyruvate into 
glyoxylate for further metabolism in the glyoxylate cycle (Kisaki and Tolbert, 1969). In 
mammalian systems, glyoxylate is produced either through oxidation of glycolate in 
peroxisomes or the catabolism of hydroxyproline before being converted into glycine via 
alanine-glyoxylate aminotransferases present in peroxisomes (Belostotsky et al., 2012; 
Salido et al., 2012). The glyoxylate cycle, a pathway that converts fatty acids into glucose 
once believed to be absent in mammalian systems, may be present in the liver (Davis and 
Goodman, 1992; Song, 2000). Genetic defects in glyoxylate metabolic enzymes have 
been attributed to metabolic diseases like primary hyperoxalurias and insulin resistance, 
though this has not been investigated in canine models (Salido et al., 2012; Song, 2000). 
Additionally, plasma glyoxylate has been indicated as an early marker for type II diabetes 
development in humans (Nikiforova et al., 2014; Padberg et al., 2014). 2-Hydroxy-3-
oxopropanoate and glycolaldehyde are additional intermediates in glyoxylate metabolism 
(Barkulis and Krakow, 1956; Gupta and Vennesland, 1964). Glycolaldehyde is also 
precursor to pyridoxine synthesis and is an intermediate in folate synthesis in bacteria 
(Vella et al., 1980). The increase in these metabolites may suggest that CBD enhanced 
amino acid degradation. 
 Decreased concentrations of N-acetyl-L-asparagine, o-tyrosine, N-acetyl-L-
adrenaline, L-threo-3-methylaspartate, L-glutamate-5-semialdehyde, 4-oxoglutaramate, 
4-oxoproline, L-1-pyrroline-3-hydroxy-5-carboxylate, isomer of 1-pyrroline-2-
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carboxylate, N-acetyl-trans-3-Hydroxy-L-proline, arginine, 2-aminomuconate 
semialdehyde, isomer of 1-aminocyclopropane-1-carboxylate, L-allothreonine, isomer of 
aspartate, 2-oxo-4-phenylbutyric acid, 2,3-dihydroxyindole, N2’-acetyl-3'-
hydroxykynurenamine, cyanate, isomer of cyanate, and N-acetyl-2-Carboxy-2,3-dihydro-
5,6-dihydroxyindole may also suggest that CBD altered amino acid metabolism. N-
acetyl-L-asparagine is a derivative of asparagine that is N-acetylated by N‐
acetyltransferase 1 (NAT1), one of several acetyltransferases known to play a role in drug 
metabolism (Carlisle et al., 2018). This enzyme has been suggested to play a role in the 
regulation of mTOR complex I activation, cancer cell proliferation, and mitochondrial 
function (Butcher and Minchin, 2012; Camporez et al., 2017; Carlisle et al., 2018). As 
CBD is suspected to exert an anti-cancer effect, it may be prudent in future work to 
investigate if CBD supplementation alters NAT1 activity.  
 o-Tyrosine is a structural isomer of tyrosine and a phenylalanine derivative. It is 
considered a marker for oxidative stress as it is produced through free-radical 
hydroxylation of phenylalanine (Molnar et al., 2005; 2016). If the decrease in o-tyrosine 
was due to CBD supplementation, this may contribute to the suspected antioxidative 
effects of CBD. N-acetyl-L-adrenaline is a methylated form of epinephrine, an adrenal 
hormone involved in the regulation of visceral functions (Malenka et al., 2015; Smith et 
al., 1992). 2-Aminomuconate semialdehyde, 2,3-dihydroxyindole, and N2’-acetyl-3’-
hydroxykynurenamide are intermediates in tryptophan metabolism. 2-Aminomuconate is 
part of the kynurenine pathway, a metabolic pathway used for NAD biosynthesis 
(Colabroy et al., 2005; Nishizuka et al., 1965). Kynurenine pathway metabolites like 2-
aminomuconate are thought to help regulate processes like immune cell response, 
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neuronal excitability, and host-microbiome signaling (Cervenka et al., 2017). N2’-
Acetyl-3'-Hydroxykynurenamine is an acetylated intermediate in tryptophan metabolism 
(Thiele et al., 2013). 2-3-Dihydroxyindole is an intermediate in an indole degradation 
pathway present in several bacterial species but is not known as a mammalian metabolite 
(Ma et al., 2018). 2-Oxo-4-phenylbutyric acid is an intermediate in phenylalanine, 
tyrosine, and tryptophan metabolism that, in microbial species, is a precursor to 
homophenylalanine (Koketsu et al., 2013); however, this pathway is not known to be 
present in mammalian species. N-Acetyl-2-Carboxy-2,3-dihydro-5,6-dihydroxyindole 
(i.e. leucodopachrome) is an intermediate in tyrosine metabolism and in betalain 
melanogenesis pathway (Land et al., 2003; Olivares et al., 2001). While these results 
would suggest an alteration of phenolic-containing amino acid metabolism by CBD, the 
implications remain unclear as the relative concentrations of phenylalanine, tyrosine, and 
tryptophan remained unchanged by treatment. 
 L-Glutamate-5-semialdehyde is a non-proteinogenic amino acid that is an 
intermediate in both proline and arginine biosynthesis from glutamate (Fons et al., 1991; 
Ginguay et al., 2017). L-1-pyrroline-3-hydroxy-5-carboxylate, and 1-pyrroline-2-
carboxylate are intermediates in arginine and proline metabolism (Abaskharon et al., 
2019; Hu et al., 1996; Watanabe et al., 2016). N-Acetyl-trans-3-hydroxy-L-proline (i.e. 
oxaceprol) is a derivative of L-proline that is an established anti-inflammatory drug used 
in the treatment of osteoarthritis (Durg et al., 2019). Combined with the decrease in 
arginine, these results suggest an impact of CBD on arginine and proline metabolism; 
however, since the relative concentration of proline was unaffected by treatment, the 
biological significance is unclear. 4-oxoglutaramate is an intermediate in one of the 
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histidine catabolism pathways that leads to the production of 2-oxoglutarate (i.e. α-
ketoglutarate), which then feeds into the citric acid cycle (Brown and Kies, 1959; Hassall 
and Greenberg, 1963).  
 L-threo-3-methylaspartate is an amino acid formed by glutamate mutase and can 
be metabolized by methylaspartate ammonia-lyase. It is found in the structures of the 
antibiotics friulimicin and vicenistatin and in carbon metabolism of haloarchaea 
(Khomyakova et al., 2011; Raj and Poelarends, 2013). Cyanate is an intermediate in 
nitrogen metabolism that can be produced spontaneously from urea. It has been suggested 
to improve insulin sensitivity and potentially exert antioxidative effects (Kang et al., 
2018). Aspartyl-glutamine, aspartyl-threonine, alanyl-proline, asparaginyl-aspartic acid, 
isoleucyl-alanine, phenylalanyl-glycine, prolyl-glutamine, and seryl-glycine are products 
of the incomplete breakdown of protein digestion or catabolism. While some dipeptides 
are known to have physiological or cell-signaling effects, none of the affected dipeptides 
have been identified as one of these bioactive molecules (Naka et al., 2015; Nakato et al., 
2019). 
 The altered concentrations of these metabolites suggest an effect of CBD on 
amino acid metabolism. However, since the relative concentrations of the individual 
amino acids like glutamate and proline were unaffected by treatment, the biological 
significance of the changes in these metabolites is unclear. Additional research is needed 
to assess the potential for CBD to alter amino acid metabolism.  
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Carbohydrate Metabolism 
 The increase in glucose, lactic acid, acetic acid, an isomer of glucosamine, 2’-
deamino-2’-hydroxy-6’-dehydroparomamine, an isomer of 2-deoxy-schyllo-inosamine, 
D-glycerate, D-tagatose, D-galactosamine, L-rhamnono-1,4-lactone, L-rhamnofuranose, 
L-fuculose, 6-deoxy-L-galactose, and 5-deoxy-D-glucuronate may suggest that 
carbohydrate metabolism was altered by CBD. The endocannabinoid system (ECS) – by 
which CBD and other cannabinoids exert physiological effects – plays a well-established 
role in glucose and energy metabolism, marking it as a target for the treatment of 
metabolic diseases like type 2 diabetes (Bielawiec et al., 2020). Cannabinoids like CBD 
and THC have been suggested to reduce hyperglycemia and increase insulin production 
in rodents (Jadoon et al., 2016; Zorzenon et al., 2019), but this has yet to be investigated 
in a canine model. Lactic acid is generated from pyruvate during anaerobic conditions in 
the muscle and red blood cells. The Cori cycle, or lactic acid cycle, removes lactate from 
tissues and transports lactate via blood to the liver where it can be converted back into 
glucose (Katz and Tayek, 1998; Nuttall et al., 2008). As both this cycle and lactic acid 
play vital roles in glucose homeostasis, the increase in plasma lactic acid indicates 
alteration of glucose metabolism by CBD. Similarly, acetic acid plays a role as an 
intermediate in several essential energetic pathways, including glycolysis, pyruvate 
metabolism, and glyoxylate metabolism via acetyl-CoA. 
 Glucosamine is an amino sugar that is readily synthesized in the body from 
glucose and glutamine. It is an essential component of mucopolysaccharides that are 
incorporated into connective tissue, mucous secretions, skin, tendons, ligaments, and 
cartilage. Additionally, it helps regulate the synthesis of collagen in cartilage (Anderson 
115 
et al., 2005; Beale, 2004; Bhathal et al., 2017). Because of its high concentration in joint 
tissues, glucosamine is commonly used as a dietary supplement in humans, horses, and 
dogs as a support for joint health and function and to relieve symptoms of osteoarthritis, 
though there is little scientific evidence supporting these effects (Henroitin et al., 2012). 
Both 2-deoxy-scyllo-inosamine and 2’-deamino-2’-hydroxy-6’-dehydroparomamine are 
intermediates in the biosynthesis of aminoglycoside antibiotics, like kanamycin, from 
glucose in Streptomyces bacterial species (Kudo et al., 2005; Park et al., 2011). However, 
since these metabolites are not known to be generated in mammalian systems, the 
biological significance of their changes is unclear. 
 D-glycerate is an intermediate in several metabolic pathways. Regarding 
carbohydrate metabolism, D-glycerate is an intermediate in the conversion of other D-
sugars and glyoxylate to 2-phosphoglycerate, which can then feed into glycolysis 
(Dawkins and Dickens, 1965; Heinz et al., 1968). D-tagatose is a monosaccharide often 
found in fruit or dairy products that is commonly used as an artificial sweetener due to its 
low glycemic index (Mu et al., 2018). It can also be produced as an intermediate in the 
catabolism of D-sugars like D-galactose prior to entry into the pentose phosphate 
pathway (Bohren et al., 1989). D-galactosamine is an amino sugar derived from galactose 
that is a constituent of glycoprotein hormones like luteinizing hormone and follicle-
stimulating hormone (Saracyn et al., 2015; Wu et al., 2014). L-rhamnono-1,4-lactone, L-
rhamnofuranose, L-fuculose, and 6-deoxy-L-galactose (i.e. fucose) are intermediates in 
fructose and mannose metabolism (Becker and Lowe, 2003; Rigo et al., 1985; Wen et al., 
2016). Fucose, in particular, is a common N-linked glycan that has been shown to play an 
important role in mammalian health, with disruption of fucosylated glycan expression 
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implicated in a number of disease mechanisms (Becker and Lowe, 2003; Vanhooren and 
Vandamme et al., 1999). 
 5-deoxy-D-glucuronate is an intermediate in the catabolism of myo-inositol in 
bacterial species like Bacillus subtilis, a common species found in the gastrointestinal 
tract of humans and ruminants (Hong et al., 2009; Yoshida et al., 2008). While not known 
to be produced in canine metabolic pathways, production of 5-deoxy-D-glucuronate in 
the gastrointestinal tract by microflora may have been absorbed into the body. The 
increase in this metabolite may suggest CBD supplementation affected gastrointestinal 
microflora populations. Decreased concentrations of arabitol may also support an impact 
of CBD on the microbiome. Arabitiol is a sugar alcohol commonly produced by several 
yeast species (Kordowska-Wiater, 2015). Elevated levels of arabitol in urine have been 
suggested as a biomarker of fungal infections (Salonen et al., 2001), and elevated plasma 
arabitol has been linked to other diseases like congenital liver cirrhosis and acute 
mountain sickness in humans (Verhoeven et al., 2001; Zhu et al., 2015). While CBD is 
believed to be beneficial in an assortment of gastrointestinal conditions (McCabe and 
Cital, 2021), little work has been done regarding its influence on microbial populations in 
the canine gastrointestinal tract, highlighting a potential avenue for future investigation of 
CBD supplementation. 
 The decrease in gamma-aminobutyric acid (GABA), glyceraldehyde, and an 
isomer of glyceraldehyde may also indicate that CBD altered carbohydrate metabolism. 
Best known as the primary inhibitory neurotransmitter in the central nervous system, 
GABA is also produced by insulin-producing β cells of the pancreas, endothelial cells, 
gut microbiota, and immune cells (Bansal et al., 2011; Franklin and Wollheim, 2004). In 
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the pancreas, GABA inhibits glucagon secretion from neighboring α cells and modulates 
glucose homeostasis (Bansal et al., 2011; Purwana et al., 2014; Rorsman et al., 1989). 
This action of GABA in the pancreas has highlighted its potential as a target for diabetes 
treatment (Wan et al., 2015). It has also been shown to regulate cytokine secretion from 
PBMCs and CD4+ T cells and is thought to exert anti-inflammatory effects (Bhandage et 
al., 2018; Jin et al., 2013; Prud'homme et al., 2013). Glyceraldehyde, a triose 
monosaccharide, is an intermediate in glycolysis in its phosphorylated form (GAP). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the enzyme that catalyzes the 
conversion of GAP into 1,3-bisphosphoglycerate, is a major regulator of carbon flux in 
the body (Hildebrandt et al., 2015). It is also known to play a role in other cellular 
functions such as redox sensing, membrane fusion, iron homeostasis, and cell death 
(White and Garcin, 2017). The decrease in glyceraldehyde might lend support to the 
suspected anti-obesity and anti-diabetic effects of CBD; however, the relative increase in 
glucose and decrease in GABA would appear to be incongruous with this potential effect. 
These results highlight a relatively unexplored avenue of CBD research that warrants 
further investigation. 
Lipid Metabolism 
 Increased concentrations of 17alpha,20alpha-dihydroxypregn-4-en-3-one, ethyl 
malonate, 3-hydroxybutyric acid, an isomer of 3-hydroxybutyric acid, 3-
hydroxypropionic acid, an isomer of hydroxypropionic acid, and butyric acid may 
indicate an alteration of lipid metabolism with CBD supplementation. Primarily known as 
a steroid hormone elevated in late pregnancy in mammals, 17alpha,20alpha-
dihydroxypregn-4-en-3-one is also thought to play a role in progesterone homeostasis in 
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non-pregnant animals (Mahajan et al., 1983; Shikita et al., 1967). Ethyl malonate is a 
branched fatty acid associated with several fatty acid metabolism disorders in humans, 
including short-chain acyl-CoA dehydrogenase deficiency and ethylmalonic 
encephalopathy (Tiranti et al., 2004; Wolfe et al., 2011), and has also been identified as a 
potential biomarker for the detection of human breast cancer (Wang et al., 2018). 3-
hydroxybutyric acid is a ketone body and a typical intermediate in the partial breakdown 
of branched-chain amino acids like valine in muscles (Miyazaki et al., 2015). 3-
Hydroxypropionic acid is an intermediate in beta-alanine, propanoate, and uracil 
metabolism (Den et al., 1959; Hawes et al., 1996). Butyric acid is an intermediate in 
butanoate metabolism, which is often formed by bacterial fermentation in the gut (Louis 
and Flint, 2009; Macfarlane and Macfarlane, 2003).  
Additionally, decreased concentrations of propane-1,3-diol, glycerol, 
ethanolamine, isomer of 9-oxononanoic acid, 9,10-12,13-diepoxyoctadecanoate, 
allotetrahydrodeoxycorticosterone 3-O-glucuronide, cortolone, and cortisol 21-O-sulfate 
may also suggest that CBD altered lipid metabolism. Propane-1,3-diol is a product of 
glycerol fermentation in bacterial species but is not known as a mammalian metabolite 
(Marçal et al., 2020). Glycerol is the backbone of glycerides and plays an essential role in 
lipid metabolism, carbohydrate metabolism, and other metabolic processes (Blötz and 
Stülke, 2017). Blood glycerol is also a biomarker for liver disease, hyperglycemia, and 
type II diabetes (Jin et al., 2018; Johnston et al., 1982; Mahendran et al., 2013). 
Additionally, glycerol is involved in endocannabinoid signaling as a product of 
endocannabinoid 2-arachidonylglycerol (2-AG) hydrolysis (Baggelaar et al., 2018). 
Ethanolamine, an amino alcohol, is an intermediate in glycerophospholipid metabolism. 
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It is also involved in retrograde endocannabinoid signaling as a product of arachidonoyl 
ethanolamide (AEA) degradation by fatty acid amide hydrolase (FAAH) (Giang and 
Cravatt, 1997). These results may suggest CBD inhibited AEA degradation, which 
supports previous work showing inhibition of cellular uptake and breakdown of AEA by 
CBD via inhibition of fatty acid binding proteins (Elmes et al., 2015; Leweke et al., 2012; 
Schroeder et al., 2016). However, as the relative concentrations of plasma AEA and 2-
AG were unaffected by treatment, the physiological significance of the changes in these 
metabolites is unclear. Future work using targeted metabolomics and pathway analysis 
may further elucidate this potential effect.  
9-Oxononanoic acid is a medium chain fatty acid product of alpha-linoleic acid 
oxidation in plants (Otte et al., 2013). Early studies showed elevated lipid peroxides and 
reduced lipogenesis in rat livers after oral administration of 9-oxononanoic acid 
(Kanazawa et al., 1986; Minamoto et al., 1988); more recent work indicates this is a 
result of arachidonic cascade induction by 9-oxononanoic acid through its activation of 
phospholipase A2 (Ren et al., 2013). If the decrease in 9-oxononanoic acid is a result of 
CBD supplementation, this may be one potential mechanism contributing to the 
suspected anti-inflammatory effects of CBD. Jasmonic acid is a plant stress hormone 
synthesized from linolenic acid that serves as a natural pesticide and promotes plant 
growth (Behr et al., 2019). Additionally, jasmonic acid has been suggested to exhibit 
anti-cancer and anti-inflammatory properties in vitro (Henriet et al., 2017). 9,10-12,13- 
Diepoxyoctadecanoate is an intermediate in the conversion of linoleic acid into 
tetrahydrofurandiols (THF-diols) (Falck et al., 2007).  
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Allotetrahydrodeoxycorticosterone (THDOC) 3-O-glucuronide is an endogenous 
neurosteroid that acts as a potent positive allosteric modulator of the GABAA receptor 
and exhibits sedative, anxiolytic, and anticonvulsant effects (Reddy, 2006; Reddy and 
Rogawski, 2002). Cortolone and cortisol 21-O-sulfate are metabolites in steroid hormone 
catabolism (Kornel et al., 1995). Cortolone is often linked to a glucuronide to help in its 
excretion (Hosoda et al., 1984; Yang et al., 2017), and cortisol 21-O-sulfate may be used 
as a biomarker for Cushing’s syndrome (Kornel et al., 1995).  
 Altogether, these results support an effect of CBD on lipid metabolism and may 
indicate potential mechanisms for its suspected anti-inflammatory effect. However, as the 
animals on this study were healthy, it is unclear how this would translate to a diseased 
population in which these metabolomic changes might be more influential, such as 
animals with Cushing’s disease. Further studies are needed in unhealthy or diseased 
populations of dogs to determine the potential physiological applications of these 
potential effects of CBD. 
Hydroxycinnamic Acid Derivatives 
 The increase in plasma isoferulic acid (IFA), trans-2,3-dihydroxycinnamate, and 
vanillic acid may suggest that CBD altered the metabolism of hydroxycinnamic acid 
derivatives. Isoferulic acid is a naturally occurring hydroxycinnamic acid derivative 
commonly found in Lobelia and Cimicifuga species. It is an isomer of ferulic acid, a 
phenolic compound that is a component of lignin, which is commonly found in cell walls 
of plants, including C. sativa (Zimniewska et al., 2018). Ferulic acid has also been 
isolated from hemp seed meal, a byproduct of hemp oil processing (Pojić et al., 2014). 
Both ferulic acid and IFA have been reported to have anti-inflammatory, anti-viral, anti-
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oxidative, and anti-diabetic properties and are commonly used as ingredients in herbal 
medicines in Japan and China (Meeprom et al., 2013; Zhao et al., 2008). Isoferulic acid 
has been shown to reduce plasma glucose in diabetic rats and to inhibit IL-8 production 
in mice (Liu et al., 2000; Hirabayashi et al., 1994). Additionally, IFA has been suggested 
to act as an anti-glycation compound. Protein glycation is a non-enzymatic reaction 
associated with oxidative stress and reactive oxygen species (ROS) production; it is 
thought to be a contributor to age-related diseases (Meeprom et al., 2015). In several 
studies, IFA protected against fructose- and glucose-mediated glycation and inhibited 
ROS production in vitro (Meeprom et al., 2013; Arfin et al., 2018). In humans, IFA has 
been shown to be an intermediate in the metabolism of plant-derived phenolic 
compounds like caffeic acid (Clifford et al., 2019), with humans obtaining the majority 
from dietary consumption.  
 Trans-2,3-dihydroxycinnamate is a derivative of cinnamic acid, which is an 
intermediate in the biosynthesis of lignin, flavonoids, and other secondary metabolites 
produced by plants like C. sativa (Vogt, 2010). Cinnamic acid and its derivatives, like 
trans-2,3-dihydroxycinnamate, possess antioxidizing activity (Santos and Vieira, 2013). 
Vanillic acid is a dihydroxybenzoic acid derivative commonly used as a flavoring agent. 
It is also an intermediate in the synthesis of vanillin from ferulic acid and a phenolic 
compound that, like IFA, is a component of lignin present in the secondary cell wall of 
plants, including C. sativa (Civolani et al., 2000; Khan et al., 2014). Like other lignin-
associated aromatic acids, vanillic acid has been reported to exert antimicrobial properties 
(Yemiş et al., 2011). If the increase in these metabolites is a result of CBD 
supplementation, it is possible that these compounds may contribute to the suspected 
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anti-microbial, anti-inflammatory, and antioxidative effects of hemp; however, additional 
work is warranted to further investigate these potential effects.   
Vitamin and Nucleotide Metabolism 
 Increased concentrations of pyrimidodiazepine, 4-amino-4-deoxychorismate, 7-
carboxy-7-carbaguanine, 2-formylglutarate, ascorbate, an isomer of threonate, 2-
hydroxy-3-oxopropanoate, nicotinate, 3-oxopropanoate, an isomer of 3-oxopropanoate, 
deoxyadenosine, and an isomer of deoxyadenosine may indicate an alteration of vitamin 
and nucleotide metabolism. Pyrimidodiazepine is a derivative of uracil and a substrate for 
pyrimidodiazepine synthase, an enzyme that can contribute to glutathione synthesis. 
Uracil derivatives like pyrimidodiazepine are also thought to possess antimicrobial and 
antioxidant properties (El-Kalyoubi et al., 2017). 3-Oxopropanoate is an intermediate in 
uracil and beta-alanine metabolism that can then be converted into malonate and enter 
fatty acid biosynthetic pathways (Scholem and Brown, 1983). Deoxyadenosine is a 
derivative of adenosine and an intermediate in purine metabolism. In the absence of 
adenosine deaminase in humans, deoxyadenosine will accumulate in and kill T 
lymphocytes, leading to the development of adenosine deaminase severe combined 
immunodeficiency disease (Bradford et al., 2017). Nicotinate, or vitamin B3, is required 
for the formation of coenzymes NAD and NADP. While it can be synthesized from 
tryptophan in humans and dogs, the process is inefficient and is thus considered an 
essential nutrient (Kirkland, 2009; Krehl and Torbet, 1946). 4-amino-4-deoxychorismate 
is a precursor for para-aminobenzoic acid (pABA) biosynthesis, which is a precursor for 
folic acid (vitamin B9) synthesis in plants and microorganisms (Sahr et al., 2006; 
Wegkamp et al., 2007). While vitamin B9 is an essential cofactor that facilitates methyl 
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transfers, mammals do not possess the enzymes to produce folic acid and instead rely on 
dietary consumption of the vitamin (Sahr et al., 2006). 7-carboxy-7-carbaguanine is 
pyrrolopyrimidine that, like 4-amino-4-deoxychorismate, is involved in the biosynthesis 
of vitamin B9 (McCarty et al., 2009). 2-formylglutarate is an intermediate in 
nicotinamide metabolism in several bacterial species (Alhapel et al., 2006; Kress et al., 
2008). Threonate is an intermediate in ascorbate metabolism that is thought to play a role 
in bone mineralization, prevent androgen-driven balding, and improve learning and 
memory when combined with magnesium (Kwack et al., 2010; Sun et al., 2016; Wang 
and Jiang, 2011). Ascorbate, or vitamin C, can be synthesized in dogs from glucose or 
ingested in the diet (Linster and Schaftingen, 2007; Meister, 1994). Vitamin C serves as a 
cofactor in several essential reactions, including collagen synthesis and wound healing, as 
well as an antioxidant. If the increase in ascorbate was due to CBD supplementation, this 
may contribute to the suspected antioxidative effects of CBD.  
 Decreased concentrations of 2-methyl-3-hydroxy-5-formylpyridine-4-carboxylate 
(Z)-3-peroxyaminoacrylate, and alpha-ribazole may also support an effect of CBD on 
vitamin and nucleotide metabolism. 2-methyl-3-hydroxy-5-formylpyridine-4-carboxylate 
is an intermediate in the pyridoxine (vitamin B6) degradation pathway (Yokochi et al., 
2009). Vitamin B6 is an essential cofactor in several enzymatic reactions, including the 
synthesis of glutathione, an important antioxidant (Dalto and Matte, 2017). alpha-
Ribazole is an intermediate in vitamin B12 synthesis in plants and bacterial species that 
can be used as a marker for vitamin B12 content in foodstuffs (Gray and Escalante-
Semerena, 2010; Pakin et al., 2005). (Z)-3-peroxyaminoacrylate is an intermediate in 
bacterial pyrimidine degradation pathway known as the Rut pathway. However, this 
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pathway and intermediate are not known to play a role in mammalian pyrimidine 
metabolism (Knapik et al., 2012).  
 Since the relative concentrations of pyridoxine, uracil, and folate were not 
affected by treatment, and since several of these metabolites are not known to be 
generated in mammalian systems, the biological significance of these changes is unclear. 
However, increased pyrimidodiazepine and ascorbate, along with decreased 2-methyl-3-
hydroxy-5-formylpyridine-4-carboxylate, may indicate an influence of CBD on 
antioxidant status. Further studies are needed to determine the roles of these metabolites 
and the potential effects of CBD on these pathways.  
Additional Metabolites 
Increased relative concentrations of 4-coumarate, 3,4-
dihydroxyhpenylpropanoate, isovanillic acid, citramalic acid, sepiapterin, and an isomer 
of sepiapterin may further suggest an alteration of metabolism by CBD supplementation. 
4-Coumarate, or 4-hydroxycinnamate, is a hydroxycinnamic acid derivative and an 
intermediate in several plant metabolic pathways, including phenylpropanoid 
biosynthesis, isoquinoline alkaloid biosynthesis, tyrosine metabolism, and more (Li et al., 
2005; Schneider et al., 2005). 3,4-Dihydroxyphenylpropanoate, or dihydrocaffeic acid, is 
an intermediate in tyrosine metabolism, specifically the conversion of L-DOPA to 
rosmarinate, and is suspected to possess antioxidant and anti-inflammatory properties 
(Ranjith et al., 2007; Wang et al., 2018). Isovanillic acid is a metabolite of isovanillin 
with suspected antibacterial properties (Panoutsopoulos and Beedham, 2005; Strand and 
Scheline, 1975). While not known as a mammalian metabolite, it can be found in plasma 
after consumption of flavonoid consumption (Loke et al., 2009). Citramalic acid is most 
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commonly produced by yeast or anaerobic bacteria as an intermediate in C5-branched 
dibasic acid metabolism (Zarzycki et al., 2009). As it is not a mammalian metabolite, 
citramalic acid is most commonly found as a urine metabolite in cases of yeast or 
bacterial overgrowth (Shaw et al., 1995). Sepiapterin is an intermediate in folate 
biosynthesis that in mammals can be metabolized into tetrahydrobiopterin, which is an 
essential cofactor in mammals for the metabolism of aromatic amino acids and 
biosynthesis of neurotransmitters (Smith et al., 2019; Wang et al., 2011). It has been 
suggested as a treatment for atherosclerosis and tetrahydropterin deficiencies in humans 
(Smith et al., 2019; Tarpey, 2002; Vásquez-Vivar et al., 2002). 
Decreased concentrations of L-glutamate-1-semialdehyde, 1-aminocyclopropane-
1-carboxylate, L-allothreonine, an isomer of 3-phenoxybenzyl alcohol, 
dihydroshikonofuran, and phenethyl alcohol also indicate an effect of CBD on 
metabolism. L-Glutamate-1-semialdehyde, 1-aminocyclopropane-1-carboxylate, and L-
allothreonine are plant metabolites. L-Glutamate-1-semialdehyde is produced as an 
intermediate in porphyrin and chlorophyll synthesis (Campanini et al., 2013). 1-
Aminocyclopropane-1-carboxylate is the direct precursor of the plant hormone ethylene 
and plays a role in the regulation of plant development (Polko and Kieber, 2019). L-
Allothreonine is a stereoisomer of threonine and an intermediate in plant glycine, serine, 
and threonine metabolism (Fiehn et al., 2000). 3-Phenoxybenzyl alcohol is a mammalian 
metabolite of the insecticide permethrin produced by carboxylesterases (Crow et al., 
2007; Stok et al., 2004). Dihydroshikonofuran is a monoterpenoid product of ubiquinone 
and other terpenoid-quinone biosynthesis from the same metabolic pathway that produces 
shikonin, a plant pigment with anti-inflammatory, antibacterial, and wound-healing 
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properties (Boehm et al., 2000; Yazaki et al., 1987). Phenethyl alcohol is a natural 
fragrance produced by rose, carnation, and other plants (Guterman et al., 2006; Politano 
et al., 2013). 
Limitations, Strengths, and Weaknesses 
 This study is the first to evaluate the impact of CBD supplementation on the 
canine metabolome. This analysis was not intended to be all-encompassing but rather a 
first look into the potential for CBD supplementation to alter the canine metabolome. 
Thus, this study was limited by the relatively short duration of CBD supplementation, 
lack of baseline sampling, small sample size, and the use of only a single CBD dosage. 
Even so, identifying potential changes in the metabolome is essential for directing future 
investigation into both the physiological relevance of these changes as well as elucidating 
potential mechanisms leading to these observed effects. 
Conclusions 
This study demonstrated the canine metabolome was altered with 4.5 mg CBD/kg 
BW/d supplementation for 3 weeks. Altered metabolites may suggest a potential for CBD 
to influence glucose, carbohydrate, lipid, amino acid, vitamin, and nucleotide 
metabolism. Additionally, the difference in relative concentrations of metabolites like 9-
oxononanoic acid, o-tyrosine, IFA, glucosamine, pyrimidodiazepine, 9-oxononanoic acid, 
and 3,4-dihydroxymandelic acid may indicate potential pathways by which CBD may 
exert suspected anti-inflammatory, antioxidant, anti-obesity, and antimicrobial effects. 
Several metabolites were identified as potential biomarkers for changes in the canine 
metabolome by CBD. Further studies with larger sample sizes, longer supplementation 
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periods and baseline comparisons to refine metabolites are necessary to elucidate the 
physiological relevance of these changes.  
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Figure 6.1. A. Partial least squares discriminant analysis (PLS-DA) scores plot and B. 
volcano plot showing the differential amine/phenol-containing metabolites. Fold change 
(FC) ≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are 
differentially increased or reduced by cannabidiol (CBD) relative to control (CON). 
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Table 6.1. Identified amine/phenol-containing metabolites affected by cannabidiol (CBD) 
compared to control (CON). Metabolites with a fold change (FC) ≥ 1.2 relative to CON 
and a false discovery ratio (FDR) ≤ 0.05 considered increased in the CBD compared to 
CON. Metabolites with a FC ≤ 0.83 and an FDR ≤ 0.05 considered reduced in CBD 
compared to CON. 
Metabolite Normalized RT1 FC FDR 
Identification 
Level2 
Pyrimidodiazepine 1029.2 2.89 0.002 Tier 2 
4-Amino-4-deoxychorismate 504.2 2.38 0.004 Tier 2 
Isoferulic acid 1075.1 1.91 0.005 Tier 1 
Isomer of D-Glucosamine 152.6 1.85 0.045 Tier 2 
7-Carboxy-7-carbaguanine 369.6 1.64 0.019 Tier 2 
2,4-Dihydroxyhept-2-enedioate 680.1 1.64 0.004 Tier 2 
Ascorbate 530.4 1.62 0.023 Tier 2 
2'-Deamino-2'-hydroxy-6'-
dehydroparomamine 761.9 1.57 0.026 Tier 2 
trans-2,3-Dihydroxycinnamate 856.8 1.53 0.001 Tier 2 
gamma-Glutamyl-gamma-
aminobutyraldehyde 337.7 1.52 0.010 Tier 2 
1,4-Diaminobutane 1281.7 1.50 0.007 Tier 1 
Tyramine 1538.7 1.50 0.007 Tier 1 
Isomer of 2-Deoxy-scyllo-
inosamine 208.1 1.47 0.031 Tier 2 
Isoleucyl-Alanine 586.8 1.45 0.026 Tier 1 
3-(4-Hydroxyphenyl)pyruvate 1068.7 1.31 0.019 Tier 2 
Aspartyl-Threonine 236.0 1.31 0.019 Tier 1 
Vanillic acid 1026.1 1.26 0.012 Tier 1 
D-Lysopine 999.8 1.20 0.019 Tier 2 
N-Acetyl-L-Asparagine 492.6 0.83 0.023 Tier 2 
Alanyl-Proline 477.2 0.82 0.026 Tier 1 
Asparaginyl-Aspartic acid 149.6 0.79 0.026 Tier 1 
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Seryl-Aspartic acid 162.3 0.78 0.045 Tier 1 
Phenylalanyl-Glycine 569.9 0.78 0.026 Tier 1 
Prolyl-Glutamine 335.6 0.78 0.012 Tier 1 
o-Tyrosine 1313.2 0.77 0.023 Tier 1 
N-Acetyl-L-Adrenaline 1650.1 0.75 0.041 Tier 2 
L-threo-3-Methylaspartate 491.9 0.74 0.045 Tier 2 
Z-3-Peroxyaminoacrylate 666.3 0.72 0.024 Tier 2 
L-Glutamate 5-semialdehyde 367.9 0.72 0.004 Tier 2 
2-Methyl-3-hydroxy-5-
formylpyridine-4-carboxylate 652.3 0.66 0.032 Tier 2 
Aspartyl-Glutamine 194.8 0.65 0.001 Tier 1 
Gamma-Aminobutyric acid 466.3 0.55 0.049 Tier 1 
1Normalized RT (retention time) shows the corrected retention time of the peak pair with 
Universal RT Calibrant data.  
2Tier 1 indicates positive metabolite identification within the chemical isotope labeling 
(CIL) metabolite library whereas Tier 2 indicates high confidence putative identification 




Figure 6.2. Candidate amine/phenol-containing biomarkers altered by cannabidiol (CBD; 
in blue) compared to control (CON; in yellow) included A. aspartyl-glutamine (AUROC 
= 1.00; P < 0.001); B. gamma-aminobutyric acid (AUROC = 1.00; P = 0.005); C. 
gamma-glutamyl-gamma-aminobutyraldehyde (AUROC = 1.00; P < 0.001); D. L-
glutamate-5-semialdehyde (AUROC = 1.00; P < 0.001); E. prolyl-glutamine (AUROC = 
1.00; P < 0.001); F. pyrimidodiazepine (AUROC = 1.00; P < 0.001); G. 4-amino-4-
deoxychorismate (AUROC = 0.98; P < 0.001); H. trans-2,3-dihydroxycinnamate 
(AUROC = 0.98; P < 0.001); I. alanyl-proline (AUROC = 0.97; P = 0.002); J. N-acetyl-
L-asparagine (AUROC = 0.97; P < 0.001); K. (Z)-3-peroxyaminoacrylate (AUROC = 
0.95; P < 0.001); L. 1,4-diaminobutane (AUROC = 0.95; P < 0.001); M. 2’-deamino-2’-
hydroxy-6’-dehydroparomamine (AUROC = 0.95; P = 0.004); N. ascorbate (AUROC = 
0.95; P = 0.003); O. D-lysopine (AUROC = 0.95; P = 0.004); P. o-tyrosine (AUROC = 
0.95; P = 0.001); Q. phenylalanyl-glycine (AUROC = 0.95; P = 0.002); R. 2,4-
dihydroxyhept-2-enedioate (AUROC = 0.94; P < 0.001); S. asparaginyl-aspartic acid 
(AUROC = 0.94; P = 0.003); T. isoferulic acid (AUROC = 0.94; P < 0.001); U. 7-
carboxy-7-carbaguanine (AUROC = 0.92; P = 0.001); V. 3-(4-hydroxyphenyl)pyruvate 
(AUROC = 0.91; P = 0.004); W. aspartyl-threonine (AUROC = 0.91; P = 0.005); and X. 







Figure 6.3. A. Partial least squares discriminant analysis (PLS-DA) scores plot and B. 
volcano plot showing the differential carbonyl-containing metabolites. Fold change (FC) 
≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are differentially 
increased or reduced by cannabidiol (CBD) relative to control (CON). 
134 
Table 6.2. Identified carbonyl-containing metabolites affected by cannabidiol (CBD) 
compared to control (CON). Metabolites with a fold change (FC) ≥ 1.2 relative to CON 
and a false discovery ratio (FDR) ≤ 0.05 considered increased in the CBD compared to 
CON. Metabolites with a FC ≤ 0.83 and an FDR ≤ 0.05 considered reduced in CBD 
compared to CON. 
Metabolite Normalized RT1 FC FDR 
Identification 
Level2 
2-Formylglutarate 569.3 1.99 0.021 Tier 2 
Glucose 371.2 1.54 0.018 Tier 1 
4-Oxoglutaramate 394.4 0.62 0.050 Tier 2 
Isomer of Glyceraldehyde 471.1 0.42 0.035 Tier 1 
Glyceraldehyde 453.2 0.38 0.040 Tier 1 
1Normalized RT (retention time) shows the corrected retention time of the peak pair with 
Universal RT Calibrant data. 
2Tier 1 indicates positive metabolite identification within the chemical isotope labeling 
(CIL) metabolite library whereas Tier 2 indicates high confidence putative identification 
within the linked identity (LI) library.  
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Figure 6.4. Candidate carbonyl-containing biomarker – Glucose (AUROC = 0.91; P = 







Figure 6.5. A. Partial least squares discriminant analysis (PLS-DA) scores plot and B. 
volcano plot showing the differential carboxyl-containing metabolites. Fold change (FC) 
≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are differentially 
increased or reduced by cannabidiol (CBD) relative to control (CON). 
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Table 6.3. Identified carboxyl-containing metabolites affected by cannabidiol (CBD) 
compared to control (CON). Metabolites with a fold change (FC) ≥ 1.2 relative to CON 
and a false discovery ratio (FDR) ≤ 0.05 considered increased in the CBD compared to 
CON. Metabolites with a FC ≤ 0.83 and an FDR ≤ 0.05 considered reduced in CBD 
compared to CON. 
Metabolite Normalized RT1 FC FDR 
Identification 
Level2 
2,5-Dioxopentanoate 741.4 3.70 0.047 Tier 2 
Isomer of Hydroxypropionic acid 380.9 2.56 <.001 Tier 1 
4-Coumarate 802.6 2.42 0.043 Tier 2 
Isomer of D-Glycerate 255.0 2.31 0.009 Tier 2 
Acetic acid 560.5 2.21 <.001 Tier 1 
D-Glycerate 299.4 2.14 0.007 Tier 2 
Isomer of Glycolate 282.4 2.09 0.008 Tier 2 
Isomer of Threonate 272.2 2.09 0.088 Tier 2 
5-Deoxy-D-glucuronate 361.4 2.04 0.002 Tier 2 
Citramalic acid 449.1 2.04 0.001 Tier 1 
3,4-Dihydroxymandelic acid 493.9 2.04 <.001 Tier 1 
Glycolate 299.4 2.03 0.046 Tier 2 
3-Oxopropanoate 361.4 1.95 0.002 Tier 2 
Ethyl Malonate 739.7 1.89 <.001 Tier 1 
Isomer of 3-Oxopropanoate 332.4 1.88 0.007 Tier 2 
Isomer of 3-Hydroxybutyric acid 474.9 1.86 0.005 Tier 1 
2-Hydroxy-3-oxopropanoate 389.2 1.81 0.080 Tier 2 
Hydroxyisobutyric acid 548.8 1.60 0.012 Tier 1 
Isovaleric acid 1039.8 1.60 0.030 Tier 1 
Butyric acid 870.3 1.58 0.009 Tier 1 
Glyoxylate 528.3 1.55 0.083 Tier 2 
Nicotinate 574.9 1.54 0.007 Tier 2 
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3-Hydroxybutyric acid 501.4 1.43 0.047 Tier 1 
S-5-Amino-3-oxohexanoic acid 596.0 1.38 0.025 Tier 2 
Hydroxypropionic acid 424.8 1.38 0.015 Tier 1 
Lactic acid 452.2 1.37 0.012 Tier 1 
Isomer of Lactic acid 471.2 1.36 0.009 Tier 1 
Isovanillic acid 739.5 1.33 0.009 Tier 1 
4-Oxoproline 798.3 0.80 0.017 Tier 2 
2-Aminomuconate semialdehyde 799.6 0.79 0.032 Tier 2 
Isomer of 9-Oxononanoic acid 1048.9 0.74 0.093 Tier 2 
L-1-Pyrroline-3-hydroxy-5-
carboxylate 372.5 0.74 0.012 Tier 2 
S-4-Amino-5-oxopentanoate 439.3 0.70 0.007 Tier 2 
Isomer of 1-Aminocyclopropane-1-
carboxylate 272.2 0.67 0.013 Tier 2 
L-Allothreonine 439.3 0.64 0.007 Tier 2 
Arginine 279.8 0.60 0.012 Tier 2 
Isomer of Aspartate 574.6 0.58 0.098 Tier 2 
Isomer of Jasmonic acid 1525.6 0.55 0.030 Tier 2 
2-Oxo-4-phenylbutyric acid 1150.3 0.53 0.007 Tier 2 
9,10-12,13-Diepoxyoctadecanoate 1333.8 0.50 0.009 Tier 2 
Jasmonic acid 1437.0 0.44 <.001 Tier 2 
Isomer of 1-Pyrroline-2-carboxylate 1160.7 0.15 0.009 Tier 2 
1Normalized RT (retention time) shows the corrected retention time of the peak pair with 
Universal RT Calibrant data. 
2Tier 1 indicates positive metabolite identification within the chemical isotope labeling 
(CIL) metabolite library whereas Tier 2 indicates high confidence putative identification 





Figure 6.6. Biomarker analysis of carboxyl metabolites for cannabidiol (CBD) and 
control (CON) treatments identified A. jasmonic acid (AUROC = 1.00; P < 0.001); B. 
(S)-4-amino-5-oxopentanoate (AUROC = 1.00; P < 0.001); C. 3,4-dihydroxymandelic 
acid (AUROC = 1.00; P < 0.001); D. isomer of 1-aminocyclopropane-1-carboxylate 
(AUROC = 1.00; P < 0.001); E. isomer of hydroxypropionic acid (AUROC = 1.00; P < 
0.001); F. L-1-pyrroline-3-hydroxy-5-carboxylate (AUROC = 1.00; P < 0.001); G. L-
threonine/L-allothreonine (AUROC = 1.00; P < 0.001); H. 2-oxo-4-phenylbutyric acid 
(AUROC = 0.98; P < 0.001); I. Arginine (AUROC = 0.98; P < 0.001); J. citramalic acid 
(AUROC = 0.97; P < 0.001); K. 4-oxoproline (AUROC = 0.95; P < 0.001); L. 5-deoxy-
D-glucuronate (AUROC = 0.95; P < 0.001); M. 9,10-12,13-diepoxyoctadecanoate 
(AUROC = 0.95; P < 0.001); N. isomer of 1-pyrroline-2-carboxylate (AUROC = 0.95; P 
< 0.001); O. isomer of aspartate (AUROC = 0.95; P < 0.001); P. 2-aminomuconate 
semialdehyde (AUROC = 0.94; P < 0.001); Q. isomer of 9-oxononanoic acid (AUROC = 
0.94; P < 0.001); R. acetic acid (AUROC = 0.92; P < 0.001); S. ethyl malonate (AUROC 
= 0.92; P < 0.001); T. isomer of jasmonic acid (AUROC = 0.92; P < 0.001); U. 3-
oxopropanoate (AUROC = 0.91; P < 0.001); V. D-glycerate (AUROC = 0.91; P < 








Figure 6.7. A. Partial least squares discriminant analysis (PLS-DA) scores plot and B. 
volcano plot showing the differential hydroxyl-containing metabolites. Fold change (FC) 
≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are differentially 
increased or reduced by cannabidiol (CBD) relative to control (CON). 
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Table 6.4. Identified hydroxyl-containing metabolites affected by cannabidiol (CBD) 
compared to control (CON). Metabolites with a fold change (FC) ≥ 1.2 relative to CON 
and a false discovery ratio (FDR) ≤ 0.05 considered increased in the CBD compared to 
CON. Metabolites with a FC ≤ 0.83 and an FDR ≤ 0.05 considered reduced in CBD 
compared to CON. 




one 1618.8 6.19 0.001 Tier 2 
D-Tagatose 235.4 2.35 0.001 Tier 2 
3,4-Dihydroxyphenylpropanoate 678.7 2.09 0.011 Tier 2 
L-Rhamnono-1,4-lactone 280.5 1.91 0.001 Tier 2 
L-Rhamnofuranose 198.0 1.67 0.008 Tier 2 
Isomer of L-Rhamnofuranose 735.3 1.66 0.008 Tier 2 
6-Deoxy-L-galactose 649.6 1.66 0.008 Tier 2 
D-Galactosamine 162.8 1.48 0.008 Tier 2 
Sepiapterin 240.1 1.48 0.014 Tier 2 
Isomer of Sepiapterin 182.5 1.46 0.028 Tier 2 
L-Fuculose 128.6 1.43 0.001 Tier 2 
Isomer of Deoxyadenosine 261.6 1.42 0.019 Tier 2 
Deoxyadenosine 243.3 1.40 0.035 Tier 2 
3-Hydroxy-L-proline 211.6 1.23 0.016 Tier 2 
N-Acetyl-trans-3-Hydroxy-L-proline 602.8 0.82 0.080 Tier 2 
Ethanolamine 398.0 0.82 0.045 Tier 2 
2,3-Dihydroxyindole 578.9 0.81 0.044 Tier 2 
143 
N2'-Acetyl-3'-Hydroxykynurenamine 425.7 0.79 0.087 Tier 2 
Cyanate 469.9 0.79 0.014 Tier 2 
Isomer of Cyanate 505.6 0.77 0.008 Tier 2 
Glycerol 447.9 0.76 0.051 Tier 2 
alpha-Ribazole 894.1 0.74 0.014 Tier 2 
Isomer of 3-Phenoxybenzyl alcohol 538.1 0.73 0.008 Tier 1 
Dihydroshikonofuran 1341.0 0.73 0.018 Tier 2 
Glycolaldehyde 613.0 0.71 0.018 Tier 2 
N-Acetyl-2-Carboxy-2,3-dihydro-5,6-
dihydroxyindole 404.7 0.69 0.014 Tier 2 
Allotetrahydrodeoxycorticosterone 3-O-
glucuronide 1167.4 0.69 0.027 Tier 2 
Phenethyl alcohol 653.4 0.63 0.002 Tier 1 
Propane-1,3-diol 945.6 0.56 0.001 Tier 2 
Cortolone 1011.9 0.46 0.092 Tier 2 
Arabitol 238.7 0.42 0.001 Tier 2 
Cortisol 21-O-sulfate 875.1 0.40 0.088 Tier 2 
1Normalized RT (retention time) shows the corrected retention time of the peak pair with 
Universal RT Calibrant data. 
2Tier 1 indicates positive metabolite identification within the chemical isotope labeling 
(CIL) metabolite library whereas Tier 2 indicates high confidence putative identification 
within the linked identity (LI) library.  
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Figure 6.8. Biomarker analysis of hydroxyl metabolites for cannabidiol (CBD) and 
control (CON) treatments identified A. L-fuculose/L-rhamulose (AUROC = 1.00; P < 
0.001); B. glyceraldehyde (AUROC = 1.00; P < 0.001); C. L-rhamnofuranose (AUROC 
= 1.00; P < 0.001); D. L-rhamnono-1,4-lactone (AUROC = 1.00; P < 0.001); E. 
Xylitol/Arabitol/Ribitol (AUROC = 1.00; P < 0.001); F. D-tagatose/L-sorbose (AUROC 
= 0.98; P < 0.001); G. propane-1,3-diol (AUROC = 0.98; P < 0.001); H. 6-deoxy-L-
galactose/L-rhamnose (AUROC = 0.97; P = 0.002); I. D-glucosamine (AUROC = 0.95; 
P = 0.001); J. phenethyl alcohol (AUROC = 0.94; P = 0.002); K. isomer of L-
rhamnofuranose (AUROC = 0.92; P = 0.001); L. 3-phenoxybenzyl alcohol (AUROC = 
0.91; P = 0.003); M. 3,4-dihydroxyphenylpropanoate (AUROC = 0.91; P = 0.003); N. 
cortolone (AUROC = 0.91; P = 0.073); and O. isomer of deoxyadenosine (AUROC = 
0.91; P = 0.008) as candidate biomarkers. 
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CHAPTER 7. FEEDING TREATS CONTAINING CANNABIDIOL DID NOT ALTER 
CANINE IMMUNE RESPONSE TO IMMUNIZATION WITH KEYHOLE 
LIMPET HEMOCYANIN 
Introduction 
While there have been preliminary investigations into the safety of its use in dogs 
(Deabold et al., 2019; Gamble et al., 2018; Vaughn et al., 2020), concerns remain 
regarding the safety of CBD use as it poses potential risks of hepatoxicity and drug 
interactions (Ewing et al., 2019; Morris et al., 2020; Yamaori et al., 2011). An additional 
concern regarding the safety of CBD is its effects on the immune system. It has been 
proposed to exert anti-inflammatory effects by enhancing adenosine signaling via the A2A 
receptor, which may protect tissues from inflammation by down-regulating over-reactive 
immune cells (Carrier et al., 2006; Ohta and Sitkovsky, 2001). Although these actions of 
CBD have been pursued as potential treatments against chronic inflammatory conditions, 
CBD may also negatively impact other functions of the immune system, such as 
responses to vaccination, through the same mechanisms. In several human case studies, 
the use of marijuana was associated with a decrease in serum IgG and IgM, B and T 
lymphocytes, and natural killer cells compared to non-smokers (El-Gohary and Eid, 
2004; Huemer et al., 2007). The production of these cells and immunoglobulins is 
essential to the generation of a proper immune response to infection or immunization. 
Thus, the potential for CBD to inhibit these processes poses a potential risk to the health 
of animals supplemented with CBD. However, this effect has yet to be tested in a canine 
model. 
Keyhole limpet hemocyanin (KLH) is considered an ideal antigen to assess 
primary and secondary immune responses to vaccination because it is harmless, has a low 
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risk of cross-reactivity, and produces an adequate immune response that allows for 
measureable differences between treatments (Swaminathan et al., 2014). The use of KLH 
as an antigen in immunotoxicology studies has been validated for use in dogs to evaluate 
both primary and secondary responses to KLH immunization (Finco-Kent and Kawabata, 
2005; Kawai et al., 2013) and has also been used to detect immunosuppressive effects of 
cyclophosphamide and cyclosporine in dogs (Legrand et al., 2012).  
The primary objective of this study was to determine the effect of industrial 
hemp-derived CBD on the immune response to immunization with a novel antigen in 
dogs. A secondary objective was to determine if CBD altered the overall health indices of 
dogs receiving immunization. The underlying hypothesis was that CBD would not 
negatively impact health indices, nor would it alter or negatively affect and KLH-specific 
antibody production of dogs receiving CBD. 
Materials and Methods 
This study was approved by the LMU IACUC (protocol 2005-RES) prior to the 
start of the study. All housing and husbandry received were in accordance with the 
Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (8th ed.), 
and all applicable LMU SOPs. 
Subjects and Housing 
Forty adult dogs (20 intact male, 17 female, 3 spayed females; 2.0 ± 1.3 years old; 
21.9 ± 6.7 kg) of various mixed breeds were received from several local shelters for 
inclusion in this study. The shelters were informed and gave consent for the use of the 
dogs for research purposes before their arrival. Before beginning the experiment, each 
dog had a hematology and serum chemistry analysis (IDEXX Laboratories, Inc., 
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Westbrook, ME) performed, along with a physical evaluation by a veterinarian and a 
fecal examination to rule out any underlying disease that might preclude enrollment. 
Dogs were excluded if they demonstrated serious behavioral issues such as aggression 
that would endanger research personnel; were severely emaciated, classified as a body 
condition score < 3.5 or > 7.5 on a 9-point scale (where 1 is emaciated and 9 is obese; 
Laflamme, 1997); or if initial evaluations revealed an underlying disease that required 
more than routine treatments (i.e. heartworm infection, metabolic or infectious disease, 
and mobility issues). Thirty-two dogs (16 intact males, 13 intact females, 3 spayed 
females; 2.1 ± 1.3 years old; 22.4 ± 6.3 kg) were selected for inclusion in the study. Dogs 
were individually housed in 1.2 x 1.8 m kennels within one of two dog wards at the LMU 
DeBusk Veterinary Teaching Center. Dogs were stratified by treatment and sex and 
evenly distributed between the two wards. 
Diets and Treatments 
Dogs were fed Purina Pro Plan EN Gastroenteric Dry Dog Food (Nestle Purina 
Inc., St. Louis, MO) to meet the daily metabolizable energy requirements of intact adult 
dogs at maintenance, calculated as (70 * BW0.75) * 1.8 and split into two meals at 
approximately 0800 h and 1800 h each day. Dogs were weighed and body condition 
scored (5-point scale) weekly and diets adjusted accordingly. Dogs were stratified by BW 
and sex before being randomly assigned to treatments arranged in a completely 
randomized design consisting of 0 (placebo treats; CON) or 114.5 ± 6.6 mg CBD/d 
(CBD). Based on the mean BW of dogs included in the study and analysis of the treats, 
mean dose of CBD was 5.0 ± 3.7 mg CBD/kg BW/d. No other cannabinoids were 
detected in the treats. The CBD was the primary constituent of a proprietary industrial 
148 
hemp isolate (AgTech Scientific, Paris, KY) that was incorporated into treats 
administered twice daily with each treat containing half the daily dose. Both control and 
CBD treats were composed of the following ingredients: chicken, chicken liver, Asian 
carp, catfish, and – in the case of CBD treats – industrial hemp extract. Treats were 
offered within 30 min of meals solely as a reward upon kennel re-entry following twice-
daily exercise. Research personnel administering the treats were blinded as to the 
treatments administered. 
Experimental Design 
 Upon intake, all dogs underwent a 7-d acclimation period for adjustment to 
treatments, environment, diet, and daily routine (Table 7.1). Following the initial 7-d 
acclimation to treatments, dogs were immunized with 10 mg KLH/dog (product #: 
H7017-5X20MG; Sigma-Aldrich, St. Louis, MO) via intramuscular injection into the 
semimembranosus muscle region. The KLH was dissolved in physiological saline at a 
concentration of 10 mg/mL with a total injection volume of 1 mL/dog. This dosage of 
KLH was selected based on previous work in dogs (Kawai et al., 2013). The solution was 
filtered using a sterile 0.02 µm membrane filter before injection. The second 
immunization of KLH was administered in the same manner on d 14 in the contralateral 
leg immediately after collection of blood samples. 
Sample Collection and Analysis 
Blood samples (~6 mL) were collected via jugular or cephalic venipuncture upon 
intake (d -9 and -8) and on d 7, 14, 21, and 28 (Table 7.1). Blood samples were split 
between serum (~5 mL) and EDTA plasma (~1 mL) tubes. Whole blood samples in 
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EDTA plasma tubes from each time point were used for hematology analysis using a 
ProCyte Dx Hematology Analyzer (Table 7.2; IDEXX Laboratories, Inc., Westbrook, 
ME). Serum samples were allowed to clot for 1 h before centrifugation at 1645 x g for 10 
min. Approximately 0.5 mL of serum was then used for serum chemistry analysis using a 
Catalyst Dx Chemistry Analyzer (IDEXX Laboratories, Inc., Westbrook, ME) while the 
remaining serum was temporarily (24-48 hr) stored at -20°C before being stored at -80°C 
for later immunoglobulin analysis.  
Serum IgG and IgM (mg/dL) were measured using a commercially available 
enzyme-linked immunosorbent assay (ELISA) kit (Dog IgG and IgM; Immunology 
Consultants Laboratory, Inc., Portland, OR) with inter- and intra-assay coefficients of 
variation of 7.2% and 6.7%, respectively for IgG and 6.4% and 4.1%, for IgM. Anti-KLH 
IgG and IgM immunoglobulins (kU/L) was analyzed using commercially available 
ELISA kits (Canine Anti-KLH IgG and IgM; Alpha Diagnostic Intl. Inc., San Antonio, 
TX) with inter- and intra-assay coefficients of variation of 8.4% and 3.6%, respectively 
for IgG and 6.86% and 5.43%, for IgM assays. 
Consumption of food and treats, stool consistency, frequency of elimination, 
mucus membrane color, subjective assessment of activity during exercise, and other 
indicators of general health status were monitored twice daily by research personnel. 
Body temperature and injection sites were also monitored immediately and 12 h after 
KLH immunization for evidence of any reaction to the immunization. Evidence of any 
adverse event – defined as any symptom occurrence that would not be expected in normal 
dogs – was also monitored. However, no adverse events were observed in any dogs 
following KLH immunization nor the administration of CBD treats during this study. 
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Statistical Analysis 
The normality of the residuals was first tested using the UNIVARIATE procedure 
in SAS 9.4 (SAS Institute, Cary, NC). In instances where data did not meet normality 
assumptions, statistical analysis was performed on transformed data. Data were then 
back-transformed for reporting purposes. The standard error of the back-transformed data 
was calculated from the confidence limits of the transformed data as follows: SEM = 
(back-transformed upper limit – back-transformed lower limit)/3.92 where the 
denominator relates to the Z-value of a 95% confidence interval (± 1.96). HGB, 
RETIC%, RETIC, MONO%, LYM, MONO, MPV, PDW, total protein, alanine 
aminotransferase, and total IgM were not normally distributed and were log-transformed 
for statistical analysis. BASO%, the blood urea nitrogen-to-creatinine ratio, alkaline 
phosphatase, and anti-KLH IgG were not normally distributed and were transformed to 
the square root for statistical analysis. Glucose and creatinine were not normally 
distributed and were transformed to the cube root for statistical analysis. Lastly, EOS%, 
EOS, and BASO were not normally distributed and were transformed to the fourth root 
for statistical analysis. At baseline, blood urea nitrogen and globulin were increased while 
albumin and the albumin-to-globulin ratio were decreased in CON compared with CBD; 
thus, baseline values were utilized as a covariate for the remaining measurements. 
Data were then analyzed using the MIXED procedure in SAS including the fixed 
effects of treatment, day, and the treatment by day interaction. Day was included as a 
repeated measure with dog nested within treatment as the subject. Results are presented 
as the mean ± SE. Effects were considered significant when P ≤ 0.05 and considered a 
tendency when P ≤ 0.10. 
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Results 
Hematology and Serum Chemistry 
Hematological variables were generally normal for dogs across both treatments 
throughout the study (Table 7.3). While there were differences or trends in RBC (P = 
0.065), hematocrit (P = 0.013), hemoglobin (P = 0.027), mean corpuscular hemoglobin 
concentration (P = 0.068), and platelets (P = 0.071) between treatments, all were within 
IDEXX normal reference ranges. Effects of experiment day were observed for almost all 
variables apart from red cell distribution width, reticulocyte %, and reticulocytes (P = 
0.260, 0.285, and 0.309, respectively). Treatment by day interactions were observed for 
platelet distribution width (P = 0.027) and a trend observed for monocytes (P = 0.065). 
No other treatment by day interactions were observed (P > 0.05). Monocytes were similar 
across treatments on each day of the experiment (P > 0.05) except for d 28, where CON 
tended to be lower than CBD (P = 0.085); platelet distribution width was similar across 
treatments on each individual day of the experiment (P > 0.05). Again, despite these 
minor differences between treatments, all remained within the laboratory’s normal 
reference ranges. 
With respect to the serum chemistry, again the variables were generally normal 
for dogs across both treatments (Table 7.4). Day of experiment affected concentrations of 
all serum chemistry variables (P < 0.05). Blood urea nitrogen and the ratio of blood urea 
nitrogen to creatinine were increased in CBD compared to CON (P = 0.027 and 0.016, 
respectively), but both treatments were within normal reference range and no treatment 
by day interactions were observed (P = 0.105 and 0.689, respectively). A treatment effect 
and treatment by day interaction were observed for serum albumin (P = 0.017 and 0.044, 
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respectively), where CON albumin tended to increase compared with CBD on d 14 (P = 
0.057) and increased on d 21 and 28 (P < 0.05). Again, despite the differences, serum 
albumin remained within normal reference range in all dogs for the duration of the study. 
Treatment by day interactions were observed for both globulin (P = 0.047) and the 
albumin to globulin ratio (P < 0.001). However, both were similar across treatments on 
each individual day of the experiment (P > 0.05). Both a treatment effect and a treatment 
by day interaction were observed for alkaline phosphatase (P = 0.045 and 0.014, 
respectively). While similar between treatments at baseline and on d 7 (Figure 7.1; P = 
0.994 and 0.183, respectively), alkaline phosphatase was elevated in CBD compared with 
CON on d 14, 21, and 28 (P = 0.006, 0.027, and 0.014, respectively). Again, despite the 
treatment differences, all stayed within laboratory reference ranges for the duration of the 
study; however, alkaline phosphatase did increase 2-fold in the CBD group from baseline 
to d 21. 
Total Immunoglobulins 
Total IgG was unaffected by both treatment and treatment by day interaction (P = 
0.930 and 0.897, respectively) but increased over time (Figure 7.2A; P < 0.001). Total 
IgM was unaffected by treatment (P = 0.817) but was affected by day (P < 0.001) and a 
treatment by day interaction (Figure 7.2B; P = 0.047). The CON IgM peaked 7 days after 
initial KLH immunization and returned to baseline levels by day 21, whereas CBD IgM 
did not peak until day 21 and returned to baseline levels on day 28. 
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Anti-KLH Immunoglobulins 
Anti-KLH immunoglobulins were undetectable in all samples on day 0. Anti-
KLH IgG was affected by day (Fig. 7.3A; P < 0.001), peaking on day 21 (218.45 ± 8.743 
kU/L), but was unaffected by both treatment and treatment by day interaction (P = 0.422 
and 0.510, respectively). Similarly, anti-KLH IgM was unaffected by treatment and 
treatment by day interaction (Fig. 7.3B; P = 0.879 and 0.927, respectively) but an effect 
of day was observed (P < 0.001). Anti-KLH IgM peaked in both treatments 7 d after the 
initial KLH immunization (354.27 ± 15.130 kU/L) before declining each subsequent 
week. 
Discussion 
Due to the potential impact of CBD on the immune system, the purpose of this 
investigation was to determine if CBD would alter the humoral immune response of dogs 
to immunization with KLH and to assess its potential to alter overall health indices. 
Acute toxicity studies in mice and monkeys have demonstrated the potential for CBD to 
cause liver injury at extremely high doses (mouse equivalent dose of 200-300 mg/kg) 
(Ewing et al., 2019; Rosenkrantz et al., 1981). While those doses are not applicable to 
most real-life scenarios, they do demonstrate the potential risk of CBD use if proper 
dosing is not established. For example, a dog may get into a box of CBD treats and 
consume all treats at once. In sub-acute studies in mice, mouse equivalent doses of 15 
mg/kg produced only hepatocyte cytoplasmic swelling, but repeated doses of 50 mg/kg 
elevated several liver enzymes and caused hepatocyte cytoplasmic swelling (Ewing et al., 
2019). This demonstrates the potential risk of liver injury at both lower doses and 
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repeated dosing regimens. The need for continued investigation is evident, particularly 
since neither toxicity nor long-term dosing studies have been performed in dogs.  
Several studies have evaluated changes in hematology and serum chemistry in 
response to short-term CBD supplementation in dogs. At doses ranging from 2 to 65 
mg/kg, CBD has been shown to increase serum alkaline phosphatase in dogs as early as 
14 d after treatment initiation (Gamble et al., 2018; McGrath et al., 2018; Vaughn et al., 
2020). Results from this study concur with these previous findings as serum alkaline 
phosphatase, though remaining within the IDEXX normal reference range, was increased 
in the CBD treatment compared with control on 14 d and remained elevated throughout 
the study. Whether this increase presents any potential detriment remains uncertain, 
particularly considering that other serum chemistry variables were similar between 
treatments. It would be beneficial for future work to investigate the potential for 
hepatoxic effects in dogs over long-term CBD supplementation as well as the use of 
multiple CBD doses.  
The anti-inflammatory actions of CBD have most often been suggested as 
potential treatments against chronic inflammatory conditions like multiple sclerosis and 
osteoarthritis; however, there is also evidence from in vitro work suggesting CBD may 
negatively impact other functions of the immune system. Notably, CBD has been shown 
to inhibit IL-2, IL-10, and IFNγ production in mice (Condie et al., 1996; Jan et al., 2007), 
which are essential for both the activation and differentiation of T and B cells in response 
to an immune challenge (Arenas-Ramirez et al., 2015; Jeurissen et al., 2004). The 
suppression of antibody production has been demonstrated in mice after a single 
intraperitoneal dose of CBD (Jan et al., 2007) and is associated with marijuana use in 
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humans (El-Gohary and Eid, 2004; Huemer et al., 2007). There is, however, conflicting 
evidence on the immunomodulatory effects of CBD. Jenny et al. (2009) reported a 
biphasic response in human peripheral blood mononuclear cells (PBMCs), with CBD 
exhibiting a stimulatory effect at lower doses and inhibitory effects at higher doses. 
Collectively, these studies highlight the possibility of CBD acting negatively on the 
immune system and the need for work evaluating this potential risk.  
The present study is one of the first to describe the potential effect of CBD on the 
immune response of dogs after immunization. Despite a minor shift in the timing of total 
IgM peak between control and CBD, the IgG and IgM responses of both groups were 
similar throughout the study. Anti-KLH immunoglobulin responses were similar to 
previous studies using this model in dogs (Finco-Kent and Kawabata, 2005; Kawai et al., 
2013), and CBD did not appear to exhibit immunosuppressive effects such as those seen 
with known immunosuppressants cyclophosphamide and cyclosporine (Legrand et al., 
2012). While these results suggest CBD does not negatively impact the immune response 
of dogs to immunization, the work is preliminary. This work utilized healthy, adult dogs 
receiving no concommittant medication that might futher impact the immune response; 
CBD may affect aged or diseased populations differently. Future work should investigate 
the possibility of different responses to CBD supplementation in diseased, young, or aged 
populations compared to healthy adults using common canine vaccines rather than KLH. 
Additionally, our study utilized a single dose (mg/kg) of CBD supplemented over 5 
weeks; longer-term CBD dosing using multiple CBD doses is necessary as well as futher 
investigation into potential drug interactions. It would be beneficial for future work to 
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evaluate B and T cell population changes with CBD supplementation as this will better 
describe any potential impact on the immune system. 
Conclusions 
Results of the current study provide initial evidence that CBD does not negatively 
impact the normal canine immune response to immunization when supplemented at 5 
mg/kg BW/d. Neither total nor KLH-specific immunoglobulin production was reduced 
by CBD supplementation. However, this work does highlight, alongside several other 
studies in dogs, the potential for CBD to alter liver function and need for further safety 
evaluations of CBD use in dogs. Considering these concerns and the increased use of 
CBD in companion animals, continued investigation into the safety of CBD use in 
companion animals is critical.  
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Tables and Figures 
Table 7.1. Schedule of events for evaluating immune response to immunization with a 
novel antigen in dogs receiving cannabidiol containing treats compared to control. 
 
Day of 
Study Event Data Collection Treats 
-9 & -8 Intake Exams Baseline blood draw Control 
-7 – -1 Acclimation None Treatment 
0 Primary immunization None Treatment 





Day 14 post-primary immunization blood 
draw prior to secondary immunization Treatment 
21 Blood Draw Day 7 post-secondary immunization blood draw Treatment 




Table 7.2. Complete blood count variables and their abbreviations. 
 
Abbreviation Variable 
RBC, M/µL Red blood cells 
HCT, % Hematocrit 
HGB, g/dL Hemoglobin 
MCV, fL Mean corpuscular volume 
MCH, pg Mean corpuscular hemoglobin 
MCHC, g/dL Mean corpuscular hemoglobin concentration 
RDW, % Red cell distribution width 
RETIC % Reticulocyte percentage 
RETIC, K/µL Reticulocytes 
RETIC-HGB, pg Reticulocyte/Hemoglobin ratio 
WBC, K/µL White blood cells 
NEU, % Percentage neutrophils 
LYM, % Percentage lymphocytes 
MONO, % Percentage monocytes 
EOS, % Percentage eosinophils 
BASO, % Percentage basophils 
NEU, K/µL Neutrophils 
LYM, K/µL Lymphocytes 
MONO, K/µL Monocytes 
EOS, K/µL Eosinophils 
BASO, K/µL Basophils 
PLT, K/µL Platelets 
MPV, fL Mean platelet volume 
PDW, fL Platelet distribution width 
PCT, % Plateletcrit 
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Table 7.3. Effect of cannabidiol (CBD) treatment (Trt), day, and the treatment by day 
(Trt*Day) interaction on hematology variables in dogs compared to control (CON). 
 
  IDEXX Reference 
Interval 
      P-value 
Variable CON CBD SEM Trt Day Trt*Day 
RBC, M/µL 5.65-8.87 6.98 7.34 0.135 0.065 <.001 0.657 
HCT, % 37.3-61.7 44.35 47.75 0.943 0.013 <.001 0.710 
HGB, g/dL 13.1-20.5 16.12 17.12 0.183 0.027 <.001 0.684 
MCV, fL 61.6-73.5 63.56 64.92 0.655 0.141 <.001 0.717 
MCH, pg 21.2-25.9 23.16 23.44 0.229 0.384 0.070 0.600 
MCHC, g/dL 32.0-37.9 36.46 35.97 0.189 0.068 0.004 0.323 
RDW, % 13.6-21.7 18.39 18.06 0.308 0.437 0.260 0.929 
RETIC %  0.43 0.39 0.027 0.654 0.285 0.610 
RETIC, 
K/µL 10.0-110.0 28.79 28.79 2.014 0.972 0.309 0.637 
RETIC-
HGB, pg 22.3-29.6 25.83 26.57 0.375 0.164 <.001 0.781 
WBC, K/µL 5.05-16.76 12.05 12.75 0.809 0.528 0.001 0.316 
NEU, %  55.89 60.13 1.881 0.111 <.001 0.629 
LYM, %  27.25 25.73 1.650 0.506 <.001 0.451 
MONO, %  6.23 6.17 0.161 0.884 <.001 0.187 
EOS, %  7.78 5.62 0.684 0.205 <.001 0.795 
BASO, %  0.60 0.57 0.028 0.754 0.037 0.140 
NEU, K/µL 2.95-11.64 6.39 7.41 0.292 0.231 <.001 0.493 
LYM, K/µL 1.05-5.10 2.97 2.92 0.132 0.883 <.001 0.100 
MONO, 
K/µL 0.16-1.12 0.72 0.76 0.023 0.582 <.001 0.065 
EOS, K/µL 0.06-1.23 0.89 0.72 0.087 0.403 <.001 0.551 
BASO, K/µL 0.00-0.10 0.07 0.07 0.004 0.754 0.008 0.152 
PLT, K/µL 148-484 259.5 225.1 13.346 0.071 0.040 0.755 
MPV, fL 8.7-13.2 12.06 12.18 0.133 0.895 0.012 0.972 
PDW, fL 9.1-19.4 12.06 12.18 0.202 0.800 0.006 0.027 
PCT, % 0.14-0.46 0.31 0.27 0.015 0.044 0.104 0.730 
RBC, red blood cells; HCT, hematocrit; HGB, hemoglobin; MCV, mean corpuscular 
volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin 
concentration; RDW, red cell distribution width; RETIC, reticulocyte; WBC, white blood 
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cells; NEU, neutrophils; LYM, lymphocytes; MONO, monocytes; EOS, eosinophils; 
BASO, basophils; PLT, platelets; MPV, mean platelet volume; PDW, platelet distribution 
width; PCT, plateletcrit 
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Table 7.4 Effect of cannabidiol (CBD) treatment (Trt), day, and the treatment by day 
(Trt*Day) interaction on serum chemistry variables indicative of liver function in dogs 
compared to control (CON). 
 
  IDEXX 
Reference 
Interval 
   P-value 
Variable CON CBD SEM Trt Day Trt*Day 
Glucose, mg/dL 74-143 88.72 88.12 1.116 0.941 <.001 0.280 
Creatinine, mg/dL 0.5-1.8 1.12 1.09 0.018 0.495 <.001 0.643 
BUN, mg/dL 7-27 16.29 18.73 0.777 0.027 <.001 0.103 
BUN/CREA  14.71 17.53 0.808 0.016 0.082 0.689 
Total Protein, g/dL 5.2-8.2 6.75 6.69 0.066 0.667 0.003 0.996 
Albumin, g/dL 2.3-4.0 3.44 3.24 0.066 0.017 <.001 0.044 
Globulin, g/dL 2.5-4.5 3.46 3.29 0.072 0.455 <.001 0.047 
ALB/GLOB  1.00 0.99 0.045 0.818 <.001 <.001 
ALT, U/L 10-125 56.83 55.70 2.729 0.874 <.001 0.387 
ALP, U/L 23-212 57.61 93.32 7.099 0.045 <.001 0.014 
BUN, blood urea nitrogen; BUN/CREA, blood urea nitrogen/creatinine ratio; 







Figure 7.1. Serum alkaline phosphatase (U/L) of control (CON) and cannabidiol (CBD) 
treatments over time. Data were not normally distributed and were transformed by the 
square root for statistical analysis, then back-transformed for reporting purposes. 
Standard error (SE) of the back-transformed data was calculated as follows: SE = (back-
transformed upper limit – back-transformed lower limit)/3.92. Alkaline phosphatase 
levels remained within IDEXX normal reference range throughout the study and were 
similar between treatments at baseline (day 0, P = 0.994) and day 7 (P = 0.183), but were 
increased in CBD treatment on days 14, 21, and 28 compared to control (P = 0.006, 
0.027, and 0.014, respectively). Asterisks (*) Indicate differences between treatments (P 








Figure 7.2. Total serum A) IgG and B) IgM (mg/dL) of control (CON) and cannabidiol 
(CBD) treatments over the 28-d experiment. Dogs were challenged with keyhole limpet 
hemocyanin on days 0 and 14 after collection of blood samples. Both total IgG and total 
IgM concentrations were altered by day (P < 0.001). Day of experiment altered both total 
IgG and total IgM concentrations (P < 0.001). Total IgG was unaffected by both 
treatment and the treatment by day interaction (P = 0.930 and 0.897, respectively). Total 
IgM was not normally distributed and was log-transformed for statistical analysis, then 
back-transformed for reporting purposes. Standard error (SE) of the back-transformed 
data was calculated as follows: SE = (back-transformed upper limit – back-transformed 
lower limit)/3.92. Total IgM was unaffected by treatment (P = 0.817) but a treatment by 








Figure 7.3. Anti-Keyhole Limpet Hemocyanin (KLH) A) IgG and B) IgM (kU/mL) of 
control (CON) and cannabidiol (CBD) treatments over the 28-d experiment. Dogs were 
challenged with KLH on days 0 and 14 after collection of blood samples. Anti-KLH IgG 
was not normally distributed and was transformed to the square root for statistical 
analysis, then back-transformed for reporting purposes. Standard error (SE) of the back-
transformed data was calculated as follows: SE = (back-transformed upper limit – back-
transformed lower limit)/3.92. Day of experiment altered both anti-KLH IgG and IgM (P 
< 0.001). Both anti-KLH IgG and IgM were unaffected by treatment (P = 0.422 and 





CHAPTER 8. SUMMARY AND CONCLUSIONS 
Interest and use of CBD in companion animals is increasing due to suspected 
benefits like antioxidant, anti-inflammatory, and anxiolytic effects. Yet despite increased 
use and favorable public opinion, scientific literature detailing mechanisms of action are 
inconsistent, and evidence of safety and efficacy of CBD use in dogs is shockingly 
limited. Therefore, the primary goal of this dissertation was to investigate the potential 
impact of industrial hemp-derived CBD treat supplementation on the health and well-
being of dogs. This objective was accomplished through assessments of canine anxiety, 
voluntary activity, metabolome, overall health indices, and immune response during CBD 
supplementation.  
To study the effect of oral CBD on canine health and well-being, industrial hemp-
derived CBD extract was included in a dog treat formulation for supplementation. 
Palatability of treats was first assessed when dogs were fed a variety of diet types. 
Neither food consumption nor treat acceptance were altered by increasing CBD inclusion 
in treats. These treats provide a simple, palatable method of administering oral CBD at 
precise dosages for research, which is an improvement from use of oils that must either 
be top-dressed or dosed via syringe.  
Despite the lack of evidence regarding efficacy of CBD as an anxiolytic, canine 
anxiety and noise aversion are some of the most common reasons that pet owners 
administer CBD to their dogs (Kogan et al., 2019a). The second part of this series of 
experiments was the first to investigate the potential anxiolytic effect of CBD in dogs 
with noise aversion through the use of a noise-induced fear response test. Cannabidiol 
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supplemented at 1.4 mg CBD/kg BW/d did not demonstrate an anxiolytic effect in this 
model. The positive control, trazodone, decreased plasma cortisol, increased heart rate 
variability variables, and increased duration of the relaxed behaviors, Other Eyes and tail 
relaxed. Cannabidiol by itself decreased duration of relaxed behavior Other Eyes and did 
not alter plasma cortisol. When supplemented in combination with trazodone, however, 
CBD appeared to attenuate the effects of trazodone on plasma cortisol, which may be 
indicative of cytochrome P450 inhibition by CBD that could lead to drug interactions. 
Instead of decreasing heart rate and increasing heart rate variability as expected from an 
anxiolytic, CBD increased heart rate and decreased some heart rate variability variables. 
The lack of anxiolytic effect by CBD may have been a result of the low dose, short 
duration of supplementation, or use of Latin square design. 
The next study in this series of experiments did not show a change in voluntary 
daily activity in dogs supplemented with 1.8 or 4.5 mg CBD/kg BW/d. The higher dose 
tended to reduce voluntary activity during Quiet and Music periods, but this did not 
translate to an overall daily effect. As this experiment utilized healthy animals to examine 
voluntary daily activity, this effect may be more evident in dogs with mobility and 
behavioral issues like osteoarthritis or anxiety. Unexpectedly, CBD reduced scratching, 
which may indicate a possible antipruritic effect warranting investigation in dogs with 
dermatological issues like skin allergies or atopic dermatitis.  
Using the same cohort of dogs from the previous study, alteration of the plasma 
metabolome was observed after 21 d of 4.5 mg CBD/kg BW/d supplementation. 
Metabolites altered by CBD may suggest a potential influence on glucose, carbohydrate, 
lipid, amino acid, vitamin, and nucleotide metabolism. Potential biomarkers identified 
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may indicate potential pathways by which CBD may exert suspected anti-inflammatory, 
antioxidant, anti-obesity, and antimicrobial effects. The identification of these metabolic 
changes will help direct future research into the elucidation of potential mechanisms and 
evaluation of the physiological relevance of these changes. 
The last experiment in this series was one of the first to assess the potential risk 
for CBD to diminish the normal immune response to immunization. When supplemented 
to healthy dogs at 5 mg CBD/kg BW/d, both total and KLH-specific immunoglobulin 
production were unaffected by CBD. While CBD demonstrated no immunosuppressive 
effects after 5 weeks of supplementation, alkaline phosphatase was elevated in dogs 
receiving CBD, highlighting the potential for CBD to alter liver function and need for 
further safety and hepatoxicity evaluations of CBD use in dogs, particularly in aged or 
diseased populations that may have compromised immune function.  
While concerns of long-term safety remain as potential drug interactions and 
altered liver function were observed, the potential therapeutic applications of CBD make 
further investigation into these effects critical. Future work utilizing larger sample sizes 
and several doses is needed to assess long-term safety and proper dosing of CBD in dogs. 
Additionally, as our work utilized only healthy dogs, additional investigation is needed to 
evaluate these potential therapeutic benefits in aged populations, dogs with diabetes, dogs 
with atopic dermatitis, or other specific disorders. 
In conclusion, this work provides initial evidence that industrial hemp-derived 
CBD may impact the health and well-being of dogs. Formulating dog treats to include 
CBD extract was shown to be a simple and palatable means of administering CBD that 
can be used by both researchers and pet owners. Although CBD did not appear to 
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influence behavioral measures in this work, it may have the potential to improve the well-
being of dogs. As the use of CBD in companion animals continues to increase, increasing 
our understanding of physiological mechanisms by which CBD exerts these effects is 
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